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Abstract
Botulinum neurotoxins (BoNTs) are the deadliest proteins known and cause flacid
paralysis through inhibition of acetylcholine release from motor neurons. Each BoNT
consists of three domains: the binding domain, the translocation domain and the
catalytic light chain. The binding domain is responsible for the targetting of neuronal
cell membranes and is able to form a dual-receptor complex with cell-surface receptors.
The BoNT is taken into the cell through endocytosis where the translocation domain
acts to release the catalytic light chain into the cell cytosol. The light chain is then
free to cleave one of the SNARE (soluble N-ethylmaleimide-sensitive-fusion-protein
attachment protein receptor) proteins, inhibiting exocytosis and thus neurotransmitter
release. BoNTs are categorised into serotypes (BoNT/A to /G) and subtypes (e.g.
BoNT/A1) based on amino acid variations. BoNTs have many therapeutic uses
including as a treatment for cervical dytonia, strabismus, and overactive bladder and
the most common commercially available product consists of BoNT/A1. Subtle amino
acid variations between BoNT subtypes may have a dramatic impact on the properties
of the protein, some of which may be useful for the production of engineered BoNTs
in the future.
In this thesis, the crystal structures of the binding domains from BoNT/A1 to /A6
were determined to high resolution and their binding to the protein-receptor SV2 was
investigated. The structures of full-length BoNTs in solution were also investigated to
confirm whether multiple domain-organisations exist across BoNT serotypes. There
are over 150 different BoNTs known and this work also includes a new open-access
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1. Introduction 1.1. Bacterial Toxins
Much of sections 1.1 and 1.2 have been duplicated verbatim from a published review,
Davies et al. (2018b). The review is included in full on page 197.
1.1 Bacterial Toxins
Many infectious diseases are caused by proteins secreted by bacterial species. For
many bacteria, the secretion of toxins results in a clear benefit to the microbe but for
others the benefit remains unclear.
Some bacterial toxins, for which the advantage to the bacteria is unclear, are capable
of inducing paralysis that can lead to host death. The tetanus neurotoxin (TeNT)
causes such a condition, tetanus, it is produced by Clostridium tetani. The anaerobic
bacterium, C. tetani, is found globally and forms spores which are found commonly in
soil. One can speculate as to whether death of the host is beneficial to spore forming
anaerobes but the advantage remains a paradox. Another deadly condition, similar to
tetanus, and caused by a bacterial toxin is botulism which is characterised by muscle
weakness which spreads throughout the body and eventually leads to death (Sobel,
2005). Botulism was first attributed to a toxin by the German doctor, Justinus Kerner,
many years before microbes were discovered (Kerner, 1817). Instances of botulism can
be categorised into one of three types: food-borne, wound or intestinal. The name
botulism originates from the Latin word for sausage, botulus. Foodbourne botulism
follows the ingestion of contaminated foods such as tinned meals which have not been
sufficiently heat sterilised. Wound botulism is caused by infection of open wounds
by BoNT-producing bacteria (Fillo et al., 2015). Intestinal botulism, which mainly
affects infants, is caused by colonisation of the gut with BoNT-producing bacteria
(Umeda et al., 2009). Individuals identified as suffering from botulism must be treated
immediately to stop the condition worsening. Treatment consists of mainly supportive
measures and in more advanced cases the patient must be intubated and subjected to
mechanical ventilation to avoid respiratory failure from the spread of muscle paralysis
(Chalk et al., 2014). Anti-toxin derived from equine-sera has been produced which
stops further intoxication from further BoNT binding to receptors (Patel et al., 2014).
While an extremely rare problem, the condition still affects many people across the
world.
2
1. Introduction 1.2. Botulinum Neurotoxins
1.2 Botulinum Neurotoxins
Botulinum neurotoxins (BoNTs) are produced mainly by Clostridium botulinum, under
anaerobic conditions (Hatheway, 1990), and are the causative agent of botulism, a rare
disease that can lead to paralysis and eventually death. The C. botulinum taxon can be
divided into four groups (I, II, III and IV), based on phenotypic differences between
the bacteria (Collins and East, 1998). C. botulinum group I (proteolytic) and group II
(non-proteolytic) are mostly responsible for human botulism whereas C. botulinum
group III is responsible for botulism in other animal species, and C. botulinum group
IV does not appear to cause botulism (Collins and East, 1998; Carter and Peck, 2015).
Across these phenotypes, a range of serologically distinct BoNTs have been identified,
based on their recognition by anti-sera, and classified within different serotypes. Up
until recently, all BoNTs have been categorised into one of seven serotypes ranging
from BoNT/A to BoNT/G. The recent identification of novel BoNTs and BoNT-like
proteins, which are not neutralisable by existing anti-sera, has lead to new serotype
classifications that do not currently continue from the classical nomenclature e.g.
BoNT/X. Some C. botulinum strains have also been identified which express more
than one serotype and some have been found to produce chimeric neurotoxins which
may have arisen from recombination events (eg. BoNT/CD and BoNT/DC).
Each BoNT is expressed as a single polypeptide chain of ~ 150 kDa in size (Figure 1.1a)
which is cleaved post-translationally by a protease to yield an active di-chain molecule
consisting of a ~ 50 kDa light chain (LC) and a ~ 100 kDa heavy chain (HC) linked by
a disulfide bond. Some BoNT serotypes are cleaved into a di-chain by an endogenous
host protease while others may be cleaved in the target organism (DasGupta and
Sugiyama, 1972; Prabakaran et al., 2001). For example, BoNT/A purified from C.
botulinum culture after 8 h is mostly as a single chain peptide but when purified from
a 96 h culture it is in the nicked di-chain form (Dekleva and DasGupta, 1989). The
Clostridial protease responsible for cleaving BoNT/A has been partially characterised
but not yet identified (Dekleva and Dasgupta, 1990). Indeed, for all other BoNTs,
no specific protease has been identified that selectively activates the protein. This
di-chain molecule is the active form, without proteolytic cleavage into a di-chain the
BoNT is much less active. Therefore the disulfide bond connecting the LC and HC
is vital for the mechanism of intoxication (Fischer and Montal, 2007; Pirazzini et al.,
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2011). The LC possesses a zinc-endopeptidase from the M27 family of peptidases,
while the HC consists of two domains – a translocation domain (HN) and a receptor
binding domain (HC). The HC domain can be further divided into two different
folds, a carboxyl-terminal β-trefoil (HCC) with an amino-terminal lectin-like jelly roll
containing fourteen β-strands (HCN). The crystal structure of BoNT/A1 shows the
domains are arranged in a ‘butterfly’ arrangement where the LC and HC are the ‘wings’
attached to the central HN ‘body’ (Figure 1b) (Lacy et al., 1998). Each domain appears
to be structurally and mechanistically distinct from one another with the exception of
a large loop, termed the belt, which wraps around the LC. The structure of BoNT/B
follows the same arrangement of BoNT/A whereas the structure of BoNT/E appears
to adopt a ‘closed wing’ compact conformation where the HC is rotated around the






Figure 1.1: Overall BoNT Structure
(a) Representation of general domain layout in BoNTs which includes the protease domain
(LC), translocation domain (HN), and receptor-binding domain (HC). The LC is linked to
the HN by a single disulfide bond. Full-length crystal structures of BoNT/A (PDB ID: 3BTA)
(b) and BoNT/E (PDB ID: 3FFZ) (c) which exhibit open and closed domain organisation,
respectively (Lacy et al., 1998; Swaminathan and Eswaramoorthy, 2000). Figure reproduced
from Davies et al. (2018b).
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1.2.1 The Receptor Binding Domain
The HC domain is responsible for targeting the protein to the neuronal membrane by
binding to receptors present on the neuronal cell surface (Figure 1.2). All classical
BoNT serotypes (/A to /G) bind to one or more polysialogangliosides and most
also bind to a protein-receptor which together form a dual-receptor complex (Monte-
cucco, 1986; Brunger and Rummel, 2009). The first evidence of ganglioside binding
was reported after inhibition of botulism through competition with free ganglioside
(Simpson and Rapport, 1971). Polysialogangliosides consist of a hydrophilic complex
polysaccharide with many sialic acid residues, bound to a hydrophobic ceramide tail.
Different forms of these gangliosides can be found embedded in the cell membrane
with the various sugar moieties displayed on the cell surface. The most common
examples found on neuronal membranes include GT1b, GD1a, GD1b and GM1. Two
types of BoNT protein receptors have also been identified to date: three isoforms of
synaptic vesicle glycoprotein 2 (SV2A-C) and two isoforms of synaptotagmin (SytI-II).
Both types are involved with the regulated secretion of neurotransmitter from synaptic
vesicles (Morgans et al., 2009; Chapman, 2002). SV2A-C contribute to the modulation
of exocytosis although their exact role is yet to be determined while SytI and SytII are
calcium-sensitive membrane proteins also involved in exocytosis (Morgans et al., 2009;
Tang et al., 2006; Chen et al., 2017; Südhof, 2002). Their involvement in synaptic vesicle
endocytosis also requires them to be recycled back into the cell through enodcytosis
making them excellent targets for BoNTs.
BoNT/A
Within the BoNT/A serotype there are currently eight identified subtypes BoNT/A1 to
/A8 which differ by between 3% and 16% at the amino acid level. The most thoroughly
characterised BoNT subtype is BoNT/A1 - this is in part due to its use as a therapeutic
for several conditions such as spasticity, dystonias, and glabellar lines (Johnson, 1999;
Montecucco and Molgó, 2005). The carboxyl-terminal half of the BoNT HC domain
(HCC) contains the peptide motif, H. . . SxWY. . . G, which constitutes the core of the
ganglioside-binding site (GBS) (Foster, 2014). In contrast to the dual ganglioside
binding sites identified on the related TeNT HC, the GBS of BoNT/A1 can only bind
one ganglioside at a time (Rummel et al., 2004b), but is capable of recognising more
5


























Figure 1.2: Mechanism of BoNT intoxication.
Free BoNT binds the neuronal cell membrane through a dual-receptor complex (a). The
BoNT-receptor complex is endocytosed and enclosed within a vesicle (b). A pH gradient
within the vesicle causes a conformational change, allowing the LC to be translocated across
the membrane (c). Trx, bound to the vesicle membrane, catalyses the reduction of a disulfide
bond, allowing the LC to release and cleave its protein target (d). Cleavage of any one of
the SNARE proteins disrupts SNARE-mediated exocytosis, stopping ACh release and thus
stopping muscle contraction. Labels: TrxR – Thioredoxin reductase; Trx – Thioredoxin; ACh –
Acetylcholine; AChE – Acetylcholine esterase; Figure reproduced from Davies et al. (2018b).
6
1. Introduction 1.2. Botulinum Neurotoxins
than one type, specifically GT1b, GD1a, and to a lesser extent GM1 (Yowler et al., 2002;
Hamark et al., 2017). The exact interactions between ganglioside and the GBS were
first determined from the crystal structure of the HC domain in complex with GT1b
(Stenmark et al., 2008) (PDB ID: 2VU9). This revealed extensive hydrogen–bonding




Figure 1.3: HC/A1 Dual-Receptor Complex
A schematic of the HC/A1 dual-receptor com-
plex produced by the superposition of two
HC/A1 crystal structure, PDB ID: 2VU9 and
5JLV. The ganglioside, GT1b is shown in green
and the protein-receptor, SV2 shown in pur-
ple. The N-linked glycan of SV2 is shown as a
purple ball and stick representation.
Depletion of gangliosides in neuroblastoma cells completely prevents entry of BoN-
T/A1 (Yowler et al., 2002), however, gangliosides alone do not mediate cellular entry;
for this, BoNT/A also requires the protein-receptor SV2 and in doing so, forms a
dual-receptor complex (Dong et al., 2006; Mahrhold et al., 2006) (Figure 1.3). Of the
three SV2 isoforms found in humans, BoNT/A1 has the greatest affinity for SV2C
(Dong et al., 2006). BoNT/A1 binds specifically to the luminal domain 4 of SV2 (SV2-
LD4) via direct backbone-backbone interactions between a β-strand of SV2-LD4 and
a β-strand of BoNT HC (Strotmeier et al., 2014; Benoit et al., 2014), and also through
interactions with an N559-linked glycan (Mahrhold et al., 2016). The significance of the
latter is highlighted by the inability of BoNT/A1 to bind to bacterially-expressed (i.e.
non-glycosylated) SV2A or SV2B, and a reduced affinity for non-glycosylated SV2C
(Mahrhold et al., 2006; Dong et al., 2008). The crystal structure of BoNT/A1–SV2C-LD4
revealed a large range of interactions, between the HC and the SV2 glycan, which
extended away from the backbone-backbone interactions almost doubling the contact
surface area (Yao et al., 2016). There is also some evidence that the HN domain of
BoNT/A1 is also capable of binding to neuronal membrances, although little is known
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about the mechanism of translocation and the role of HN binding (Ayyar et al., 2015).
The other subtypes of BoNT/A (/A1–/A8) are predicted to bind the same receptors
as BoNT/A1 due to their high sequence identity between the binding domains. The
crystal structure of the BoNT/A2 HC domain in complex with a non-glycosylated
SV2C-LD4 showed that the binding mode is conserved. There are some differences
in amino acid sequence between BoNT/A1 and /A2 but SV2C recognition is still
conserved as the interaction is mostly mediated by the peptide backbone which is
able to tolerate some side-chain variation (Benoit et al., 2017; Gustafsson et al., 2018).
There are also some interactions at the SV2 interface which involve protein side-
chains. F563 of the SV2-LD4 forms a π-stacking interaction with R1156 of BoNT/A1
while a glutamic acid residue in BoNT/A2 (E1156) causes F563 to adopt a different
conformation and the BoNT interacts instead directly with H564 of SV2C-LD4. Such
mutations indicate flexibility with respect to the backbone-backbone interaction of SV2
which may also be tolerated due to the extra interactions that occur with the N-linked
glycan (Yao et al., 2016). BoNT/A2 has also been shown to have a higher affinity for
gangliosides than BoNT/A1 although the interactions mediating this difference have
not yet been identified (Kroken et al., 2017). The crystal structures of the BoNT/A3 and
/A4 HC domains suggest a similar mode of interaction to ganglioside compared to
BoNT/A1 – the GBS of the former shows a potential loss of a hydrogen bond to one of
the terminal sialic acids due to a difference in amino acid (phenyalanine rather than a
tyrosine), whereas the latter is conformationally conserved (Davies et al., 2018c). With
regard to the SV2 binding site, both structures show slight differences in conformation
compared to that of BoNT/A1 due to differences in the primary sequence. Whether
this will affect interactions with the SV2 glycan is yet to be determined. Despite
high sequence identity between BoNT/A subtypes, significant differences in their
intoxication properties have been identified. For example, BoNT/A2 is more potent in
neuronal cells than BoNT/A1 possibly due to faster cell entry (Pier et al., 2011; Torii
et al., 2011; Pellett et al., 2015) and BoNT/A4 has been reported to be three orders of
magnitude less potent than BoNT/A1 (Pellett et al., 2015). It is difficult to attribute
these differences to just interactions between the HC and receptors, and is instead
likely as a result of contributions from the HC, HN and LC combined.
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BoNT/B
There are currently eight subtypes within the BoNT/B serotype (BoNT/B1 to /B8)
and they differ by between 1.5% and 7% at the amino acid level (Wangroongsarb et al.,
2014). Although the crystal structure of BoNT/B1 exists in an open conformation
similar to that of BoNT/A (Swaminathan and Eswaramoorthy, 2000) (Figure 1.1), the
BoNT/B serotype targets a different protein receptor on the neuronal cell membrane,
namely SytI or SytII (Nishiki et al., 1996; Dong et al., 2003; Rummel et al., 2007; Dong
et al., 2007). Crystal structures of the HC domain from BoNT/B in complex with
murine SytII revealed the high specificity of the binding interface where the SytII
peptide forms a helix and binds to a hydrophobic groove via six hydrophobic residues
(Chai et al., 2006; Jin et al., 2006). Interestingly, BoNT/B displays a much lower affinity
toward human SytII than murine SytII due to a single mutation at residue 54 - Phe
in rodents and Leu in humans (Strotmeier et al., 2012; Peng et al., 2012; Chai et al.,
2006). Considering that SytII is more abundant on human motor neurons than SytI, a
significantly larger dose of BoNT/B needs to be administered in order to achieve a
similar therapeutic effect as that for BoNT/A. A commercially available formulation
of BoNT/B is available which has had lower success, potentially due to the need for
increase dosing (Fonfria et al., 2018). To overcome this issue, the BoNT/B binding
domain has recently been engineered to increase its binding affinity. Two mutations
were identified (E1191M, S1199Y) which showed an 11-fold higher functional efficacy
in human cells compared to wild-type BoNT/B1 (Tao et al., 2017). BoNT/B is only
capable of entering cells once it has bound to both the Syt receptor and its ganglioside
receptor (Figure 1.4), either GT1b or GD1a (Kohda et al., 2007; Rummel et al., 2004b;
Nishiki et al., 1996).
The crystal structure of the BoNT/B1 binding domain in complex with both SytII and
GD1a show strong interactions with the Sia5 moiety in much the same manner as
BoNT/A1 (Berntsson et al., 2013). Although there is no direct contact between SytII and
GD1a, there is some evidence that each can influence binding to the other possibly due
the spatial arrangement of both binding sites (Atassi et al., 2014). The dual-receptors
are what enable the BoNT to target neuronal cell membranes so specifically but there
may be another method by which BoNT/B and some other serotypes interact with
neuronal membranes. In addition to the dual-receptors, BoNT/B has been reported
9




Figure 1.4: HC/B1 Dual-Receptor Complex
A schematic of the HC/B1 dual-receptor com-
plex from its crystal structure (PDB ID: 4KBB).
The ganglioside, GD1a is shown in green and
the protein-receptor, SytII is shown in red.
to interact directly with the cell membrane through an exposed hydrophobic loop
(termed the ‘lipid-binding loop’) located between the ganglioside and Syt binding
sites on the HC (Stern et al., 2018). This interaction may help the BoNT anchor itself to
the membrane, increasing the affinity to neuronal cells.
BoNT/C
BoNT/C (specifically known as BoNT/C1) is predominantly associated with botulism
in animals rather than humans (Collins and East, 1998; Lindström et al., 2004). There
are no other subtypes identified within the BoNT/C serotype – only two distinct
protein sequences that have been identified to date (UniProtKB: P18640 (Hauser et
al., 1990), Q93HT3 (Takeda et al., 2005)) which both share 99.9% identity. Perhaps
confusingly, there are two other botulinum toxins called ‘C2 toxin’ and ‘C3’ which
are not ‘traditional’ neurotoxins, but rather refer to different gene products – a binary
AB toxin and an exoenzyme, respectively (Stiles et al., 2014; Chellapandi and Prisilla,
2017; Evans et al., 2004). The mechanisms of cell-binding is of great interest despite the
association with non-human botulism because unlike the majority other BoNTs, no
protein receptor for BoNT/C1 has yet been identified (Tsukamoto et al., 2005; Kroken
et al., 2011a). Interestingly, while the conserved SxWY ganglioside-binding motif is
absent from the HC domain, BoNT/C1 is still able to bind gangliosides (Rummel
et al., 2009). Indeed, an extended hydrophobic loop termed the ‘ganglioside binding
loop’ (GBL) was reported to be essential for neuronal binding, however, the specific
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interactions to a ganglioside have yet to be determined (Kroken et al., 2011a). Crystal
structures of the BoNT/C1 HC domain in complex with sialic acid – a monosaccharide
which may indicate a the potential for ganglioside binding – revealed two potential
binding sites that are spatially independent of the GBS identified in other BoNTs
(Strotmeier et al., 2011; Karalewitz et al., 2012).
BoNT/D
Like BoNT/C, there are no subtypes of BoNT/D, of which there are multiple sequences
that share a primary sequence identity of > 96%. BoNT/D appears to recognise all
three isoforms of SV2 (Rummel et al., 2009; Strotmeier et al., 2011). Cells lacking SV2 do
not get intoxicated by BoNT/D, however this can be restored by the expression of any
of the three SV2 isoforms (SV2A, B, C) (Peng et al., 2011). It was further demonstrated
that SV2A/B knockout neurons displaying a chimeric form of SV2-LD4 (SV2A, B or C)
alone were unable to mediate BoNT/D entry despite rescuing intoxication for other
serotypes including BoNT/A and /E. Mutation of the N537 N-linked glycosylation
site of SV2 also had no effect on BoNT/D entry despite blocking entry to BoNT/E
(Peng et al., 2011). This suggests that the SV2 receptor binding domain in BoNT/D
may be distinct from other SV2-interacting BoNTs such as BoNT/A and the glycan
interaction plays less of a role. Gangliosides are also required for BoNT/D cell entry
(Strotmeier et al., 2010), however like BoNT/C, BoNT/D does not contain an SxWY
motif in the GBS although the site is still able to recognise gangliosides (Zhang et al.,
2010). It is also proposed to contain a second binding site termed Sia-1, since mutation
of this site results in reduced ganglioside binding (Kroken et al., 2011b).
BoNT/E
There are currently twelve known BoNT/E subtypes (BoNT/E1 to /E12) whose amino
acid identities vary by up to 12%. The protein receptor for BoNT/E is SV2, although
only isoforms SV2B and SV2C are capable of mediating entry (Dong et al., 2008; Stefan
et al., 2013), and in the presence of gangliosides (Kamata et al., 1986). The SxWY motif
is conserved in the BoNT/E GBS and direct binding of GT1b has been observed (Sun
et al., 2012). No crystal structures of BoNT/E in complex with receptor or ganglioside
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have yet been solved, therefore, the precise molecular basis of their interactions have
yet to be determined. The native crystal structure of BoNT/E has been solved and it
reveals a conformation that is significantly different to that of BoNT/A and BoNT/B
(Kumaran et al., 2009). As previously discussed, the HC domain wraps around the
toxin giving the protein more compact shape overall (Figure 1.1). BoNT/E is capable
of entering cells much faster than BoNT/A (Keller et al., 2004), and this domain
organisation has been proposed to prime the toxin for translocation resulting in a
faster onset of paralysis (Kumaran et al., 2009). However, investigations using various
chimeras of BoNT/A1 and BoNT/E1 showed that the speed of translocation is not
affected by the HC domain (Wang et al., 2008).
BoNT/F
In addition to BoNT/F1, there are eight other BoNT/F subtypes (BoNT/F2 to /F9)
which differ by up to 30% sequence identity. The exact protein receptor for BoNT/F1
has been reported to be glycosylated SV2 (Fu et al., 2009; Rummel et al., 2009) but
this remains to be established conclusively. For example, one study showed that
BoNT/F activity decreased when HC/A was introduced as a competitor molecule
(Rummel et al., 2009), whereas a separate study demonstrated that BoNT/F1 entry in
neurons was unaffected by a double SV2A/B knockout in cortical neurons (which have
negligible expression of SV2C) (Yeh et al., 2010). For ganglioside binding, BoNT/F1
requires gangliosides containing an α2,3-linked sialic acid on the terminal galactose,
i.e. GT1b or GD1a (Fu et al., 2009; Rummel et al., 2009). The SxWY motif is conserved
in BoNT/F and the crystal structure of the HC domain from BoNT/F1 in complex
with GD1a confirmed the existence of a GBS (Benson et al., 2011). The evidence for a
protein receptor of BoNT/F is inconclusive and further insights into neuronal binding
are needed, possibly through a structural approach.
BoNT/G
Only two protein sequences of BoNT/G are currently known to exist, and they share
99.9% amino acid identity. The protein receptor for BoNT/G is either SytI or SytII
although interestingly the interface diverges from BoNT/B and it has been found to
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possess a lower binding affinity (Dong et al., 2007; Stenmark et al., 2010; Willjes et al.,
2013). Only 5 of 14 residues involved in the BoNT/B–SytII interaction are conserved
in BoNT/G (Rummel et al., 2007; Stenmark et al., 2010). Like BoNT/B, BoNT/G also
displays a low affinity for the human SytII receptor due to a human/chimpanzee
specific mutation (Strotmeier et al., 2012). The BoNT/B HC domain was successfully
engineered to improve human SytII binding and a similar approach would be worth
investigating here if BoNT/G were to be assessed as a candidate for a human thera-
peutic (Tao et al., 2017). BoNT/G possesses the conserved SxWY motif in its GBS and
binds preferentially to GT1b (Schmitt et al., 2010). In addition to the dual-receptor
interactions, BoNT/G also contains a ‘lipid-binding loop’ (residues 1252-1256) similar
to that of BoNT/B which can directly interact with the cell membrane to further
contribute binding affinity (Stenmark et al., 2010; Stern et al., 2018), and deletion of
this loop has been shown to dramatically decrease neurotoxicity (Stern et al., 2018).
BoNT/CD
BoNTs composed of domains or regions from multiple different serotypes also exist
in nature. BoNT/CD is a mosaic toxin composed of a LC domain and a HN domain
that is most similar to BoNT/C, and a HC domain that is most similar to BoNT/D.
Interestingly the binding domain of BoNT/CD binds synaptosomes more tightly than
BoNT/D (Tsukamoto et al., 2005). This may be due to a few specific residues, K1118
and K1136 (which differ from the equivalent residues in BoNT/D, E1114 and G1132),
since mutation of these lysines results in a dramatic loss in synaptosome binding
affinity (Zhang et al., 2011). The role of these residues in binding is unknown. Protein
residues which may also interact with a ganglioside have also been identified through
crystallisation with a sialic acid molecule (Zhang et al., 2013).
BoNT/DC
The BoNT/DC chimeric protein possesses a LC domain and a HN domain with 96%
sequence identity to BoNT/D, and a HC domain similar to that of BoNT/C (74%
sequence identity) (Moriishi et al., 1996; Nakamura et al., 2010). Botulism caused by
BoNT/DC is usually found outside of humans in birds and other mammals but it has
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also been found capable of binding human neuronal cells (Nakamura et al., 2010; Peng
et al., 2012). Despite having a binding domain similar to BoNT/C, BoNT/DC targets
a protein receptor and binds to either SytI or SytII. This interaction is mediated by
hydrophobic residues, and is distinct from that of BoNT/B (Berntsson et al., 2013). The
BoNT/DC protein is particularly interesting as it appears it may not require complex
gangliosides to enter target neurons (Zhang et al., 2017a; Karalewitz et al., 2010).
However, the crystal structure of BoNT/DC in complex with Sialyl-T suggests that
BoNT/DC is capable of recognising a single sialic acid and thus potentially a range of
gangliosides. The structure also reveals the presence of an extended ‘lipid-binding
loop’ that is also observed in BoNT/B and BoNT/G (Zhang et al., 2017a; Stern et al.,
2018).
BoNT/FA(HA)
BoNT/FA was recently identified in 2014 from a case of infant botulism (Barash and
Arnon, 2014; Dover et al., 2014). At the time it was referred to as BoNT/H (and
sometimes still as BoNT/HA) due to its non-neutralisable antigenicity (Barash and
Arnon, 2014) and phylogenetic analysis of the bont sequences placed the gene in a
lineage distinct from other serotypes (Dover et al., 2014). After a protracted period of
data restriction due to supposed safety concerns (Hooper and Hirsch, 2014; Relman,
2014; Johnson, 2014) the sequence was finally released to the scientific community
after which it was determined that the molecule was a mosaic toxin composed of a
LC similar to that of BoNT/F5, an HN domain similar to that of BoNT/F1, and an HC
domain simliar to that of BoNT/A1 (Gonzalez-Escalona et al., 2014). Direct binding of
the BoNT/FA HC domain has been confirmed for glycosylated SV2C-LD4 (Yao et al.,
2017) and crystal structures of this binding domain show some slight differences with
respect to BoNT/A1 which would be consistent with a decreased affinity towards the
protein backbone of SV2 (Yao et al., 2017; Davies et al., 2018a). Although no ganglioside-
bound structure of BoNT/FA has yet been solved, the structure of the GBS appears to
maintain the same fold as that observed for BoNT/A1 (Davies et al., 2018a). SV2 is
likely the protein receptor for BoNT/FA and direct binding has been confirmed for
glycosylated SV2C-LD4 (Yao et al., 2017). The BoNT/FA sequence contains mutations
with respect to BoNT/A1 which result in decreased affinity towards the protein
backbone of SV2, as determined by a pull-down assay against non-glycosylated SV2C,
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while the equivalent residues involved in glycan binding remain unchanged (Yao et al.,
2017). The effect of these mutations towards different isoforms of SV2 remains to
be seen. The ganglioside-binding site is able to maintain the same fold as BoNT/A1
but no ganglioside bound structures yet exist so the exact interactions remain to
be determined (Davies et al., 2018a). In recent assays using cultured rat embryonic
spinal cord neurons and rat cortical neurons, BoNT/FA was found to be much more
potent than BoNT/A1. However, counter intuitively the toxin was much less potent
when assayed using an ex vivo mouse phrenic nerve hemidiaphragm (mPNHD). These
results along with the methods used for each assay point toward a toxin that may have
a slow speed of onset despite a highly active LC (Hackett et al., 2018). Understanding
interactions of BoNT/FA with its receptors are crucial to both determine what causes
intoxication differences and for developing novel therapeutics.
BoNT/X
Recent bioinformatic analysis of online protein databases identifed a novel BoNT
serotype termed BoNT/X (Zhang et al., 2017b). C. botulinum strain 111, that already
was known to express BoNT/B, was found to contain the gene for another BoNT
molecule that shared low primary sequence identity to other serotypes (<30%) and was
previously unidentified. It is unknown yet whether this molecule is capable of causing
human botulism. This suggests that this toxin significantly diverged from other
serotypes during its evolution, despite this, recent structural characterisation of the LC
has revealed a core fold common to all BoNTs (Masuyer et al., 2018). Little is known
about the BoNT/X HN and HC domains and attempts are underway to determine the
specific receptor/s that it targets and how it functions in vivo. The BoNT/X HC does
contain an SxWY sequence motif indicating it potentially shares similar ganglioside
binding characteristics with other BoNTs. Due to its divergence and low sequence
similarity to existing BoNTs, structural and functional characterisation could lead to
new insights into receptor binding which could be exploited for future therapeutics.
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BoNT-like proteins
Considering that BoNTs are the deadliest biological agents that exist, it was surprising
to find BoNT-like proteins produced by non-Clostridium species. The first was found in
2015 and is now referred to as ‘BoNT/Wo’, named after the bacterium that produced it,
Weissella oryzae SG25 (Tanizawa et al., 2014; Mansfield et al., 2015). Characterisation of
the BoNT-like protein determined its differences to be significant enough that it is not
recognised using existing BoNT antisera, specific for BoNT/A – BoNT/G, although
some cross-reactivity with anti-BoNT/C and anti-BoNT/D was noted (Zornetta et al.,
2016). BoNT/Wo does not contain any typical BoNT motifs in the receptor-binding
domain (Zornetta et al., 2016). This is be consistent with zero reported cases of
botulism in humans; indeed, it has been speculated that BoNT/Wo may instead
target SNARE-mediated plant defence systems (Mansfield et al., 2015). Identification
of the receptors for BoNT/Wo may shed new light on alternative receptor-binding
mechanisms that BoNTs and BoNT-like proteins can utilise. More recently, another
BoNT-like gene cluster was discovered in the bacterium Enterococcus faecium, which is
a ubiquitous commensal microorganism commonly found in the gut of mammals. The
BoNT-like protein, referred to as BoNT/En (or eBoNT/J), possesses many traditional
BoNT motifs, including a HExxH zinc-binding motif in the LC and a ganglioside-
binding SxWY motif in the HC domain (Zhang et al., 2018; Brunt et al., 2018). Early
studies indicate that rodents do not possesses the receptor/s for BoNT/En intoxication
(Zhang et al., 2018) and so it is unlikely to also affect humans.
1.2.2 Translocation
The mechanism of BoNT intoxication is a multipart process, after neuronal cell binding
the BoNT is internalised while attached to its receptors into an endocytic vesicle. The
protease action of the LC is of no use within a vesicle as its target peptides are within
the cytosol, thus the BoNT must translocate the LC through the vesicle membrane.
This process is the least well understood part of the intoxication process and recent
advances in techniques such as cryo-electron microscopy have yet to uncover the
exact process. Following endocytosis, the vesicle matures into an endosome and the
endosomal pH is decreased by proton pumps within the vesicle membrane to pH
≈ 5.4 (Overly et al., 1995), which causes BoNTs to undergo a conformational change.
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Structural changes of the entire BoNT have been observed in response to pH change,
and it appears that these changes are reversable (Chellappan et al., 2015). The exact
mechanism of translocation is still not well understood but it is proposed that the HN
forms a pore through which a partially unfolded LC passes into the neuronal cytosol
(Koriazova and Montal, 2003; Pirazzini et al., 2016; Fischer et al., 2012). Evidence of a
transmembrane pore, whose internal diameter is estimated to be ∼15 Å, is too small
to accommodate the fully-folded LC (Cai et al., 2006). In order to cross the pore, the
LC must partially unfold, likely into a molten globule state (Cai et al., 2006), and
reassemble into a function protease in the cytosol. The other BoNT domains, the HC
and HN, may act as chaperones that helps to drive the LC translocation through a
pore (Fischer, 2013). Following translocation, the LC remains bound to the HN on the
cytosolic side due to a single disulfide bond. The bond bridges two cysteine residues
close to a surface exposed loop which is cleaved post-translation leaving the LC and





Figure 1.5: BoNT Activation Loop and Inter-Chain Disulfide Bond
The activation loop (dashed line) and C429-C435 disulfide bond from the BoNT/A1 crystal
structure (PDB ID: 3BTA) (Lacy et al., 1998). Parallel lines on the activation loop indicate the
general area where the peptide is nicked into a di-chain activated protein.
The specific protease responsible for the inter-chain proteolysis is unknown though
likely a host protease (Dekleva and Dasgupta, 1990), the chain may also be cleaved by
other proteases such as trypsin and Lys-C as is the case when producing recombinant
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BoNTs (Hackett et al., 2018). Single-chain BoNTs may still have some residual activity
(Shi et al., 2008), but in the case of therapeutic molecules this would be inefficient. The
reduction of the interchain disulfide bond is mediated by thioredoxin (Trx), which
itself is regenerated by thioredoxin reductase (TrxR). Disulfide cleavage is essential to
full intoxication, inhibition of Trx is sufficient to block the LC release (Pirazzini et al.,
2014; Zanetti et al., 2015).
1.2.3 Cleavage of SNARE Target
The paralytic action of the BoNT is a result of the LC alone, and the other domains
play no role after binding and translocation (de Paiva and Dolly, 1990). The BoNT
LC is a zinc-dependent protease which cleaves a soluble N-ethylmaleimide-sensitive
factor attachment protein receptor (SNARE). Cleavage of any one of the three SNARE
proteins is sufficient to block SNARE complex formation, preventing vesicle-plasma
membrane fusion and thus inhibiting exocytosis and release of acetylcholine, causing
flaccid paralysis. The structure of the LC is highly conserved across all BoNTs despite
some sharing as little as 30% amino acid identity. BoNT/A, /C and /E cleave the
protein SNAP-25, while BoNT/B, /D, F, and /G cleave VAMP1, 2, and 3 (Schiavo
et al., 1993a; Williamson et al., 1996; Schiavo et al., 1992; Schiavo et al., 1993b; Schiavo
et al., 1994). The BoNT/C LC the outlier of all LCs as it is able to additionally cleave
Syntaxin I (Blasi et al., 1993b). Each BoNT LC possesses extremely high specificity for
its target SNARE protein in all cases, cleaving at a single peptide bond within the
SNARE (Rossetto et al., 1994). The first crystal structure of a BoNT LC in complex with
a SNARE peptide was determined by Breidenbach and Brünger (2004), and it revealed
a range of exosites which are responsible for the remarkable specificity (Figure 1.6).
The recent emergence of novel BoNT serotypes and BoNT-like proteins has increased
the repertoire of potential SNARE targets. BoNT/Wo, while not thought to induce
botulism in humans, is capable of cleaving human VAMP at a unique location (Trp89–
Trp90) (Zornetta et al., 2016). In addition, following the discovery of BoNT/X, its
LC was investigated and found to cleave non-canonical substrates such as VAMP4,
VAMP5 and Ykt6 while still containing the core fold common to all BoNTs (Zhang
et al., 2017b; Masuyer et al., 2018).
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a b
Figure 1.6: LC/A1 in Complex with SNAP-25
(a) Crystal structure of BoNT/A1 LC (green) in complex with its SNARE target, SNAP-25 (red;
PDB ID: 1XTG, Breidenbach and Brünger, 2004). (b) Surface representation displaying the
surface charge of the LC in the absence of the SNAP-25 peptide.
At high doses, some BoNTs can not only cause blockage of synaptic vesicle release but
also result in cell death (Peng et al., 2013). The SNARE proteins Syntaxin and SNAP-25
are both essential for membrane fusion functions that are independent of synaptic
vesicle release and near complete loss of them can result in neuronal cytotoxicity
(Peng et al., 2013; Berliocchi et al., 2005).
1.2.4 Duration of Action
The duration of action between different BoNT serotypes and even high identity
subtypes can vary drastically. The cause of this variation is not fully understood and
may be influenced by a range of factors. An example of duration variation between
subtypes was demonstrated through a long-term study of BoNT/A1 - /A5 activity
within a mouse model. It was determined that BoNT/A1, 2, 4, and 5 have a similar
duration of action (> 10 months), while the duration of BoNT/A3 is significantly
shorter (around 3 months) (Pellett et al., 2015). This observation has also been con-
firmed in cultured neurons (Whitemarsh et al., 2014). The mechanism controlling the
duration of action is not fully understood but it is likely a result of the LC alone. An
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engineered hybrid toxin containing the LC/A1 and LHN/A3 was found to maintain a
long duration of action whereas a hybrid containing LC/A3 and LHN/A1 resulted
in a much shorter duration (Pellett et al., 2018). There is some evidence to suggest
that the localisation of the LC within the cytosol is a significant factor that determines
its duration and efficacy, and as such, mutations that affect localisation have been
identified. The LC of BoNT/A1 is known to localise at the plasma membrane within
the cytosol while A3 is spread throughout the cytosol.
The terminal residues of LC/A1 may contain signals which direct the LC to the
plasma membrane, in particular, disruption of a dileucine motif at the C-terminus
(D/EXXXLL) present in LC/A may cause the LC to become more diffuse in the cytosol
(Fernández-Salas et al., 2004). Mutation of residues in and around the dileucine motif
can be used to modulate the duration of action of BoNT/A1 (Scheps et al., 2017). This
alone cannot fully explain the differences between BoNT/A1 and /A3 as both contain
the dileucine motif. All BoNT/A subtypes contain the motif whereas it is not present
in any other BoNT, as other serotypes also display varying durations with respect to
each other, another mechanism may be at play. The N-terminus of the LC has also
been implicated with membrane localisation. N-terminal residues of BoNT/A1 LC
can interact with high-affinity directly with the SNARE target, SNAP-25, present at
the plasma membrane. An N-terminal truncation of 7 amino acids causes the LC to
become more diffuse in the cytosol rather than strongly associated with SNAP-25
at the plasma membrane, but intriguingly does not affect the longevity of SNAP-25
cleavage (Chen and Barbieri, 2011). A double N-terminal mutant of BoNT/A1 LC
(K6A, K11A) also results in loss of association at the membrane, the mechanism for
this is not fully understood (Chen and Barbieri, 2011). Interestingly, BoNT/A3 is the
only BoNT/A subtype that has a mutation at K11R. The ability to remain bound at
the plasma membrane may help the LC to avoid proteolysis and increase the protein
half-life, remaining active for a longer period of time but it is certainly not the only
cause.
Another mechanism to increase the half-life and avoid degradation within the cytosol
may involve avoiding ubiquitination by host ubiquitin-ligases. A protein implicated in
ubiquitination, TRAF2, has been found to associate directly with BoNT/E LC, a short-
lasting BoNT, promoting proteasomal-degradation within the cell, while BoNT/A
LC appears not susceptible (Tsai et al., 2010). More recent evidence suggests that
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the BoNT/A LC is also targetted by a ubiquitin-ligase, HECTD2, but it is able to
evade ubiquitin-dependent degradation by direct association with the deubiquitinating
enzyme VCIP135/VCPIP1 (Tsai et al., 2017). Together, these data suggest that the
localisation of the LC within the cytosol, and its ability to avoid degradation by host
proteolysis, are what drives the long duration of action identified in some BoNT
subtypes.
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Table 1.1: BoNT Receptors and SNARE-Targets
Serotype Protein-receptor Ganglioside-recptor SNARE-target
BoNT/A SV2A1, SV2B1, SV2C1,2 GT1b3,4, GD1a3, GM13 SNAP-255,6
BoNT/B SytI7, SytII7 GD1a8, GT1b8 VAMP9
BoNT/C None identified† GT1b10,11 = GD1b10,11 > GD1a11 > GM1a11 SNAP-2512, Syntaxin13
BoNT/D SV2A14, SV2B14, SV2C14 GM315, GM215, GM115 and GD1a15, or GM315 VAMP6
BoNT/E SV2A16, SV2B16 GD1a17, GT1b17, and GQ1b17 SNAP-256
BoNT/F SV2A18,19, SV2B18,19, SV2C18,19 GT1b18,19 = GD1a19 > GM319 VAMP20
BoNT/G SytI21, SytII21 Unknown preference22‡ VAMP23
BoNT/X24 VAMP24, Ykt624
† BoNT/C utilises dual ganglioside binding sites and has no protein receptor.
‡ While gangliosides have been confirmed as a receptor, the ganglioside preference is yet to be determined.
1 Dong et al. (2006), 2 Mahrhold et al. (2006), 3 Yowler et al. (2002), 4 Rummel et al. (2004b), 5 Blasi et al. (1993a), 6 Schiavo et al. (1993a),
7 Nishiki et al. (1994), 8 Ogasawara et al. (1991), 9 Schiavo et al. (1992), 10 Tsukamoto et al. (2005), 11 Karalewitz et al. (2012), 12
Williamson et al. (1996), 13 Blasi et al. (1993b), 14 Peng et al. (2011), 15 Strotmeier et al. (2010), 16 Dong et al. (2008), 17 Kamata et al.
(1993), 18 Rummel et al. (2009), 19 Fu et al. (2009), 20 Schiavo et al. (1993b), 21 Rummel et al. (2004a), 22 Dong et al. (2007), 23 Schiavo
et al. (1994), 24 Zhang et al. (2017b)
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1.3 Applications of BoNTs
Although BoNTs are deadly toxins with the potential for misuse as bioweapons,
they are perhaps surprisingly best known for their use in cosmetic applications
(Hexsel et al., 2011). For over 30 years the main application has been the treatment
of glabellar lines, however recently the powerful action of BoNTs has been exploited
for many therapeutic applications including hyperhidrosis and spasmodic dysphonia
(Bhidayasiri and Truong, 2008; Watts et al., 2008; Kessler et al., 1999). There are
currently four different BoNT formulations (Dysport, Botox, Myobloc and Xeomin)
which are each approved for use in multiple indications within the United States and
Europe (Kane et al., 2015; Fonfria et al., 2018).
Currently all approved BoNT formulations include protein that has been purified
directly from its associated C. botulinum strain and all apart from Xeomin contain
addition neurotoxin associated proteins. When considering BoNTs as therapeutic
agents, it would be advantageous to produce a cleaner product, free of contaminating
proteins, so as to minimise the potential for an immunogenic reaction (Benecke,
2012). Recombinant neurotoxins provide the answer to a simpler production method
and expression systems including E. coli are being explored. There is currently one
recombinant BoNT in phase I clinical trials (Fonfria et al., 2018).
The modular structure of BoNTs allows flexibility with respect to protein engineering
and this has been exploited to produce novel therapeutics that are capable of targeting
different cell types. By replacing the binding domain with a different targetting
peptide the BoNT can be designed to inhibit SNARE mediated exocytosis from cells
other than neuronal cells . These novel proteins have been termed Targetted Secretion
Inhibitors (TSIs). One example of a TSI is a protein which consists of the LC and HN
domains from BoNT/D and a fragment of the growth hormone releasing hormone
(GHRH) which targets pituitary somatotroph cells through binding to the GHRH-
receptor (Masuyer et al., 2015). By inhibiting vesicle release from pituitary somatotroph
cells this molecule can be used to investigate acromegaly (Garcia et al., 2013)
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1.4 Summary
BoNTs are highly specific and potent exotoxins that can be exploited for therapeutic
gain. Our knowledge of the molecular aspects of botulinum neurotoxin, such as
mechanism of cell targeting and internalisation is incomplete. We have yet to fully
understand the binding mechanism of others and also how subtle amino acid differ-
ences may result in differences of intoxication (i.e., between subtypes). From what we
know so far, X-ray crystallography has suggested that the mechanism of binding is
more complex than was initially thought, and many serotypes have evolved unique
mechanisms of receptor recognition. It is possible that BoNTs, such those as from the
/A, /D and /E serotype may accommodate heterogeneous glycosylation of its protein
receptor and all may target a variety of gangliosides to ensure successful binding to
the neuronal cell membrane. It is not a trivial task to determine how BoNTs bind to
their receptors on neuronal cell membranes, especially when trying to replicate the
conditions in vivo. With the recent discovery of new BoNTs and BoNT-like molecules
in other bacterial species, this raises questions regarding the evolution of the bont gene
cluster, their ability to be transferred between species, the potential implications to
biosafety, and the need for an agreed, consistent naming convention to avoid confusion
and ambiguity (Mansfield and Doxey, 2018; Williamson et al., 2017). Fast characterisa-
tion of exiting subtypes along with each of these novel toxins would provide a greater
understanding of the mechanisms employed for intoxication and how different BoNTs
utilise distinct methods. In particular, atomic data from individual subtypes would
help to reveal the causes of different intoxication properties and could be used for
structural and functional analyses, providing insights for the design of novel BoNTs
(Kammerer and Benoit, 2014).
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1.5 Aims
1. Investigate how sequence variation affects the BoNT receptor binding do-
main structure. BoNTs are extremely potent neurotoxins that have a tremen-
dous potential for treating a number of conditions. They first target neuronal
cell membranes and bind receptors on the cell surface. Very little research has
focussed on how the sequence variation between subtypes affects the structure
and function of the receptor binding domain. The HC domains from six BoNT/A
subtypes will be produced in order to investigate whether they were suitable for
structural studies. Crystallisation will be attempted for each and structures will
provide an insight into the affect of subtle differences on receptor binding and
become the basis for future modelling of engineered recombinant proteins.
2. Determine the domain organisation of full-length BoNTs in solution. Follow-
ing receptor binding, BoNTs must enter the cytosol of the cell. The translocation
of BoNTs into the cytosol after neuronal cell entry is one of the key steps of
intoxication for which very little is known. The crystal structure of BoNT/E
unveiled a novel conformation of the protein compared to the existing BoNT/A
structure. It has been suggested that the ‘closed’ conformation is what allows
BoNT/E to translocate faster into the cytosol than other BoNTs. Investigation of
the solution structure will be performed to confirm whether the crystal structure
is representative of the BoNT in vivo.
3. Generate a BoNT protein sequence database. Finally, to further highlight
BoNT variation and in an effort to improve reporting of the exact BoNT protein
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2.1 Introduction
X-ray crystallography is a powerful technique that is used to uncover and understand
the molecular structure of molecules including proteins. Determining the structure of
a protein allows researchers to deduce the function and other aspects of the mechanism
of action through careful analysis of atomic positions. Existing knowledge of a protein
and its function as determined through biochemical characterisation can complement
a protein crystal structure leading to full understanding of the biochemical process
that it is involved in.
Proteins are extremely small and generally range between a few and tens of nanome-
tres – too small to view by methods such as light microscopy due to the wavelength
of visible light. Electromagnetic radiation in the visible range is useful for character-
ising protein samples using techniques such as circular dichroism (CD) or dynamic
light scattering (DLS) but these methods are not able to produce precise information
about the atomic positions of atoms within the molecule. Instead X-rays, with their
wavelength being much shorter than visible light, can be used to visualise proteins.
X-ray crystallography exploits a property of crystals called diffraction where photons
interact with repeating planes of atoms and are reflected where they can be detected.
The first crystal structure determined was that of myoglobin in 1958 by John Kendrew
et al., and since then over 130,000 protein structures have been released publicly in the
Protein Data Bank (PDB). Crystallography, as the name suggests, requires crystals of
the molecule of interest to be produced – this is the major challenge of the technique,
one which, while now capable of automation, still poses a challenge more than half a
century after the first structure. Other techniques for studying protein structure such
as NMR or cryo-electron microscopy avoid the need for crystals but have their own
drawbacks. In general, NMR has an upper size limit of ~ 40 kDa for the protein under
investigation while cryo-electron microscopy has a lower size limit of ~ 150 kDa.
Many of the results presented in this thesis make extensive use of X-ray crystallography
and so an overview of the technique and theory is given below.
27
2. X-ray Crystallography 2.2. Crystals and Symmetry
2.2 Crystals and Symmetry
The production of proteins crystals or other small molecule crystals is usually a
challenging task and the exact conditions that result in crystallisation must be exper-
imentally determined. It is now common to screen hundreds, if not thousands, of
conditions to find the ideal environment to crystallise a specific protein (Stock et al.,
2005). One method to produce protein crystals is by vapour diffusion (Figure 2.1)
(Luft et al., 2014). Here, a small volume of concentrated protein solution is mixed with
another small volume of the screening condition. A larger reservoir of the screening
solution is sealed within the same well as the protein solution. Due to the dilution
of the screening condition when mixed with protein, the reservoir will contain a
higher concentration of precipitant and vapour diffusion will occur between the two.
Water will move from the protein solution to the reservoir causing the precipitant
and protein concentration to increase, in some cases to a supersaturated state. The
screening condition will usually lead to either precipitation of protein or a clear drop,
but very occasionally the supersaturated protein solution will nucleate and crystallise
– some luck is needed.
a b
c
Figure 2.1: Vapour Diffusion
Proteins can be crystallised by vapour
diffusion in either a (a) sitting-drop
or (b) hanging-drop format. Water
vapour will diffuse between the drop
and the reservoir with a net flow to-
ward the reservoir causing the protein
and precipitant concentration to rise.
(c) A schematic of the crystallisation
phase diagram. The dashed-line de-
picts the path taken during a success-
ful crystallisation experiment.
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The simplest unit within a crystal is called the asymmetric unit which can combine to
form a repeating unit cell. The asymmetric unit is duplicated, translated and rotated as
described by specific symmetry operations to generate the unit cell. Mirror symmetry
is also possible in small molecule crystals but does not occur in protein crystal due to
the presence of chiral centres of amino acids. The unit cell can produce a crystal when
repeated and translated, which in turn leads to a repeating arrangement of atoms and
planes. The unit cell is a parallelepiped that can be defined by three vectors, a, b, and







Figure 2.2: Unit Cell
Crystals are made up of repeating units termed unit cells
which are parallelepipeds defined by their lengths, a, b,
c and the angles between, α, β, γ.
There are seven types of crystal systems with each specifying allowed vector lengths
and angles of the unit cell (Table 2.1). The vector lengths and angles are a result of the
underlying symmetry and can be used to indicate the point group of a crystal. The
point group describes the rotational symmetry of the asymmetric unit along the X, Y,
and Z axis. Further to the point group there exist screw axis, denoted by a subscript
number (e.g. P21) which describes a combined rotation and translation. Combining
all possible symmetries (point groups and screw axes) there exist 230 difference space
groups. However as proteins are chiral molecules and mirror symmetries are not
available, protein crystals are limited to one of a possible 65 different space groups.
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Table 2.1: Crystal Systems
The names of different crystal systems and their possible point groups given the possible values
of the unit cell lengths a, b, c, and angles α, β, γ. Point groups are given in Hermann-Mauguin
notation (Hermann, 1928; Mauguin, 1931).
System Angles (◦) Cell-lengths Point group
Triclinic α 6= β 6= γ 6= 90 a 6= b 6= c 1
Monoclinic α = γ = 90 and β 6= 90 a 6= b 6= c 2
Orthorhombic α = β = γ = 90 a 6= b 6= c 222
Tetragonal α = β = γ = 90 a = b 6= c 4, 422
Trigonal α = β = 90 and γ = 120 a = b 6= c 3, 32
Hexagonal α = β = 90 and γ = 120 a = b 6= c 6, 622
Cubic α = β = γ = 90 a = b = c 23, 432
2.3 X-ray Diffraction
To determine a protein crystal structure is to determine the arrangement of atoms
within the crystal. The periodic and repeating nature of a crystal can be exploited
with the use of X-rays to uncover the underlying atomic arrangement. When subjected
to a intense beam of X-ray photons, the repeating planes within the crystal, that
are themselves a result of the underlying repeating atomic arrangement, cause the
photons to diffract and exit the crystal at a different angle to the incoming angle.
During diffraction the incoming photons will simultaneously interact with all atoms
of a crystallographic plane and its phase will be affected upon diffraction. If the
phase angle of the reflected wave constructively interferes with the phase angle
of waves reflected by equivalent crystallographic planes then the intensity of the
diffracted wave can be measured. Bragg’s law (Equation 2.1) describes the condition
on the scattering angle (θ) at which constructive interference of the diffracted waves is
strongest depending on the incoming wavelength, λ, and the interplanar spacing, d
(Bragg and Bragg, 1913). Under these specific conditions of constructive interference,
the properties of the diffracted X-ray photons can be used to calculate the internal
crystallographic arrangement.
nλ = 2d sin θ (2.1)
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Figure 2.3: Bragg‘s Law When a
crystal diffracts X-rays, peaks are
observed when the angle of inci-
dent X-rays equals the angle of re-
flected X-rays and when the path
length difference, 2d sin θ, is equal
to n wavelengths.
2.4 X-ray Diffraction Data Collection
The interaction of X-rays with matter results in many phenomena including absorption,
fluorescence, and scattering. The aim of a diffraction experiment is to accurately
determine the intensities of the Bragg reflections from a crystal which result from X-
ray scattering. When collecting diffraction data, there are a number of parameters that
can be adjusted. In the past it was typical to collect X-ray diffraction data ‘in-house‘ on
an X-ray source such as a rotating copper anode. In this case, the X-ray source consists
of an electron beam from a cathode hitting the anode which causes atoms within the
anode to lose an inner-shell electron. A higher energy outer-shell electron is then able
to fill its place, emitting an X-ray photon in the process. However, it is now routine to
screen crystals and collect X-ray diffraction data at a synchrotron source due to their
increased availability. Synchrotrons have the enormous benefit of producing highly
brilliant X-ray light, enabling fast and high-resolution data collection. Synchrotrons
produce X-rays by first accelerating electrons to high energies around a ‘storage-ring’.
The ‘storage-ring’ is not actually circular and is instead a polygon consisting of many
straight sides connected by bending magnets. As the electron beam changes direction
through each bending magnet on the storage ring, an intense beam of radiation is
released. Straight sections of the synchrotron storage-ring can also be used to produce
beams of radiation through the use of an undulator. An undulator consists of a linear
series of magnets each with opposing poles that cause the electron beam to follow
the magnetic field in a wave, releasing radiation in the process. The beams of X-ray
radiation produced at a synchrotron is then focussed and the wavelength tuned for
experimental use on beamlines.
On the beamline, a crystal is mounted on a goniometer and centred so that the X-ray
beam passes directly through. A goniometer is a device that allows precise positioning
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of the crystal – modern goniometers allow up to six axes of movement. To collect X-ray
diffraction data, the crystal is typically centred with respect to the beam and rotated
around one axis, while images of diffracted photos recorded at regular intervals
(Figure 2.4). On modern, high-brilliance beamlines with fast pixel-array detectors it
is now common to collect fine-sliced and low-intensity data. Fine-slicing refers to an
X-ray data collection strategy where small oscillations (typically around 0.1◦) of the
goniometer are used to collect a greater number of diffraction frames, leading to an
increase in data quality (Mueller et al., 2012). Instead of full-reflections being recorded
on a single frame, fine-slicing results in the recording of partial reflections which can
give a much greater background separation and thus a better measurement of the
true reflection intensity. Pixel-array detectors also have a much greater signal-to-noise
ratio and can detect single diffracted photons (Broennimann et al., 2006). Inclusion
of weak-intensity X-ray diffraction data has been shown to not only improve the
quality of crystal structures (Wang and Wing, 2014) but also allow collection of near
radiation-damage free data (Carugo and Djinović, 2005).
Many macromolecular X-ray crystallography beamlines at synchrotrons are setup to
have a fixed energy near to the selenium k-edge (12.6578 keV). While ideal for solving
selenomethionine labelled proteins by Se-SAD or MAD, this energy can also exploit
the anomalous scattering of zinc, which is natively present among many proteins
(Figure 2.5).
2.5 Cryo-cooling Crystals
Before x-ray data collection, it is now common practice to cryo-cool the crystals to
a temperature of 100 K to mitigate some effects caused by X-ray induced radiation
damage. The cryo-cooling of crystals comes with its own set of limitations. The
collection of diffraction data at room temperature is increasingly avoided, however
in some rare cases cryo-cooling can disrupt the crystal lattice and room temperature
collection is necessary. Another problem with the cooler temperatures is ice-formation.
Typically crystals are mounted onto a loop whereby the crystal is surrounded by a
small amount of the crystallisation solution before plunging into liquid nitrogen. This
crystallisation solution can form ice crystals which can both cause disruption to the
crystal lattice and/or the ice crystals themselves can diffract X-ray photons, producing
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Figure 2.4: Diffraction An example diffraction image from a crystal of botulinum neurotoxin
HC/A1. Each spot (or reflection) is a result of diffraction that satisfies Bragg‘s law. The red
cross indicates the location of the beam centre, with crystals diffracting to higher resolutions,
the further their spots from the centre.
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Figure 2.5: X-ray Absorption and Scattering Factors. Theoretical absorption scattering factors
for sulfur, selenium and zinc over the energy range available accross MX beamlines at Diamond
Light Source. Energy can be readily converted to wavelength using E = hcλ .
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unwanted artefacts in recorded data (Parkhurst et al., 2017). Methods to avoid ice
formation aim to increase the cooling rate through fast quenching into liquid nitrogen
and cryo-protecting the crystal through the addition of chemicals which disrupt ice
formation such as glycerol (Warkentin and Thorne, 2007). At cooler temperatures, the
radiation damage caused to the crystal by the X-ray beam is greatly reduced (Low
et al., 1966). Radiation damage is a major concern, especially when collecting data
using a high brilliance x-ray source such as a synchrotron. X-rays can cause damage to
protein crystals by producing reactive species, for example H∗ from solvent, directly
damaging covalent bonds or through thermal energy dissipation (Carugo and Djinović,
2005). By reducing the temperature of the crystal and surrounding mother liquor to
100 K, the spread of reactive species within the crystal is reduced and thermal damage
becomes less of a problem.
2.6 X-ray Data Reduction
2.6.1 Indexing and Integration
Following data collection the location of each reflection on the diffraction image is
recorded. This is then converted to a Miller Index, which related the reflection to
a specific plane that produced the diffracted photons, and the Laue group of the
diffracting crystal can then be determined following the conditions set out in Table 2.1.
The data are then integrated across images to calculate the intensity of each measured
reflection. The intensity of a given reflection is the result of subtracting the background
intensity from the recorded peak intensity. Following integration, the full space group
and be inferred from systematic absences within the list of reflections. The space group
can be determined with a high confidence in most cases but it can not be confirmed
until the structure has been solved. Improvements in software and automation have
led to this once time consuming process now only taking a matter of minutes following
collection of a full X-ray dataset.
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2.6.2 Scaling and Merging
After integration, the data are scaled to correct for some experimental variables during
data collection. At modern synchrotrons, the X-ray beams are extremely stable but
still can have slight variations of intensity during the course of an X-ray diffraction
experiment. The process of scaling compares integrated reflections between images
and adjusts their intensities to account for some of the non-uniformity. Following
scaling the data are then merged to determine the average intensity for each of the
Miller indices and their associated standard deviation. During merging, a number
of statistics are used to assess the quality of the collected data across bins or ranges
of resolution. By recording multiple observations of the same reflection, one can
determine to what extent they agree with one another and if there are any outliers.
Most scaling programs will remove weak or poor data which is classed as an outlier
with respect to other observations. An early method to determine the quality of















The Rmerge sums for all reflections: the difference between the intensity of a measured
reflection and the average of all intensities for the same reflection. Lower Rmerge values
typically indicate better agreement between all observations of the same reflections
and thus better data overall. When using data that contains a high multiplicity – that
is, many observations of the same reflections – such as those merged from multiple
crystals or datasets, the Rmerge quantity is unable to accurately reflect the data quality.
Rmerge will increase with multiplicity even when the included data is of high quality. A
new quality indicator, Rmeas (Equation 2.3), was introduced by Diederichs and Karplus
(1997) which is a modification of Rmerge that accounts for multiplicity. Rmeas is obtained
by adjusting Rmerge by a value of
√
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Rmeas is always greater than Rmerge but as the data multiplicity increases toward infinity,
they will become equal. To realise the importance of a quality indicator for datasets
of high multiplicity, Rpim was created. Rpim is used to give an indication of the data


















Another method to quantify the quality of unmerged data is by determining the
correlation coefficient between two half-datasets (CC1/2). To calculate the CC1/2,
reflections are first be binned by resolution and then split into two half-datasets. A
Pearson’s correlation coefficient is then used to calculate the agreement (Equation 2.5).
At higher resolutions the spot intensity decreases and the data becomes increasingly
noisy thus, the correlation between half-datasets decreases. A CC1/2 calculated from
un-binned data is not helpful as low-resolution reflections tend to overpower the
calculation.
CC1/2 =
∑(ai − ā)(bi − b̄)
√
∑ (ai − ā)2
√
∑ (bi − b̄)2
(2.5)
Assigning reflections randomly to one of the half-datasets will occasionally result in
a situation where you are left with a lone reflection. For example, when a unique
reflection is observed an odd number of times. In such a case, a random number can
be assigned as its pair in the opposing half-dataset (Prof. Kay Diederichs, personal
communication, 25th May 2017). Including random data in this way can result in
different outcomes if the CC1/2 is calculated more than once. To overcome this
problem some programs implement a loop to calculate the value multiple times and
then report the average value. An alternative approach suggested by Assmann et al.
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Each of these metrics is used by a crystallographer to assess the recorded data quality
during reduction of the diffraction images into merged data. Abnormal values, such
as a particularly high Rmeas for low multiplicity data indicates problems which may
cause issues during structure solution. Many data problems are the result of poor
data collection strategies or data artefacts from ice-rings but some are simply the
result of the intrinsic properties of a particular crystal. These metrics are also used to
determine where to decide a resolution cut-off or in other words, deciding when the
data simply becomes noise. Some publications have suggested that data in the highest
resolution shell should be included as long as the CC1/2 is greater than 0.1 (Karplus
and Diederichs, 2015) and indeed there seems to be little negative impact to the final
model from including this weak data (Evans and Murshudov, 2013).
2.7 Solving a Crystal Structure
As mentioned in the previous sections, recorded X-ray diffraction data contains the
location of each reflection on the detector and thus its Miller index, and the intensity
of each reflection. A third parameter is needed to calculate the underlying atomic
structure and that is the phase angle of each reflection. There is no direct way to
record the incoming phase and so this information is lost. To convert the recorded
data into electron density, into which a molecular model can be built, the information









|F(hkl)| exp[iφ(hkl)] exp[−2πi(hx + ky + lz)] (2.7)
Here, the structure factor amplitute, F(hkl), is directly proportional to to the square
root of the intensity of each reflection, but the phase of each reflection, φ(hkl), must
be known or calculated. In an X-ray diffraction experiment there are three ways
to calculate or estimate the phase of each reflection – direct methods, experimental
phasing or molecular replacement – with the latter of these methods most commonly
used in modern protein crystallography due to the complexity of protein structures.
Direct methods relies on prior knowledge that correct phases will result in a positive
electron density map which is evenly distributed within the unit cell. It involves
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multiple trials whereby the phases are estimated and in a small number of cases,
where enough of the phases are correct, the structure can be solved (Hauptman, 1997).
Molecular replacement exploits the similarity between proteins of similar sequence
and thus presumably similar structure to estimate the unmeasured X-ray diffraction
phases (Rossmann, 1990). First the Patterson function is calculated from both the
experimental data and the existing molecular model. A Patterson function is derived
from the electron density equation but with the phase contribution set to zero, resulting









|F(hkl)|2 exp[−2πi(hx + ky + lz)] (2.8)
This results in two 3-dimensional representations (maps) of the intermolecular vectors
and intramolecular vectors within the unit cell, which appear as peaks. The vectors
can be measured and atomic positions calculated. The search model is then rotated
and a new map calculated until there are peaks which match the experimental data.
Following a rotation search, a translation search is carried out in the same manner.
Once a highly likely solution has been found, the calculated phases from the search
model can be included with the F(hkl) of the experimental data and electron density
can be determined (Rossmann, 1990). Molecular replacement is the most common
approach to solving crystal structures now as only partial knowledge of the protein
fold is needed (McCoy, 2007). Modern software is further pushing the boundaries
of molecular replacement and in the case of high resolution data, a small amount of
protein fragments such as α-helices can suffice (Sammito et al., 2014).
2.8 Refinement of the Atomic Model
The starting model must be manually built or edited into the density, in real space,
following phasing, be it experimentally or from molecular replacement. The two
most common types of electron density map are 2Fo − Fc and Fo − Fc where Fo is the
observed structure factor amplitudes and Fc are the amplitudes calculated from the
atomic model. The 2Fo − Fc map is what one would usually build the atomic model
into, it is the best available estimate for the true electron density. The Fo − Fc map is
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known as a Fourier difference map, simply because it displays differences between
the model and the crystal – positive differences indicate the model does not account
for some electron density and negative differences are the opposite. Generally, the
electron density toward the start of model building is poor as the phases need to
be improved from the model. Some parts of the protein structure may be poorly
ordered within the crystal, such as solvent-exposed side-chains and loops, and in
these cases it can be impossible to accurately generate parts of the model. After a
model has been built or modified to fit the density it can be refined to minimise the
differences between the Fo and Fc. In turn the improved atomic coordinates can also
improve the structure factor phases used to calculate the electron density. Modern
refinement software uses the maximum likelihood method to refine the protein model
(Murshudov et al., 1997; Afonine et al., 2012). The refinement software is provided
with parameters including the structure factor amplitudes, phases from calculated or
experimental methods, and model coordinates. In addition, most software makes use
of prior knowledge such as empirical geometry restraints (Engh and Huber, 1991).
The resolution is also an importance factor when modelling and refining a protein
structure. There exists a ‘sweet-spot’ with regard to the resolution of the determined
protein structure. At low resolution (less than 3 Å), one cannot accurately position
side-chains, α-helices can resemble single tubes of density, and model building is very
challenging. At medium resolutions (between 3 Å and 1.6 Å), most side-chains are
apparent, there are a reasonable number of water molecules, and model-building
is generally very easy. At very high resolutions (better than 1.6 Å), it is common to
observe more than one conformation of side-chain, backbone, ligand, etc., and many
waters can be found, all of which can become extremely difficult to understand and
model. Of course given the choice, no real crystallographer will opt for anything
other than the very best resolution possible, but even the prettiest of crystals give no
guarantee of high resolution.
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2.8.1 B-factor Refinement
Every atom described in the model contains an additional factor which is used to
describe the displacement of the atom from mean position of the atom – this is usually
referred to as the temperature factor or B-factor. No atoms within a crystal are static,
even at very low temperatures, thus the B-factor is an essential term in refinement since
the goal is to improve agreement between the model and the measured reflections.
Most protein models contain isotropic B-factors, which describe the displacement of
an individual atom using a single term. At higher resolutions, and with many more
reflections, it is possible to better describe the atomic displacement using anisotropic B-
factors which normally utilise six parameters instead of the usual one. The anisotropic
displacement parameters (ADPs) are capable of describing the atomic displacement in
three dimensions which, at higher resolutions, can better describe the crystallographic
data (Figure 2.6).
Refinement is an iterative process between manual editing of the model and automated
refinement. The automated refinement and minimisation of the distance between the
model and data cannot fix major errors, nor can it fix minor errors such as incorrectly
orientated side-chains. There is still no replacement for the human crystallographer
who can refine to the best of their ability and experience, but even so — and as first
quoted by Philip R Evans — most crystallographers refine ad tedium.
a b
Figure 2.6: Isotropic and Anisotropic B-Factors
Graphic representation of isotropic (a) and anisotropic (b) B-factors of atoms from a methionine
amino acid.
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2.9 Validation of the Atomic Model
2.9.1 Model bias and R f ree
When refining a model against crystallographic data, it is useful to quantify their
agreement. The Rwork (also referred to as the R value) is a quantity which is produced
by calculating the sum of the difference between the observed structure factors and
the calculated structure factors, and dividing by the sum of the observed structure
factors (Equation 2.9). As the model is built and refined it will have a better agreement
to the recorded data and therefore the Rwork will approach zero. In practice, the
Rwork will never reach zero owing to noise in the data and the limited resolution
available. During refinement the Rwork will generally decrease until the model cannot
be improved further. It is possible to artificially reduce the Rwork below its true value









To reduce the chance of over-fitting, some reflections can be kept aside – free reflections
– and not used for the refinement of the model, instead they can remain independent
and used to calculate an unbiased statistic (Brünger, 1992). Equation 2.9 can be reused
with the free reflections to calculate the R f ree value. If a model has been refined with
the free reflections excluded from the total data then model should be unbiased with
respect to the free reflections. Generally, a small percentage of reflections are chosen at
random from a list of unique reflections while ensuring an equal distribution across
each resolution bin. The error of R f ree is approximately equal to R f ree/(2n)1/2 (Tickle
et al., 2000). Thus, for an R f ree value of 24%†, selecting 2000 free reflections would give
an approximate error of 0.38%. During model building and refinement, both the Rwork
and R f ree should decrease in response to an improved fit to the experimental data. An
increase in R f ree is strong indication of over-fitting and should be avoided.
†The mean R f ree across all structures in the PDB is 24% (n = 116570, correct as of 04 Jan 2018)
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2.9.2 Ramachandran Plot
Another method for quickly ensuring that protein model geometry is reasonable is
to produce a Ramachandran plot (Ramachandran et al., 1963). The Ramachandran
plot can be used to visualise the allowed angles for backbone dihedral angles (φ and
ψ, Figure 2.7,2.8) within a protein structure. By analysing existing high resolution
structures, one can produce confident approximations of allowed angles for φ and
ψ and use these to validate a new protein model. Modern Ramachandran plots use
data from thousands of structures which have been filtered to ensure only models
regarded as good are used as a reference (Read et al., 2011). Of course, every method
of validation has its limitations and many proteins contain a small percentage of
residues with backbone dihedral angles that sit outside of the allowed regions.
Figure 2.7: Ramachandran angles.
Representation of two peptide residues indicating
locations of φ, ψ and ω angles. Image redrawn and
modified from Ramachandran et al., 1963.
In addition to bond angles, the bond lengths can also be used as a good indicator of
model quality. After analysis of many small molecule crystal structures as a reference,
Engh and Huber (1991) released the first set bond length parameters for use in protein
structure refinement. As the reference parameters are derived from atomic or near-
atomic resolution small molecule crystal structures, all protein model (which are
generally produced from lower resolution data) should fit without many deviations.
There is some still some debate about how closely to follow ideal bond-angle and
bond-length values and in practice, following the electron density should always be
the primary method for building your model. Large deviation from ideal however
should cause concern and would need strong justification (Wlodawer et al., 2013).
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Figure 2.8: Ramachandran Plot
An example Ramachandran plot showing
the residues from the full-length crystal
structure of BoNT/A1 (Lacy et al., 1998).
2.10 Summary
X-ray crystallography is an incredibly powerful technique for studying protein struc-
ture. The background and theory presented here should serve as a general overview
and aid in understanding both the reasoning and approach followed for some of the
presented data in the following chapters.
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CHAPTER 3
Structural Studies of BoNT/A HC Domains
3.1 Introduction
Botulinum neurotoxins (BoNTs) comprise a family of proteins produced predomi-
nantly by Clostridium botulinum (Schiavo et al., 2000; Rossetto et al., 2014). There are
seven distinct serotypes termed BoNT/A through BoNT/G that cause the deadly
condition botulism in vertebrates. Of these serotypes, /A, /B, /E and /F are most
commonly associated with human botulism (Coffield et al., 1997). Each BoNT serotype,
for example BoNT/A, can be further categorised into subtypes based on amino acid
sequence identity. For BoNT/A there are currently eight known subtypes (BoNT/A1–
/A8) which share between 84% and 97% sequence identity (Table 3.1). The most widely
used commercially available therapeutic BoNT is the subtype BoNT/A1 (Fonfria et al.,
2018). One other serotype, BoNT/B is also commercially available although it is less
potent than BoNT/A formulations due to a residue difference within the protein
receptor for BoNT/B, human synaptotagmin II, compared with its murine counterpart
(Peng et al., 2012; Strotmeier et al., 2012; Tao et al., 2017). Other BoNT serotypes have
been explored for use as therapeutic molecules but much less work has focussed on
differences between subtypes from within BoNT serotypes.
Table 3.1: HC/A subtype identities.
Percentage identities are given for full-length and HC domain sequence alignments of each
BoNT/A subtype†. For the HC alignments, sequences were aligned to BoNT/A1 residues
K870 to L1296.
A1 A2 A3 A4 A5 A6 A7 A8







tyA2 90.04 – 98.83 88.47 89.65 90.12 90.35 93.43
A3 84.66 93.19 – 88.24 88.94 89.65 89.88 92.72
A4 89.19 88.12 84.29 – 86.85 85.92 85.92 90.14
A5 97.15 90.50 85.21 87.34 – 93.43 92.72 89.91
A6 95.68 91.74 86.29 87.72 95.91 – 91.08 87.32
A7 93.75 89.81 84.90 86.64 94.37 92.98 – 89.67
A8 93.36 93.44 87.69 88.81 93.60 93.06 91.36 –
Full-length identity
† Uniprot accession codes for BoNT/A1 to /A8 are A5HZZ9 (Betley et al., 1989; Gimenez and DasGupta,
1993; Sebaihia et al., 2007; Smith et al., 2007), Q45894 (Dover et al., 2013), Q3LRX9 (Jacobson et al., 2008),
Q3LRX8 (Jacobson et al., 2008), C7BEA8 (Dover et al., 2009), C9WWY7 (Luquez et al., 2009), K4LN57
(Mazuet et al., 2012) and A0A0A7PDB7 (Kull et al., 2015), respectively.
Despite their high sequence identity and similarity, it is important to determine the
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differences between BoNT subtypes and their impact on intoxication as these may
be useful therapeutically. The sequences of HC domains from BoNT/A subtypes
align well and all sequences share at least 80% identity with one another (Figure 3.1).
Alignment of the known sequences for BoNT/A subtypes identifies many amino acid
variations overlapping or in close proximity to residues involved in receptor binding
(Figure 3.1). The regions of the HC domain involved in receptor binding have been
characterised to various extents. While the SxWY motif within the ganglioside binding
site (GBS) is conserved, many of the residues around this site show high variability.
Some BoNT/A subtypes have been reported to exhibit different properties to BoNT/A1
such as onset of symptoms and duration of action. For example, BoNT/A3 has been
shown to be less effectively neutralised by anti-BoNT/A1 antibodies whilst also
inducing symptoms of intoxication in mice that are distinct from BoNT/A1 (Mazuet
et al., 2010; Tepp et al., 2012). It has been suggested that these differences are due to
structural differences within the HC of BoNT/A3 (HC/A3).
Between subtypes from the same serotype there can be distinct intoxication character-
istics. A long-term study of BoNT activity in cultured neuronal cells and in a mouse
model found that while BoNT/A1, /2, /4, and /5 have a similar duration of action
(over 10 months), the duration of BoNT/A3 is significantly shorter (3 months) (Pellett
et al., 2015). The reduced duration of action may be due to differences in the LC alone.
A hybrid toxin containing the LC/A1 and LHN/A3 maintains a long duration of
action whereas a hybrid containing LC/A3 and LHN/A1 results in a much shorter
duration (Pellett et al., 2018). Interestingly, it has also been determined that BoNT/A2
displayed a much faster onset of paralysis compared to other BoNT/A subtypes
(Pellett et al., 2015). The rate limiting step, determining the onset of durations is most
probably a result of the HC and HN region of the BoNT which is responsible for
binding and translocation of the LC (Pellett et al., 2018). Other evidence of differences
between subtypes intoxication was identified by Pellett et al. (2015), who discovered
that BoNT/A4 is ~1000-fold less potent than BoNT/A1, the reason for this is as yet
unknown. Such examples highlight the need to investigate BoNT subtypes and their
function. Due to the modular nature of the BoNT structure, it may prove useful in
future to produce hybrid BoNTs containing domains from different subtypes to tailor
the intoxication properties.
In addition to the BoNT/A subtypes, a recently discovered BoNT hybrid toxin (BoN-
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Figure 3.1: HC/A Primary Sequence Alignment
Residues that interact with receptors are identified with a symbol below the sequence: ganglio-
side ; SV2–backbone ; SV2–glycan . Primary sequences of HC/A subtypes aligned using
Clustal Omega and figure produced using ESPript (Robert and Gouet, 2014).
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T/FA) has some interesting features (Barash and Arnon, 2014; Dover et al., 2014). It
was found to contain a HC domain similar to that of BoNT/A1 and a LC and HN
domain similar to BoNT/F5 (Gonzalez-Escalona et al., 2014). As the HC is similar to
BoNT/A1, it likely shares the same receptors and could provide valuable information
when exploring the engineering of novel therapeutics.
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3.2 Methods
All materials were purchased from Sigma Aldrich unless otherwise specified.
3.2.1 General - SDS-PAGE
SDS-PAGE was carried out using precast 4–12% gradient gels. 5 µL of 5x protein
sample buffer (10% w/v SDS, 50% v/v Glycerol, 250 mM Tris-HCl and 0.5% w/v
bromophenol blue dye, pH 6.8) was added to 15 µL of the protein sample to be
analysed. Each sample was heated to 95◦C for 2 minutes prior to loading. SDS-PAGE
gels were run at 200 V for 45 minutes in a solution of TruPAGE TEA-Tricine SDS
buffer. The gels were removed from electrophoresis, washed in water and stained
using InstantBlue protein stain (Expedeon) for 1 hour. Gels were destained in water
for 1 hour.
3.2.2 General - Microbiological Techniques
All experiments were performed using standard aseptic technique under flame. Media
and glassware used for bacterial culture was autoclaved prior to use at 121◦C, 100 kPa
for 15 min. All buffers were filtered through a 0.2 µm membrane. The pH of each
buffer was adjusted using 5 M NaOH or concentrated HCl where appropriate and
measured at room temperature using a pH meter calibrated with standard buffers at
pH 7.0, pH 4.0, and pH 10.0.
3.2.3 Cloning of HC/A and HC/FA Expression Constructs
BoNT/A1 to /A6, and /FA HC domains were sub-cloned from constructs containing
the respective full-length bont sequences (provided by Ipsen Bioinnovation Ltd.). The
region corresponding to the HC was amplified by PCR using the primers listed in
Table 3.2. The forward primers encode an additional N-terminal 6xHistidine-tag for
protein purification. Amplified DNA fragments were flanked by an N-terminal NdeI
and a C-terminal HindIII restriction site. The DNA was cleaved by restriction digestion
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using both NdeI and HindIII (NEB) at 37◦C for two hours. Digested DNA was purified
using a PCR clean up kit (Wizard, Promega). The vector, pJ401 (DNA2.0), was also
digested using NdeI and HindIII and purified by gel purification. Inserts were ligated
into digested pJ401 using T4 DNA ligase (NEB) at 22◦C for 16 hours. Ligated vectors
were transformed into E. coli TOP10 cells (Invitrogen) using the following method.
A 50 µL aliquot of frozen cells were thawed on ice for 10 min. 2 µL DNA from the
ligation was added and the cells returned to ice for 15 min. Cells were heat-shocked
at 42◦C for 30 seconds before returning to ice for a further 5 minutes. 150 µL SOC
media (2% w/v tryptone, 0.5% w/v yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM
MgCl2, 20 mM glucose) was added to each aliquot and cells were grown at 37◦C
for 1 hour while shaking at 225 rpm. 100 µL of cell culture was used to inoculate a
pre-warmed LB (Miller) agar plate containing 50 µg mL−1 kanamycin sulfate. Plates
were incubated at 37◦C overnight. Individual colonies from each ligation plate were
used to inoculate 10 mL LB (Miller) media and the culture was grown for 16 hours at
37◦C while shaking at 225 rpm. Plasmid DNA was extracted from each culture using
a miniprep kit (Wizard, Promega) and sent for DNA sequencing (Eurofins Genomics,
Germany) to confirm successful cloning.
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3.2.4 Generation of bacterial glycerol stocks
A single colony from an LB (Miller) agar plate containing transformed E. coli colonies
was used to inoculate 5 mL LB (Miller) media in a 50 mL conical-based centrifuge
tube containing an appropriate antibiotic. The tube was placed in an incubator at
37◦C while shaking at 220 rpm for 16 hours. 200 of culture medium mixed with 200
50% (v/v) sterile glycerol in a sterile 1.5 mL Eppendorf tube before flash-freezing in
liquid nitrogen and storing at -80◦C indefinitely.
3.2.5 E. coli protein expression
A glycerol stock was used to inoculate a starter culture consisting of 100 mL TB
(containing 50 µg mL−1 kanamycin sulfate) in a 250 mL flask. The starter culture
was incubated at 37◦C for 16 hours while shaking at 225 rpm. 10 mL from the starter
culture was then used to inoculate each of two 2 L flasks containing 500 mL TB. The
flasks were incubated at 37◦C while shaking at 225 rpm, when the OD600 reached 0.6
the temperature was decreased to 16◦C. Protein expression was induced in both flasks
when the OD600 reached 1 by the addition of (Isopropyl β-D-1-thiogalactopyranoside)
IPTG to a final concentration of 1 mM. Following induction the flasks were left for
another 16 hours before harvesting cells. Cells were harvested by centrifugation at
4000 xg and stored at -80◦C until needed.
3.2.6 Purification of HC/A1–/A3, /A5, /A6 and /FA Domains
Cell pastes were resuspended using 10 mL of Buffer A (50 mM Tris-HCl, 500 mM NaCl,
20 mM imidazole-HCl, pH 7.4) per gram of cells. Resuspended cells were passed
through a cell disruptor (Constant Systems Ltd.) at 20 kPSI with the temperature
maintained at 4◦C. Cell debris was removed by centrifugation at 75,000 x g for 30 min
at 4◦C. Clarified lysate was filtered manually using 0.7 µm syringe filters (Minisart,
Sartorius). Cleared lysate was loaded onto a pre-equilibrated 5 mL HisTrap HP column
(GE Healthcare) at a flow rate of 5 mL min−1. The column was washed with Buffer
A and protein eluted using a gradient from 0% to 100% Buffer B (50 mM Tris-HCl,
500 mM NaCl, 500 mM imidazole-HCl, pH 7.4). Fractions containing eluted protein
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were pooled and concentrated using a 10 MWCO centrifugal filter (Millipore) before
loading onto a Superdex200 (GE Healthcare) size-exclusion chromatography column
which was pre-equilibrated with Buffer C (50 mM Tris-HCl, 500 mM NaCl, pH 7.4).
The column was run at 1.5 mL min−1 and fractions containing HC were pooled and
concentrated using a 10 MWCO centrifugal filter (Millipore) to 1 mg mL−1 for storage
at -20◦C.
3.2.7 Purification of HC/A4 Domain
Cell pastes were resuspended using 10 mL of Buffer A (50 mM Tris-HCl, 200 mM NaCl,
10 mM trehalose, 20 mM imidazole-HCl, pH 7.4) per gram of cells. Resuspended cells
were passed through a cell disruptor (Constant Systems Ltd.) at 20 kPSI with the
temperature maintained at 4◦C. Cell debris was removed by centrifugation at 75,000 x
g for 30 min at 4◦C. Clarified lysate was filtered manually using 0.7 µm syringe filters
(Minisart, Sartorius). Cleared lysate was loaded onto a pre-equilibrated 5 mL HisTrap
HP column (GE Healthcare) at a flow rate of 5 mL min−1. The column was washed
with Buffer A and protein eluted using a gradient from 0% to 100% Buffer B (50 mM
Tris-HCl, 200 mM NaCl, 10 mM trehalose, 500 mM imidazole-HCl, pH 7.4). Fractions
containing eluted protein were pooled and concentrated using a 10 MWCO centrifugal
filter (Millipore) before loading onto a Superdex200 (GE Healthcare) size-excluision
chromatography column which was pre-equilibrated with Buffer C (50 mM Tris-HCl,
200 mM NaCl, 10 mM trehalose, pH 7.4). The column was run at 1.5 mL min−1 and
fractions containing HC were pooled and concentrated using a 10 MWCO centrifugal
filter (Millipore) to 1 mg mL−1 for storage at -20◦C.
3.2.8 Crystalisation of BoNT HC Domains
Crystallisation Screening
Initial crystallisation screening for all proteins followed the following method. Crys-
tallisation conditions were screened using commercially available 96-well screens from
Molecular Dimensions, UK. The Crystal Phoenix robot (Art Robbins Instruments) was
used to dispense 50 µL of each screening solution into each well of a 96-well sitting-
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drop 3-drop crystallisation plate (Intelli-well®, Art Robbins Instruments). In the first,
second, and third sitting drop shelf of each well was dispensed 200 nL, 200 nL, and
100 nL of screening solution respectively. To the first, second, and third sitting drop
shelf of each well, 200 nL, 100 nL, and 200 nL of concentrated protein solution was
dispensed to create three crystallisation ratios (1:1, 1:2, and 2:1) of protein to screen-
ing solution. The plate was sealed manually using a ClearVue™ sheet (Molecular
Dimensions). Crystallisation plates were stored at 16◦C.
HC/A1
HC/A1 was concentrated 10 mg mL−1 using a 10 kDa MWCO centrifugal filter (Milli-
pore) and crystallisation conditions screened. Crystals of HC/A1 were grown at 16◦C
using a 1:1 ratio of protein solution (10 mg mL−1) to reservoir solution (0.1 M MIB, pH
4.0, 25% w/v PEG 1500). Crystals were soaked in cryoprotectant (equal volume of
reservoir solution and 50% v/v glycerol) before vitrification in liquid nitrogen. Data
were collected on beamline I04 at Diamond Light Source (UK).
HC/A2
HC/A2 was concentrated to 7.5 mg mL−1 using a 10 kDa MWCO centrifugal filter
(Millipore) and crystallisation conditions were screened. Crystals were grown in
the condition E9 from the SG1 screen (Molecular Dimensions, UK) (0.1 M Potassium
thiocyanate, 30% w/v PEG 2000 MME). Crystals were cryoprotected using 50% v/v
glycerol and reservoir solution in a 1:1 ratio before flash-cooling in liquid nitrogen.
Data were collected on beamline I04-1 at Diamond Light Source (UK). 7200 images of
0.1 degree oscillation were taken with a wavelength of 0.92 Å.
HC/A3
HC/A3 was concentrated to 6 mg mL−1 using a 10 kDa MWCO centrifugal filter
(Millipore) and crystallisation conditions were screened. HC/A3 crystals were grown
in condition B1 from the PACT premier™ screen (0.1 M MIB pH 4.0 25% w/v PEG
1500). Individual crystals were mounted in a loop and dipped in a solution containing
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reservoir and 50% v/v glycerol in a 1:1 ratio for cryoprotection before flash-cooling
and storage in liquid nitrogen.
HC/A3 with GD1a
HC/A3 was concentrated to 6 mg mL−1 using a 10 kDa MWCO centrifugal filter
(Millipore) and GD1a (Elicityl, France) was added to a final concentration of 100 µM.
The protein and ganglioside solution was used for crystallisation screening. Crystals
were obtained in condition G1 (0.1 M sodium formate, 0.1 M ammonium acetate, 0.1 M
sodium citrate tribasic dihydrate, 0.1 M sodium potassium tartrate tetrahydrate, 0.1 M
sodium oxamate, 0.1 M imidazole, 0.1 M MES monohydrate pH 6.5, 20% v/v PEG 500
MME, 20% w/v PEG 20000) from the MORPHEUS screen (Molecular Dimensions,
UK). Individual crystals were mounted in a loop and flash-cooled and stored in liquid
nitrogen. Diffraction data for HC/A3 were collected over 7200 images using 0.1°
oscillations and exposures of 0.02 s on beamline IO3 at Diamond Light Source (UK).
HC/A4
HC/A4 was concentrated to 4 mg mL−1 using a 10 kDa MWCO centrifugal filter
(Millipore) and crystallisation conditions screened. Crystals were grown in condition
H1 (10 mM Spermine tetrahydrochloride, 10 mM Spermidine trihydrochloride, 10 mM
1,4-Diaminobutane dihydrochloride, 10 mM D-L-Ornithine monohydrochloride, 0.1 M
MOPSO/bis-tris pH 6.5, 15% (w/v) PEG 3 K, 20% (v/v) 1,2,4-butanetriol, 1% (w/v)
NDSB 256) from the MORPHEUS II screen Gorrec, 2015. Crystals were mounted in a
loop and then flash-cooled for storage in liquid nitrogen.
HC/A5
HC/A5 was concentrated to 4 mg mL−1 using a 10 MWCO centrifugal filter (Millipore)
and crystallisation conditions screened. Crystals were produced in the condition
G2 (0.1 M Sodium formate, 0.1 M Ammonium acetate, 0.1 M Sodium citrate tribasic
dihydrate, 0.1 M Sodium potassium tartrate tetrahydrate, 0.1 M Sodium oxamate, 0.1 M
Imidazole, 0.1 M 2-(N-morpholino)ethanesulfonic acid, pH 6.5, 10% v/v Ethylene
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glycol, 10% w/v PEG 8000) from the MORPHEUS screen. Crystals were flash-cooled
in liquid nitrogen under a stream of nitrogen gas. Data were collected on beamline
I03 at Diamond Light Source (UK). 7200 images of 0.1 degree oscillation were taken
with a wavelength of 0.9763 Å.
HC/A6
HCA6 was concentrated to 6 mg mL−1 using a 10 MWCO centrifugal filter (Millipore)
and crystallisation conditions screened. Crystals appeared in condition G7 (0.2 M
Sodium acetate trihydrate, 0.1 M Bis-Tris propane-HCl pH 7.5, 20% w/v PEG 3350)
of PACT Premier (Molecular Dimensions). Optimised crystals were produced by the
increasing the precipitant concentration (0.2 M Sodium acetate trihydrate, 0.1 M Bis-
Tris propane-HCl pH 7.5, 22% w/v PEG 3350) in the hanging-drop vapour diffusion
method. Crystals were grown at 16◦C and cryoprotected using 50% v/v glycerol and
reservoir solution in a 1:1 ratio before flash-cooling in liquid nitrogen. 7200 images of
0.1 degree oscillation were taken with a wavelength of 0.9763 Å on beamline IO4 at
Diamond Light Source (UK).
HC/FA
HC/FA was concentrated to 10 mg mL−1 and crystallisation conditions were screened.
Crystals were grown in condition A9 (4 M sodium formate, 0.1 M sodium acetate pH
5.5) from the Clear Strategy Screen II (Molecular Dimensions). Crystals were soaked
in cryoprotectant (equal volume of reservoir solution and 50% v/v glycerol) before
vitrification in liquid nitrogen. 7200 images of 0.1 degree oscillation were taken with a
wavelength of 0.976 25 Å on beamline IO3 at Diamond Light Source (UK).
3.2.9 X-ray Data Reduction and Structure Solution
For all proteins studied, X-ray reflections across all images were indexed and inte-
grated using DIALS (Waterman et al., 2016). Integrated data were scaled and merged
using Aimless (Evans, 2006; Evans and Murshudov, 2013) from the CCP4 suite (Winn
et al., 2011). The phases for all X-ray diffraction data collected were solved by molecu-
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lar replacement using Phaser (McCoy, 2007). Manual model building and refinement
was carried out using Coot (Emsley et al., 2010). Models were refined using REF-
MAC5 (Murshudov et al., 2011) and structural validation performed using PDB_REDO
(Joosten et al., 2014), MolProbity (Chen et al., 2010), and wwPDB Validation (Gore et al.,
2017). Figures of protein models were produced using either PyMOL (Schrödinger,
LLC, 2015) or CCP4mg (McNicholas et al., 2011).
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3.3 Results and Discussion
Some of the results described in this chapter have been published within Davies et al.
(2018c) and Davies et al. (2018a).
3.3.1 HC/A1 Crystal Structure
Expression and Purification
The HC/A1 construct was produced by sub-cloning the HC domain DNA from a
full-length BoNT/A1 sequence (UniprotKB: P0DPI1). Expression in mTB medium
produced a good quantity of soluble protein - approximately 50 mg per litre of cell
culture. Purification by immobilised metal affinity chromatography (IMAC) using a
gradient elution resulted in a single peak of recombinant HC/A1 (Figure 3.2a) which






























































Figure 3.2: Purification of HC/A1
(a) IMAC purification of HC/A1 resulted in a large single peak of eluted protein. Clarified E.
coli lysate was loaded onto a HisTrap column and the column washed before a gradient elution.
(b) Size exclusion chromatography removed small residual contaminants and imidazole from
the IMAC purification.
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The whole peak was pooled and the imidazole along with residual contaminants were
removed through a second stage purification using size exclusion chromatography


























Figure 3.3: HC/A1 Purification SDS-PAGE.
12% SDS-PAGE following purification of Hc/A1. Lane 1:
Molecular weight marker. Lane 2: Crude lysate before
purification. Lane 3: Unbound protein following HisTrap
capture. Lane 4: Pooled fractions after His-tag purifica-
tion. Lane 5: Pooled fractions after gel filtration.
Crystallisation and Data Processing
Crystallisation conditions for HC/A1 were identified by screening the purified protein
against commercially available crystallisation screens. The protein was concentrated
for automated screening however at concentrations over 10 mg mL−1, some of the
protein auto-crystallised into small needles, visible by light microscopy. The protein
was not concentrated further and used directly for crystallisation screening. Mul-
tiple hits were identified in the screen Pact premierTM (Molecular Dimensions, UK)
(Newman et al., 2005). The largest of the crystals from the hits identified were found
in condition B1 (0.1 M MIB, pH 4.0, 25% w/v PEG 1500). Attempts to optimise this
condition through variation of pH and PEG concentration using the hanging-drop
vapour diffusion method yielded poorer diffracting crystals. Instead, the condition
B1 was used to fill an entire 96-well crystallisation plate in combination with HC/A1
(10 mg mL−1) to produce further crystals for structure determination. About 30%
of the wells yielded large individual crystals within one week. A second crystal
morphology which appear to have rounded edges, grew within the same plate ~ six
months after the initial setup (Figure 3.4).
X-ray diffraction data from both crystal morphologies were collected on beamline I04
(Diamond Light Source, UK). Initial data contained artefacts from ice-rings and so
the crystals used for final data collection were cryo-protected by brief immersion in a
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Figure 3.4: HC/A1 Crystal Morphologies A HC/A1
crystallisation drop from the condition 0.1 M MIB,
pH 4.0, 25% w/v PEG 1500 containing two crystal
morphologies. Crystal form 1 (a) and crystal form
2 (b) have the space group symmetry P212121 and
P21, respectively. The image shown is a composite
from two photographs at different focal points from
the same location.
Table 3.3: HC/A1 Crystallographic Data Collection and Refinement Statistics
HC/A1 form 1 HC/A1 form 2
Data collection
Beamline I04 DLS I04 DLS
Wavelength (Å) 0.97949 0.97949
Crystallographic statistics
Space Group P212121 P21
Cell lengths a,b,c (Å) 39.8, 107.3, 107.6 61.4, 53.9, 62.7
Cell angles α, β, γ (◦) 90.00, 90.00, 90.00 90.00, 106.10, 90.00
Resolution (Å) 24.10–1.45 (1.48–1.45) 60.24–1.80 (1.84–1.80)
Rmerge 0.076 (0.692) 0.142 (0.539)
Rmeas 0.097 (0.920) 0.150 (0.588)
Rpim 0.058 (0.601) 0.046 (0.225)
CC1/2 0.997 (0.357) 0.962 (0.954)
Mean < I/σI > 6.9 (1.3) 14.4 (3.7)
Completeness (%) 95.3 (95.1) 98.6 (89.1)
Total reflections 261047 739637
Total unique reflections 78738 36131
Multiplicity 3.3 (2.7) 20.4 (11.7)
Refinement statistics
Rwork/R f ree 0.176/0.221 0.188/0.223
RMSD bond lengths (Å) 0.002 0.005












PDB Code 5MK6 5MK7
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solution containing 50% v/v condition B1 and 50% v/v glycerol before cryo-cooling
in liquid N2. Complete datasets for both crystal morphologies, termed crystal form 1
and 2, were collected after cryo-protection and the best of each crystal form diffracted
to 1.45Å and 1.8Å, respectively. The data was indexed and integrated using DIALS
(Winter et al., 2018); the CCP4 program POINTLESS (Evans, 2006) was used to identify
the correct space groups. The two crystal morphologies were of different space groups,
with crystal form 1 determined to be in the orthorhombic P212121 space group while
crystal form 2 was of the P21 space group (Table 3.3).
Structure Refinement and Analysis
The phases for initial structural refinement of both datasets were produced by molecu-
lar replacement using an existing HC/A1 crystal structure (PDB ID: 2VUA, Stenmark
et al., 2008). Both structures are generally very similar and superpose well with an
RMSD between all atoms of 0.78 Å (Figure 3.5). There are some striking differences
between the two crystal forms, the first of these is at the N-terminus (Figure 3.5b).
HC/A1 was crystallised with a 6x histidine-tag present at the N-terminus but no
density is present for either crystal form likely due to disorder within the crystals.
For crystal form 1, the first residue is not visible but the following residues form
a small loop before joining the jelly-roll fold, as previously identified in BoNT/A1
(Lacy et al., 1998) which consists of fourteen β-strands. For crystal form 2 however,
the first fourteen residues after the histidine-tag have no clear density and residues
889–894 form a small α helix. As a result the typical jelly-roll fold is missing two of
the fourteen β-strands. The significance of this is not known but it is noteworthy that
the translocation of BoNTs is not well understood and the N-terminal residues of the
HC may play a role in translocation with the HN domain.
Immediately obvious in the resulting electron density maps for the crystal form 2
was a backbone rearrangement, compared with crystal form 1, in the region near to
the GBS which allowed two nearby cysteine residues (Cys1235 and Cys1280) to form a
covalent disulfide bond (Figure 3.6). This has also been observed in the full length
crystal structure of BoNT/A1 (PDB ID: 3BTA, Lacy et al., 1998). The density of the
sulfur atom from Cys1235 is weaker than that of Cys1280 but this may be due to X-ray
induced radiation damage of the disulfide bond which is generally more sensitive
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Figure 3.5: HC/A1 Crystal Structures
(a) The crystal structures from both crystal form 1 (black) and crystal form 2 (blue) of HC/A1
superposed to display similarity. (b) The N-terminus of both structures (Asn886 and Ile873)
diverge significantly.
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than other protein atoms (Petrova et al., 2010). No disulfide bond was observed in the
structure from the crystal form 1. Instead, Cys1235 rotated away from the Cys1280 due
to a backbone rotation, bringing the neighbouring Lys1236 toward Cys1280 (Figure 3.6).
This is consistent with previous HC/A1 structures either in complex with GT1b (PDB
ID: 2VU9, Stenmark et al., 2008), SV2-LD (PDB ID: 4JRA, Benoit et al., 2014; 5JLV,
Yao et al., 2016) or in the apo form (PDB ID: 2VUA; Stenmark et al., 2008). This
finding suggests that the crystallisation condition is not the only determinant as to
whether or not the disulfide bond in the HC is formed. The two cysteine residues in
question are highly conserved across all BoNT subtypes which suggests they are of
high importance, however their function is unknown.
a b
Figure 3.6: Location of Cys1235 and Cys1280 residues in HC/A1
Cys1235 and Cys1280 are not covalently bound in the HC/A1 crystal form 1 (a). A disulphide
bond is formed in crystal form 2 (b). Composite OMIT maps were produced using Phenix
(Terwilliger et al., 2008)) and are shown for each model at 1σ. Figure generated using CCP4mg
(McNicholas et al., 2011). Figure reproduced from Davies et al. (2018a).
They may be required for disulfide bond formation to aid structural stability or for
efficient function of a nearby ganglioside-binding pocket. It is important to note that
the previous crystal structure determined of HC/A1 in complex with a ganglioside
analogue of GT1a does not contain the disulfide bond and therefore binding does
not require the bond to be present (Stenmark et al., 2008). In addition, the protein
expression system does not appear to select for reduced or non-reduced forms of
these cysteine residues – each have been observed in different structures of BoNT/A
purified from both the native C. botulinum and E. coli (Garcia-Rodriguez et al., 2007;
Stenmark et al., 2008; Fu et al., 2009; Gu et al., 2012; Przedpelski et al., 2013; Benoit
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et al., 2014; Yao et al., 2017; Davies et al., 2018a).
Figure 3.7: Conservation of Cysteines in BoNT HC Domains
Amino acid sequence alignment of BoNT subtypes emphasising the strong conservation
of two cysteine residues near the protein C-terminus. UniprotKB accession numbers – A1:
A5HZZ9, A2: Q45894, A3: Q3LRX9, A4: Q3LRX8, A5: C1IPK2, A6: C9WWY7, A7: K4LN57,
A8: A0A0A7PDB7, HA(FA): WP_047402807*, B1: P10844, B2: A0A0B4W2B0, B3: A2I2S2,
B4: A2I2S4, B5: A0A0E1L271, B6: H3K0G8, B7: H9CNK9, B8: M9VUL2, E1: Q00496, E2:
A2I2S6, E3: A0A076L133, E4: P30995, E5: Q9K395, E6: A8Y878, E7: G8I2N7, E8: G8I2N8,
E9: WP_017352936*, E10: A0A076JVL9, E11: A0A076K0B0, E12: A0A0A7RCR1, F1: A7GBG3,
F2: Q9ZAJ5, F3: D2KHR6, F4: D2KHQ8, F5: D2KHQ9, F6: D2KHS6, F7: D2KHS9, F8: WP_-
076177537 *, F9: A0A1P8YWK9, G: Q60393, X: WP_045538952* (*indicates NCBI accession code
where UniprotKB accession is not available). Figure reproduced from Davies et al. (2018a).
It is unusual, but not unheard of, for the same protein in the same condition to produce
multiple crystal forms of different space groups. The second crystal form may have
appeared over time as a result of a slight change to the crystallisation condition as its
components degrade. However, this is unlikely and in fact the second crystal form
was found to differ from the first by a single disulfide bond within the structure and
it may simply have been present at a lower concentration, requiring a longer period to
crystallise.
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3.3.2 HC/A2 Crystal Structure
The HC/A2 construct was produced by sub-cloning the HC domain DNA from a
full-length BoNT/A2 sequence (UniprotKB: Q45894). Expression produced a low
quantity of soluble protein when compared to HC/A1 but still plenty for structural
biology experiments. Purification by immobilised metal affinity chromatography
(IMAC) using a gradient elution resulted in a small single peak of recombinant
HC/A2 (Figure 3.8a). The protein peak was pooled before desalting and further

































































Figure 3.8: Purification of HC/A2
(a) IMAC purification of HC/A2 resulted in a single peak of eluted protein. Clarified E. coli
lysate was loaded onto a HisTrap column and the column washed before a gradient elution.
(b) Size exclusion chromatography removed small residual contaminants and imidazole from
the IMAC purificaiton.
Crystallisation and Data Processing
Crystallisation conditions for HC/A2 were found by screening the purified protein
against commercially available crystallisation screens. A single hit was identified in the
SG1 screen (Molecular Dimensions, UK) (Newman et al., 2005). Crystals appeared in
the condition E9 (0.1 M Potassium thiocyanate, 30% w/v PEG 2000 MME) after sixteen
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months. Attempts to optimise this condition in 24-well hanging-drop crystallisation
plates containing a varied salt and PEG concentration failed to produce crystals. Data
from multiple crystals were collected on beamline I04-1 of Diamond Light Source.
Crystals were of space group P212121 and the best produced good diffraction data
to 1.75 Å. A total of 9999 frames, of low-dose fine-sliced data (0.1◦ oscillation) were
collected. The data exhibited some artefacts which were likely due to low levels of
ice-rings in the recorded diffraction data despite the addition of a cryoprotectant.
Structure Refinement and Analysis
A model was produced from the HC/A2 protein sequence using Phyre2 web server
(Kelley et al., 2015) for molecular replacement. HC/A2 shares 87.29% identity with
HC/A1 (Table 3.1) with some of those residue differences covering the SV2 binding-site
and the SV2-glycan binding-site (Figure 3.1). The X-ray structure was solved and
with a single protein molecule in the asymmetric unit. The overall fold of HC/A2 is
highly similar to HC/A1 with an RMSD between Cα atoms of 0.46 Å. The electron
density was generally very good with the exception of three small loop regions which
could not be modelled (Val1271–Arg1276, Asp1228–Ile1231, Tyr1165–Asp1170). This is the
highest resolution HC/A2 structure determined to date; two other crystal structures
of HC/A2 in complex with non-glycosylated SV2 have previously been determined to
2.3 Å (PDB ID: 5MOY, Benoit et al., 2017) and 2.0 Å (PDB ID: 6ES1, Gustafsson et al.,
2018). The structure of HC/A2 in complex with non-glycosylated SV2 determined
by Gustafsson et al. (2018) suggests the SV2 binding-site may have some flexibility
and is able to accommodate small angular deviations in binding. Our structure is
the first of HC/A2 without its protein receptor bound and displays little structural
change from the previously structures. Any flexibility in the SV2-binding region is
likely due to crystal packing and/or whether the SV2 peptide is correctly glycosylated.
Our structure also contained a single disulfide bond between Cys1235 and Cys1280.
Interestingly, of the two previous HC/A2 structures, only one (PDB ID: 6MOY) has
the same disulfide bond present.
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Cell lengths a,b,c (Å) 39.71, 99.81, 115.54
Cell angles α, β, γ (◦) 90.00, 90.00, 90.00





Mean < I/σI > 13.6 (3.0)
Completeness (%) 100 (99.8)
Total reflections 1,408,426 (67,617)
Total unique reflections 47,356 (2,538)
Multiplicity 29.7 (26.6)
Refinement statistics
Rwork/R f ree 0.203/0.255
RMSD bond lengths (Å) 0.02
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90°
Figure 3.9: HC/A2 Crystal Structure
Cartoon representation of the HC/A2 crystal structure. Missing loops are displayed as dashed
lines.
68
3. Structural Studies of BoNT/A HC Domains 3.3. Results and Discussion
3.3.3 HC/A3 Crystal Structure
Protein Purification
No structural information for HC/A3, which shares 86.82% identity with HC/A1
(Table 3.1), was available and so we attempted crystallisation of the protein in order to
determine whether any sequence differences in BoNT/A3 would affect the structure
of either the ganglioside or SV2 binding-sites. The HC/A3 construct was produced by
sub-cloning the HC domain DNA from a full-length BoNT/A3 sequence (UniprotKB:
Q3LRX9) and adding an N-terminal histidine tag. Expression produced a good
quantity of soluble protein which was first purified IMAC using a gradient elution
resulting in multiple but well separated protein peaks (Figure 3.10a). The protein peak

































































Figure 3.10: Purification of HC/A3
(a) IMAC purification of HC/A3 resulted in multiple peaks of eluted protein. Clarified E. coli
lysate was loaded onto a HisTrap column and the column washed before a gradient elution.
(b) Size exclusion chromatography removed residual contaminants and imidazole from the
IMAC purification resulting in a clean single peak.
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Crystallisation and Data Processing
The protein was concentrated for crystallisation, some precipitation was present at
concentrations above 7 mg mL−1, therefore crystallisation trials were attempted at a
concentration of 6 mg mL−1. After one week, some small crystals appeared in the
condition B1 (0.1 M MIB pH 4.0, 25% w/v PEG 1500) from the Pact premierTM screen
(Molecular Dimensions, UK). The crystals grew in size significantly and resembled
long, individual rods (Figure 3.11). Interestingly this is the same condition that
produces good quality crystals of HC/A1 (Figure 3.4), with both HC/A1 crystal
form 1 and HC/A3 sharing the same crystal morphology. Three other crystallisation
conditions were also later identified which produced crystals of a similar appearance.
a b
Figure 3.11: HC/A3 Crystal Morphologies
(a) Crystals of HC/A3 grew into long individual rods. (b) Crystalisation of the HC/A3–GD1a
analogue complex produced very small clusters of rods which were possible to manually
break into invidividual crystals.
X-ray diffraction data were collected from multiple crystals, with the best data arising
from crystals that were cryoprotected using glycerol in the same manner as HC/A1
crystals. In total, 11 datasets were collected from 11 individual crystals obtained
across multiple conditions with the best producing usable data to 1.6 Å (Table 3.6).
The best dataset was manually processed to determine a resolution cut-off. The data
were indexed and integrated using DIALS into the space group P212121. Data were
scaled and merged using AIMLESS and a resolution cut-off of 1.6 Å was imposed
based on all available statistics with particular attention to the outer-shell CC1/2 and
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Table 3.5: X-ray Datasets Collected for HC/A3
Screen (Well) Composition Crystals (Datasets) Auto Resolution
PP† (B1) 1 (3) 1.54 Å
PP† (B10) 1 (0) – ‡
MORP† (B9) 7 (5) 1.55 Å
SG1 (H5) 2 (2) 1.84 Å
† Screen names are abbreviated. PP: Pact premier; MORP: Morpheus. ‡
Autoprocessing failed to complete.
completeness (Evans and Murshudov, 2013). To produce the electron density map, the
data were solved by molecular replacement using the Phaser software (McCoy et al.,
2007). A starting model was produced by homology modelling using the Phyre2 web
server (Kelley et al., 2015) – the existing HC/A1 structure (PDB ID: 2VUA) was used
as a template for the HC/A3 sequence.
Structure Refinement and Analysis
The electron density map following molecular replacement was very clear for most
of the structure with exception of three loop regions between residues: 1198–1201,
1268–1277 and 1227–1231. It is likely that disorder is the cause as none of these regions
are involved in crystal packing. The HC/A3 protein sequence is most similar to that of
the BoNT/A2 subtype, where both binding domains share 98.8% identity. This is also
reflected by a high structural similarity between the two, where the RMSD between
Cα atoms is 0.83 Å.
Recent structures of both HC/A1 and HC/A2 bound to their protein receptor, SV2
isoform C (SV2C), suggest that the overall binding mode is generally conserved (Benoit
et al., 2014; Yao et al., 2016; Benoit et al., 2017). The high conformational similarity with
our structure suggests that HC/A3 may also bind SV2C in the same manner. One
notable point of variation in sequence however, is position 1156 (BoNT/A1 numbering,
Figure 3.1). BoNT/A3 (and subtypes /A4 to /A8) contain a methionine which has the
potential to form an electrophilic interaction or weak hydrogen bond with H563 of
SV2C (Pal and Chakrabarti, 2001), whereas BoNT/A1 has an arginine that forms a
cation-π stacking interaction, and BoNT/A2 has a glutamate that forms a salt bridge
with the equivalent histidine of SV2C (Benoit et al., 2014; Yao et al., 2016; Benoit
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Table 3.6: HC/A3 Crystallographic Data Collection and Refinement Statistics
HC/A3 HC/A3 – GD1a
Data collection
Beamline I03 DLS I04 DLS
Wavelength (Å) 0.97622 0.9795
Crystallographic statistics
Space Group P212121 P21
Cell lengths a,b,c (Å) 39.76, 96.47, 110.98 45.56, 72.47, 144.74
Cell angles α, β, γ (◦) 90.00, 90.00, 90.00 90.00, 94.82, 90.00
Resolution (Å) 96.47–1.60 (1.63–1.60) 72.31–2.15 (2.21–2.15)
Rmerge 0.126 (1.352) 0.313 (1.924)
Rmeas 0.131 (1.415) 0.366 (2.286)
Rpim 0.036 (0.408) 0.187 (1.214)
CC1/2 0.997 (0.639) 0.985 (0.415)
Mean < I/σI > 10.3 (1.9) 4.9 (1.0)
Completeness (%) 96.9 (79.6) 99.8 (98.2)
Total reflections 715,684 (25,075) 372,245 (27,398)
Total unique reflections 55,445 (2,169) 51,328 (4,114)
Multiplicity 12.9 (11.6) 7.3 (6.7)
Refinement statistics
Rwork/R f ree 0.179/0.214 0.243/0.265
RMSD bond lengths (Å) 0.016 0.01












PDB Code 6F0O –
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et al., 2017). This substitution may have an effect on the binding affinity of SV2 but a
structure of the SV2 complex is needed to accurately describe any potential interaction.
N-linked glycosylation of SV2C is also important for binding of BoNT/A1 to the
neuronal cell membrane (Yao et al., 2016). Under normal physiological conditions
SV2 is glycosylated. The glycan forms an array of interactions with BoNT residues
that neighbour those which interact with the protein chain directly. Within BoNT/A3
(and subtypes /A2, A6 and /A8), a mutation to a residue involved in glycan binding,
H1064R (BoNT/A1 numbering, Figure 3.1), may cause a change to glycan binding
specificity, or indicate a potentially different but conserved binding mode to a glycan
compared to BoNT/A1.
The ganglioside binding site of BoNT/A1 appears to be mostly conserved in the
HC/A3 structure except for a tyrosine at position 1113 (instead of phenylalanine) and
an unresolved conformation of R1276 – which could not be confirmed due to poor
electron density. Considering that BoNT/A1 binds to GT1b (Stenmark et al., 2008), it
is highly likely that BoNT/A3 binds gangliosides in a similar manner however the
tyrosine to phenylalanine substitution would likely result in the loss of hydrogen
bonding to the Sia5 moiety.
To further analyse ganglioside binding to HC/A3 we attempted to produce a crystal
structure of the protein in complex with a ganglioside analogue. Crystallisation
screens were setup in which HC was mixed with an equimolar quantity of a GD1a
analogue which lacked the ceramide group (Elicityl, France). We were successful in
attaining a crystallisation condition for HC/A3 in complex with the GD1a analogue.
The sugar part of GD1a differs from GT1b by a single sialic acid, Sia7, which is not
involved in the BoNT/A1 to ganglioside interaction (Stenmark et al., 2008). Crystals
produced for the complex were extremely small and diffracted to a resolution of 2.15 Å
(Figure 3.11). Unlike the HC/A3 crystal, the complex was in the space group P21 and
contained two molecules in the asymmetric unit. Following molecular replacement
using the HC/A3 structure, some unmodelled density around the expected ganglioside
binding site was observed indicating bound ligand, however modelling of any part
of a ganglioside was challenging and precise atom locations were not immediately
obvious. While still weak, the electron density did improve after multiple rounds of
refinement and most of the GD1a molecule could be placed with exception to Sia6 for
which there was no apparent density (Figure 3.13).
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Figure 3.12: HC/A3 Crystal Structures
Overall cartoon representation of two crystal structures: (a) HC/A3 (PDB ID: 6F0O, Davies
et al., 2018c) and (b) HC/A3 in complex with GD1a. GD1a displayed as black sticks.
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Figure 3.13: HC/A3–GD1a Electron Density and Interactions
(a) GD1a (green sticks) located in the ganglioside binding site of HC/A3 (blue ribbon and
sticks). 2mFo–Fc electron density is shown for GD1a at 1σ. (b) Interactions of the GD1a gan-
glioside with HC/A3. Hydrogen bonds are illustrated with green dashed lines. Hydrophobic
interactions are displayed as red crescents.
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Of the modelled GD1a atoms, hydrogen bond interactions are only visible for Sia5
and Gal4 of the GD1a molecule. The Phe at position 1113 has maintained a similar
orientation to the equivalent Tyr in BoNT/A1 but now only contributes hydrophobic
interactions. The loss of hydrogen bonding to Sia5 when compared to HC/A1 does
not seem to have had an impact structurally on the ganglioside binding.
The crystal structure of HC/A3 was published (Davies et al., 2018c) and deposited in
the PDB under the accession code 6F0O.
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3.3.4 HC/A4 Crystal Structure
Protein Purification
Initial attempts to purify HC/A4 using the same conditions as other HC/A subtypes
resulted in low levels of soluble protein due to protein precipitation. Expression levels
were generally lower than other HC/A subtypes and optimisation of the purification
was required. It was determined that HC/A4 was more stable in a decreased salt
buffer that contained the additive, trehalose. Under these conditions a larger quantity





























































Figure 3.14: Purification of HC/A4
(a) IMAC purification of HC/A4 resulted in a small peak of eluted protein. Clarified E. coli
lysate was loaded onto a HisTrap column and the column washed before a gradient elution.
(b) Size exclusion chromatography was performed to removed small residual contaminants
and imidazole from the IMAC purification.
Crystallisation and Data Collection
HC/A4 was able to be concentrated to 4 mg mL−1 before signs of protein precipita-
tion were present. Crystallisation conditions were screened and multiple hits were
identified. The best crystal of approximately 60 µm3 diffracted to 1.34 Å (Figure 3.15).
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Figure 3.15: HC/A4 Crystal Morphology
Crystallisation of HC/A4 produced a single well
defined crystal.
Structure Refinement and Analysis
The crystal belonged to space group P213 with one molecule in the asymmetric unit
(Table 3.7) (Figure 3.16). A model of HC/A4 was produced using the Phyre2 web server
(Kelley et al., 2015) which was used to solve the structure by molecular replacement.
The exceptional quality of the electron density map allowed modelling of all residues,
as well as the clear identification of a single disulfide bond between C1235 and C1280.
Of all the different subtypes of BoNT/A, the binding domain of BoNT/A4 is most
similar to that of BoNT/A1 sharing 91.78% sequence identity and a RMSD of 0.72 Å
between Cα atoms.
After multiple rounds of model building a large region of unmodelled electron density
remained which appeared attached to His1259. The density was eventually modelled
as a nickel atom coordinated by the Nδ of His1259 and a single bis-Tris methane (Bis[2-
hydroxyethyl]amino-tris[hydroxymethyl]methane) molecule (Figure 3.17). Bis-Tris
methane is a common buffer which is capable of complexation of metals including
nickel (Ferreira et al., 2015). The metal coordination was validated using the Check-
MyMetal server (Center for Structural Genomics of Infectious Diseases, US) which
confirmed octahedral geometry and found the bond distances to fall within accepted
ranges (Zheng et al., 2017). The source of the metal was likely from the IMAC column
which contains immobilised nickel, while the bis-tris methane buffer was present
in the crystallisation condition. Interestingly, while this feature is not biologically
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Cell lengths a,b,c (Å) 116.00, 116.00, 116.00
Cell angles α, β, γ (◦) 90.00, 90.00, 90.00





Mean < I/σI > 17.5 (1.1)
Completeness (%) 100 (100)
Total reflections 2,516,326 (60,014)
Total unique reflections 116,165 (5,700)
Multiplicity 21.7 (10.5)
Refinement statistics
Rwork/R f ree 0.144/0.158
RMSD bond lengths (Å) 0.001
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90°
Figure 3.16: HC/A4 Crystal Structure
Overall cartoon representation of HC/A4.
Figure 3.17: HC/A4 bis-Tris
Electron density contoured to 1σ for a Ni atom coordinated by His1259 and a single molecule
of bis-tris methane.
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relevant, it is extremely rare and only five other structures in the PDB have a modelled
bis-Tris methane, nickel, and histidine coordination complex. All of the equivalent
residues involved in ganglioside binding for BoNT/A1 (Stenmark et al., 2008) remain
unchanged in HC/A4 suggesting the BoNT/A4 may share the same ganglioside
binding preference as BoNT/A1.
When comparing binding sites, BoNT/A4 is predicted to have the both the same
ganglioside preference as BoNT/A1 and is also predicted to bind to SV2C, according
to sequence alignment (Figure 3.1). Most interactions to the SV2C peptide are likely
unchanged owing to the nature of backbone-backbone interactions between β-strands,
however like HC/A3, the HC/A4 structure shows a methionine at position 1156 rather
than an arginine at the equivalent position for HC/A1, which may form an important
interaction with SV2C. This may have an important impact on binding as Arg1156 of
HC/A1 forms electron stacking interactions with an aromatic side chain of SV2.
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3.3.5 HC/A5 Crystal Structure
Protein Purification
We attempted crystallisation of HC/A5 which shares 93.9% identity with HC/A1
(Table 3.1). A construct was produced by subcloning the HC domain from the full-
length BoNT/A5 sequence (UniprotKB: C7BEA8) and adding an N-terminal His tag.
Expression produced soluble protein which was purified by IMAC using a gradient
elution resulting in a peak corresponding to HC/A5 (Figure 3.18a). This peak was
pooled and further purified using size exclusion chromatography (Figure 3.18b) to
give a highly pure product (Figure 3.19).
Crystallisation and Data Processing
HC/A5 was concentrated to 4 mg mL−1 for crystallisation experiments. Some precipi-
tation was visible for concentrations higher than this. Crystals initially appeared in
the condition G5 of The MORPHEUS screen (Molecular Dimensions) and manual
optimisation was attempted. After another month, further crystallisation hits were
identified and X-ray diffraction data collection was attempted for each. Crystals from
condition G5 of The MORPHEUS screen diffracted best to 1.14Å. Crystals from the
original hit and optimisation screen all produced highly anisotropic data for which it
was not possible to find an indexing solution. The structure was solved by molecular
replacement using a model produced on the Phyre2 web server (Kelley et al., 2015)
from the sequence of HC/A5.
Structure Refinement and Analysis
Immediately apparent in the crystal structure was density between the Sγ of Cys1280
and Nζ of Lys1236. Both sidechains were modelled into the density and following a
round of refinement there was clearly density for a covalently bound atom between
the two side chains. A methyl group was placed in between the Sγ of Cys1280 and
Nζ of Lys1236, connecting them. After refinement, the atomic model fit the density
extremely well. Some residual negative electron density in the Fourier difference map
82

































































Figure 3.18: Purification of HC/A5
























kDa Figure 3.19: HC/A5 Purification SDS-PAGE.
4 – 12% gradient SDS-PAGE following purification of
Hc/A5. Lane 1: Molecular weight marker. Lane 2:
Crude lysate before purification. Lane 3: Pooled frac-
tions after His-tag purification. Lane 4: Pooled fractions
after gel filtration.
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Cell lengths a,b,c (Å) 43.55, 60.27, 185.15
Cell angles α, β, γ (◦) 90.00, 90.00, 90.00





Mean < I/σI > 10.7 (1.5)
Completeness (%) 99.8 (97.8)
Total reflections 1,667,857 (61,786)
Total unique reflections 177,879 (8,513)
Multiplicity 9.4 (7.3)
Refinement statistics
Rwork/R f ree 0.139/0.159
RMSD bond lengths (Å) 0.01
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a b c
Figure 3.20: HC/A5 Crystal Morphologies
A single crystal of HC/A5 initially appeared in (a) G5 of The MORPHEUS screen (Molecular
Dimensions). Manual optimisation produced further crystals (b,c) which failed to produce
good quality diffraction data.
(Fo-Fc) was observed around the Sγ atom, while not unusual, this is an indication
of some X-ray induced radiation damage. This is not a normal motif found in
botulinum neurotoxins and so we looked for further evidence to justify the modelling
of such a bond. Fortunately, some weak anomalous data were observed during initial
data collection which could be used to generate an anomalous difference map. The
anomalous map contained a high level of noise but by decreasing the contour level,
the largest of the peaks could be identified which each appeared in the location of
sulfur atoms. The sulfur anomalous peaks confirm the locations of each cysteine
around the methylene-bridged cysteine and lysine (Figure 3.22)
This specific bond between a lysine and cysteine side chain is quite perplexing
although there are some examples of a similar bond identified in previous protein
crystal structures – although in most cases it has not been modelled (Ruszkowski
and Dauter, 2016). The mechanism surrounding the formation of a methylene-bridge
lysine and cysteine is not fully known but Ruszkowski and Dauter (2016) suggest
two possible routes. The first would involve the reaction of Lys Nζ with CO2 forming
a carbamic acid which is susceptible to nucleophilic attack from the Cys Sγ. Then,
further dehydration would result in an S-alkyl thiocarbamate bridge which may be
reduced to form a methyl-bridge. Another possible mechanism involves a reaction
with Lys and the biologically relevant formaldehyde molecule. Lys can be dehydrated
by HOCO in an acidic environment to produce an iminium cation which is itself
prone to react with nucleophiles such as Cys residues and would result in a methylene
85
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Figure 3.21: HC/A5 Crystal Structure
Overall cartoon representation of HC/A5.
a b
Figure 3.22: A methylene-bridged cysteine and lysine bond in HC/A5
(a) The 2mFo-DFc map is shown (blue, contoured to 1σ), a small amount of negative electron
density is observed in the Fo-Fc difference map (red, contoured to 3σ) map around cys. (b)
A Composite Omit map (blue, contoured to 1σ) and an anomalous difference map (pink,
contoured to 4σ) confirms the location of each sulphur atom.
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bridge. Whether this bond is biologically relevant remains to be seen. It is worth
noting that other HC structures have indications of the presence of this bond such as
Lys – Cys probe clashes and unmodelled electron density.
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3.3.6 HC/A6 Crystal Structure
Protein Purification
HC/A6 shares 90.61% identity with HC/A1 (Table 3.1). The HC/A6 construct was
produced by sub-cloning the HC domain DNA from a full-length BoNT/A6 sequence
(UniprotKB: C9WWY7) and adding an N-terminal histidine tag. The protein was
purified in a two step process (Figure 3.23) and the peak corresponding to HC/A6 was
pooled for crystallisation experiments (Figure 3.24). Some lower molecular weight
bands were visible directly under the band corresponding to HC/A6 on an SDS-PAGE
gel indicating possibly some degradation or truncated forms (Figure 3.24). These
could not be removed by size-exclusion chromatography and crystallisation screening
was attempted with this purity.
Crystallisation and Data Processing
Initial BoNT/A6 crystals were grown in condition G7 from Pact Premier (Molecular
Dimensions) after two weeks and another condition (A4) produced crystals two
weeks later. The crystals from the condition G7 were optimised though manual
screening around the hit condition using hanging-drop vapour diffusion. Manual
screening resulted in much larger, rod-shaped crystals (Figure 3.25), which were
screened for diffraction on beamline I04 at Diamond Light Source. The commercial
and optimised conditions all produced good quality crystals with high resolution
diffraction (Table 3.9). The best diffraction resulted from an optimised crystal which
produced good data to resolution of 1.16 Å (Table 3.10).
Table 3.9: X-ray Datasets Collected for HC/A6
Screen (Well) Composition Crystals (Datasets) Auto Resolution
PP† (A4) 1 (1) 1.71 Å
PP† (G7) 1 (1) 1.35 Å
Optimised 2 (2) 1.16 Å
† Screen names are abbreviated. PP: Pact premier;
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Figure 3.23: Purification of HC/A6

























Figure 3.24: HC/A6 Purification SDS-PAGE.
4 – 12% gradient SDS-PAGE following purification of
Hc/A6. Lane 1: Molecular weight marker. Lane 2:
Crude lysate before purification. Lane 3: Pooled frac-
tions after His-tag purification. Lane 4: Pooled fractions
after gel filtration.
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Cell lengths a,b,c (Å) 39.63, 105.74, 112.86
Cell angles α, β, γ (◦) 90.00, 90.00, 90.00





Mean < I/σI > 18.8 (3.5)
Completeness (%) 98.6 (95.7)
Total reflections 5,676,108 (233,693)
Total unique reflections 162,192 (7,703)
Multiplicity 35.0 (30.3)
Refinement statistics
Rwork/R f ree 0.162/0.201
RMSD bond lengths (Å) 0.02
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Figure 3.25: HC/A6 Crystal Morphology
Crystals of HC/A6 grew into long individual rods
in crystallisation drops which also produced many
small spherulites.
Structure Refinement and Analysis
The structure was solved by molecular replacement using a model produced on the
Phyre2 web server from the HC/A6 sequence (Kelley et al., 2015). A single protein
molecule was present in the asymmetric unit and electron initial electron density
was very clear. Surprisingly, the crystal structure of HC/A6 also revealed interesting
density around the Sγ of Cys1280 and Nζ of Lys1236, similar to what was observed for
HC/A5. In this structure however, there appeared to be no methylene-bridge, instead
the Cys Sγ and Lys Nζ appear covalently bound to each other (Figure 3.28a).
There is a large negative peak present in the Fo-Fc difference map for Cys1235 indicating
some level of radiation damage (Figure 3.28a). To discover whether X-ray induced
radiation damage is causing this bond to form, the diffraction data were reprocessed
to only include the first 10% of images (100◦). As the data were collected using a
low transmission during high multiplicity collection strategy, cutting the extra images
increases the noise of the data (outer shell CC1/2 = 0.226) and the completeness drops
to 87% overall. The resulting electron density reveals weaker density for the Cys–Lys
bond but it is still clearly present (Figure 3.28b).
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a b
Figure 3.26: HC/A6–GD1a Crystal Morphology
Crystals which grew following screening of HC/A6 in combination with equimolar GD1a
produced small rod-like crystals which grew out of spherulites.
90°
Figure 3.27: HC/A6 Crystal Structure
Overall cartoon representation of HC/A6.
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a b
Figure 3.28: A cysteine – lysine bond in HC/A6
(a) The 2mFo-DFc map is shown (blue, contoured to 1σ), a small amount of negative electron
density is observed in the Fo-Fc difference map (red, contoured to 3σ) map around Cys1235.
(b) The electron density map was recalculated using only the first 1000 images (100◦ of data)
revealing less negative density.
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3.3.7 HC/FA Crystal Structure
Protein Purification
BoNT/FA is a hybrid toxin whose HC domain shares 84% identity with HC/A1 and
a LC and HN domain similar to BoNT/F5. The HC/FA construct was produced by
first identifying the HC domain through alignment with HC/A1 and then sub-cloning
the HC domain DNA from a full-length BoNT/FA sequence (NCBI: WP_047402807.1),
and adding an N-terminal histidine tag. The protein was purified in a two step
process in the same manner as the HC/A subtype domains (Figure 3.29) and the peak






























































Figure 3.29: Purification of HC/FA
(a) IMAC purification of HC/FA resulted in a multiple small peaks of eluted protein. Clarified
E. coli lysate was loaded onto a HisTrap column and the column washed before a gradient
elution. (b) Size exclusion chromatography removed the residual contaminants and imidazole
from the IMAC purificaiton.
A crystallisation condition was identified which yielded crystals of HC/FA in the
space group P422. A high-multiplicity dataset was collected containing 360 degrees of
data over 3,600 images. No significant radiation damage was observed over the course
of data collection and thus all data were used. The CC1/2 value for the outer shell was
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0.832 using a resolution cut-off of 1.95 Å, indicating there was still usable data at this
resolution (Evans and Murshudov, 2013) (Table 3.10). The structure was solved by
molecular replacement, using a model produce on the Phyre2 web server, and phasing
located two molecules related by non-crystallographic symmetry in the asymmetric
unit. During preparation of our HC/FA manuscript, Yao et al. (2017) published the
same crystal structure (PDB ID: 5V38). Both molecules superpose well with a root
mean squared deviation (RMSD) value of 0.35 Å between all atoms.
The crystal structure of HC/FA is highly similar to the existing structure (PDB ID:
5V38, Yao et al., 2017) and each molecule in the asymmetric unit has an RMSD with
this structure from 0.54 Å to 0.36 Å (Figure 3.30). Unlike the existing structure, our
data contained density for a previously unresolved loop (R1261 – R1268) which is likely
involved in ganglioside-binding (Figure 3.31). Yao et al. (2017) suggested that the
lack of density observed for R1261 – R1268 loop was due to high flexibility, which is
consistent with the high B-factors (74 Å2) we observed in this region relative to the
rest of the protein.
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Cell lengths a,b,c (Å) 90.00, 90.00, 90.00
Cell angles α, β, γ (◦) 118.00, 118.00, 118.00





Mean < I/σI > 12.6 (2.3)





Rwork/R f ree 0.180/0.209
RMSD bond lengths (Å) 0.007


















Figure 3.30: Comparison Between HC/FA Crystal Structures
(a) Our crystal structure of HC/FA (blue, PDB ID: 5MK8) is superposed onto an existing struc-
ture of HC/FA (black, PDB ID: 5V38). Both structures are displayed as a wire representation of
the backbone. Circled in orange is the inferred ganglioside binding site and a zoomed image
of this region (b) is provided for clarity.
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Figure 3.31: HC/FA Ganglioside Binding Site
(A) Electron density from a composite omit map for HC/FA. The location of a disulphide
bond is marked with an asterisk. (B) The equivalent loop from HC/A1 (2VU9) with GT1b
shown in glycoblock representation. Map produced using Phenix package (Terwilliger et al.,
2008). Figure reproduced from Davies et al. (2018a).
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3.3.8 Comparison of HC/A Crystal Structures
Ganglioside Binding Site
The ganglioside binding site of BoNT/A subtypes is particlarly flexible and in many
structures (BoNT/A2, BoNT/A3, BoNT/A6) the electron density for the 1292–1280
loop cannot be fully resolved (Figure 3.32). As identified in the HC/A1–GT1b crystal
structure, the ganglioside interacts with many residues, some of which hydrogen
bond while others act to form a hydrophobic pocket. A particularly important and
well conserved residue is W1266 which forms an electron stacking interaction with
the Gal4 moiety of the ganglioside. There is one key variation which appears across
the subtypes, that is Y1117F which appears in BoNT/A2, /A3, and /A6. Data from
our HC/A3–GD1a crystal structure indicates that this variation is tolerated and does
not seem to have an appreciable effect on ganglioside binding (Figure 3.13). It may
however, cause a decrease in binding affinity as multiple hydrogen bonds are lost
with the Sia5 moiety of the ganglioside. Our HC/A crystal structures provide a great
starting point for the engineering of HC domains with greater affinity for ganglioside
binding.
SV2 Binding Site
The SV2 binding site of HC/A subtypes can be separated into two parts, firstly the
binding interactions with the SV2 backbone (Figure 3.33), and secondly the binding
interactions with the SV2 glycan (Figure 3.34). Many of the HC/A subtypes contain
sequence variation along the β-strand which forms backbone interactions with the
SV2 molecule. Variations such as M1144V in HC/A2, and S1142N in HC/A4 may be
tolerated as the side chains do not form direct interactions. In the case of HC/A2,
a crystal structure of the protein bound to SV2 does indeed show this mutation is
tolerated (Benoit et al., 2017). Other mutations may have a much greater effect on the
affinity toward SV2. HC/A1 is the only subtype to contain an Arg at position 1156
which, in the crystal structure bound to glycosylated SV2 (Yao et al., 2016), appears
to form a π-stacking interaction with a Phe of SV2. All other HC subtypes contain a
Met at this position, with the exception of HC/A2 which contains a Glu. Variations
such as these do not appear to effect the local fold but may have a strong effect on
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binding affinity. Another interesting residue is R1249 of BoNT/A1 which extends over
the SV2 protein forming a direct interaction with a second β-strand of SV2. In the
case of BoNT/A6 the residue is instead a Lys which may still form a hydrogen bond
with SV2. The other BoNT/A subtypes contain the R1294S variation, in the crystal
structures the Ser residue does not extend as far as the Arg and would likely not be
involved in any SV2 interaction (Figure 3.33) – this is also the case as observed in the
HC/A2–SV2 crystal structure (PDB ID: 5MOY) (Benoit et al., 2017).
The Cys1235 and Cys1280 Disulfide Bond
From the initial crystal structure of full-length BoNT/A1 (PDB ID: 3BTA) determined
by Lacy et al. (1998) it was found that two cysteine residues within the HC are capable
of forming a disulfide bond. The role of this disulfide is unknown but one would
assume a structural role whereby the covalent bond acts to stabilise the fold. Structures
determined of the HC domain of BoNT/A1 since the first full-length structure have
revealed a range of possible conformations of the cysteine residues in question.
The identification of a condition that produces two crystal forms of HC/A1 has
prompted further questions regarding the role of the Disulfide bond. Namely, are
two distinct species of protein produced during protein expression or is the redox
state of this bond sensitive to its environment over time? Considering their location
near the ganglioside-binding pocket, and conservation across BoNT subtypes, the
redox status of these conserved cysteines may have implications in BoNT stability and
manufacture. Botulinum neurotoxins are used therapeutically for many indications
and their production is currently from the native host Clostridium botulinum. However,
considering the safety implications and the advent of engineered BoNT derivatives,
such as Targetted secretion inhibitors (TSIs) (Masuyer et al., 2014), production from a
recombinant source would be highly desirable. Of the other crystal structures that
we have determined, HC/A2, and HC/A4 also contain the equivalent disulfide bond.
Understanding the role of this bond is very important and further work is required to
investigate any impact it may have on the BoNT function.
In the HC/A5 crystal structure, instead of a disulfide bond, Cys1280 forms a bond with
Lys1236 through a methylene bridge. This highly unusual bond has been previously
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observed in other unrelated crystal structures but its significance and the mechanism
of bond formation are little understood (Ruszkowski and Dauter, 2016). Confusing
matters further, the crystal structure of HC/A6 contains a bond between Cys1280 and
Lys1236 but without a methlyene bridge, i.e. an N–S bind which is highly unusual
and likely unstable. Cysteine is regarded as a reactive amino acid and modifications
including oxidation but the Lys-CH2-Cys or even Lys-Cys modification is not well
known or understood. It is plausible that these bonds are artefacts of the reducing
power of synchrotron radiation and may not have biological relevance. However, they
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BoNT/A5 BoNT/A6 BoNT/FA
Figure 3.32: BoNT Ganglioside Binding Site
Displayed is the ganglioside binding site of different BoNT/A subtypes. For each HC the protein is represented in cartoon form with residues that may
form interactions with the ganglioside displayed in ball-and-stick format. For BoNT/A1 the crystal structure of the HC in complex with GT1b is shown.























































Figure 3.33: BoNT SV2 Binding Site The SV2 binding site of different BoNT/A subtypes. For each HC the protien is represented in cartoon form
with residues that may form interactions with SV2 displayed in ball-and-stick format. For BoNT/A1 the crystal structure of the HC in complex with



















































































Figure 3.34: BoNT SV2 Glycan Binding Site
Displayed is the SV2 glycan binding site of different BoNT/A subtypes. For each HC the protein is represented in cartoon form with residues that may
form interactions with the SV2 glycan displayed in ball-and-stick format. For BoNT/A1 the crystal structure of the HC in complex with glycosylated SV2
is shown. SV2 is coloured black and the glycan represented in glycoblock form.
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3.4 Conclusions
The work presented in this chapter has resulted in nine crystal structures including the
highest resolution BoNT HC domains determined to date. Previous structural studies
have focussed solely on HC/A1 or HC/A2 and the data presented here reveals for the
first time the precise atomic details of further BoNT/A subtypes. Subtypes from the
BoNT/A serotype bind to, or are proposed to bind to, a dual-receptor complex on
the cell surface. Investigation of the binding sites through sequence and structural
analysis reveals many amino acid variations across the subtypes which may cause
differences in binding-affinity to each receptor. Our high resolution models further
add to the body of knowledge around BoNT receptor binding and will increase the
available information when exploring the possibility of future engineered BoNTs.
105
CHAPTER 4
Characterisation of SV2 Binding
4. Characterisation of SV2 Binding 4.1. Introduction
4.1 Introduction
There are seven distinct serotypes of botulinum neurotoxins (BoNTs) termed BoNT/A
through BoNT/G (Coffield et al., 1997). Each serotype can be further categorised
into subtypes based on amino acid sequence identity. In the BoNT/A serotype there
are eight subtypes (BoNT/A1–/A8) which share between 84% and 97% sequence
identity. One of these subtypes, BoNT/A1 is a widely used and commercially available
therapeutic used to treat a number of conditions including cervical dystonia, overactive
bladder, strabismus, and glabellar lines (Kane et al., 2015; Fonfria et al., 2018; Johnson,
1999). BoNTs utilise an incredible technique for targetting neuronal cell specifically
through the dual-receptor complex. BoNT/A binds to a dual-receptor complex
consisting of a ganglioside and synaptic vesicle glycoprotein 2 (SV2) on the neuronal
cell surface during intoxication (Dong et al., 2006; Yao et al., 2016; Hamark et al., 2017).
The crystal structure of HC/A1 in complex with glycosylated SV2 was determined by
Yao et al. (2016) and it reveals an array of interactions with the SV2-glycan. Previous
data had only shown interaction with the SV2 backbone, an interaction which would
not account for the extreme toxicity of the BoNT (Benoit et al., 2014). A detailed
understanding of the structural aspects of the BoNT subtypes will prove useful in
identifying regions of variability that may help uncover conserved mechanisms of
binding. In addition to structural work, attempts to accurately measure the binding
affinity to each receptor will in turn help to guide efforts in developing novel BoNT
therapeutics. Despite the specificity, it is still desirable to produce a therapeutic BoNT
with the greatest possible binding affinity and efficiency, which would avoid the
spread of the toxin away from the application site (Kerscher et al., 2012; Tao et al.,
2017).
Establishing a robust technique for analysing the binding affinity of BoNTs to their
receptors is highly desirable. Not only would it enable better characterisation of
existing BoNTs but it could also be used to characterise novel BoNTs which may have
engineered HC domains to improve affinity to target receptors.
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4.1.1 Biolayer Interferometry
One technique for analysing binding interactions between a protein and a target-
receptor is biolayer interferometry (BLI). BLI is an optical technique based on reflec-
tometric interferometry spectroscopy (RIfS) that analyses the interference pattern of
light that has been reflected from two surfaces. In the case of BLI, light is sent down an
optical fibre and reflects back to the detector. When protein is bound to the sensor tip,
light reflects back from not only the internal surface but also from the layer of protein












Figure 4.1: Biolayer Interferometry
Measurement of protein binding constants using Biolayer interferometry (BLI) requires the
bait protein to bind to the sensor end. Following this the association and dissociation of the
prey protein can be measure by recording the light reflected from the sensor tip.
To analyse protein–protein interactions, the BLI sensor must first bind to one of the
proteins (bait). The sensor tip can be coated in an antibody-containing matrix which
allows targetting of specific proteins, for example an anti-glutathione-S-transferase
(anti-GST) sensor tip will selectively bind to GST-tagged proteins. After binding of
the first protein, the resulting interference signal can be normalised and the second
protein (prey) allowed to bind. The additional layer of protein from the second binding
event can be measured and processed to provide association parameters. The sensor
can then be transferred into a solution containing no protein and the dissociation
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parameters also measured.
Presented here is an investigation into the feasability of utilising BLI for analysing
the interaction between the BoNT HC domain and a protein-receptor, specifically
glycosylated SV2C.
4.2 Methods
All materials were purchased from Sigma Aldrich unless otherwise specified.
4.2.1 Construct Cloning and DNA Production
DNA encoding human SV2C luminal domain 4 was provided by Ipsen Bioinnovation
Ltd. The final construct for mammalian cell expression was produced in multiple
stages. First a GST-tag was added to the N-terminal end of the SV2C sequence
through sub-cloning into the pOPINJ vector from the Oxford Protein Production
Facility (OPPF) (Berrow et al., 2007). Next, an N-terminal IL2 signal sequence was
added before the GST-tag by PCR amplification of GST-SV2C using a primer encoding
IL2. Finally, the entire construct was ligated into linearised pOPINJ which lacked
any gene insert. The final plasmid was confirmed by sequencing (MWG Eurofins,
Germany) and transformed into E. coli Top10 cells for production of a large quantity
of DNA for transfection. 500 mL cultures were grown and processed by alkaline lysis
using a GigaPrep kit (Qiagen) according to manufacturers instruction to isolate the
DNA.
4.2.2 HEK293T Transient Transfection
Transfections were performed in two expanded surface (2125 cm2) roller bottles
(Cellmaster™, Greiner Bio-One). Each bottle was seeded using HEK293T cells from a
T175 flask at > 90% confluency. Briefly, media was removed from a T175 flask and
cells washed once using 10 mL PBS. 5 mL trypsin solution was added and the flask
was rocked until all cells had dissociated. 20 mL DMEM (Dulbecco’s Modified Eagle
Medium, ThermoFisher Scientific, 41965039) containing 10% (v/v) FBS was mixed
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with the trypsin solution and the total volume (25 mL) added to one roller bottle. The
final volume of each roller bottle was 250 mL after addition of 225 mL DMEM (10%
(v/v) FBS). Roller bottles were incubated at 37 ◦C in a 5% CO2, humidified atmosphere
incubator whilst rotating at 0.5 rpm for the first 24 hours post-seeding and 0.8 rpm
thereafter. The media was then removed from each roller bottle and replaced with 200
mL DMEM (2% (v/v) FBS). To produce the transfection solution, 100 mL DMEM (2%
(v/v) FBS) was divided equally between two vessels. To the first, 1 mg plasmid DNA
was added and to the second 1.75 mL of 1 mg mL−1 polyethylenimine (PEI, Sigma
Aldrich, 408727) pH 7.5. Both solutions were combined and vortexed briefly before 10
min room temperature incubation. A 50 mL volume of the transfection solution was
subsequently added to each roller bottle which was then incubated at 37 ◦C in a 5%
CO2, humidified atmosphere incubator whilst rotating at 0.8 rpm. Four days later the
media was harvested and stored at -20 ◦C until needed. 250 mL DMEM (10% (v/v)
FBS) was added to each roller bottle which was left to incubate for a further four days.
Finally the media was again harvested from each bottle, stored at -20 ◦C and the cells
discarded.
4.2.3 Protein purification
Raw cell media was purified in batches of 500 mL using the following method. Cell
media was centrifuged at 4000 g for 30 min and filtered through a 0.2 µm filter
to remove cell debris. An XK 16/20 (GE Healthcare) column was packed with 10
mL Glutathione Sepharose 4B (GE Healthcare). The column was equilibrated using
phosphate buffered saline (PBS; Oxoid, BR0014). Cleared cell media was loaded onto
the column using a flow rate of 0.5 mL min−1. After loading, the column was washed
using two column volumes of PBS and protein eluted into 1 mL fractions using 50
mM Tris-HCl, 200 mM NaCl, 20 mM reduced glutathione, pH 8.0. Eluted fractions
were analysed by SDS-PAGE (see section 3.2.1). Fractions containing GST-SV2C were
buffer-exchanged into 50 mM Tris-HCl, 200 mM NaCl, pH 8.0 and concentrated to
0.5 mg mL−1 using a 10 MWCO spin concentrator. Finally, protein was stored at
-20◦C until needed.
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4.2.4 Glycosylated hSV2C Mass Spectrometry
20 µg of purified hSV2C was run on a 10% SDS-PAGE gel. The band was excised
using a sterile blade and sent to the Discovery Proteomics Facility (Oxford University)
for mass spectrometry.
4.2.5 Protein – Protein Binding Assay
BoNT HC domain to gSV2C binding interactions were assayed using BLI on an
OctetQK. GST-tagged gSV2C was diluted to 10 µg mL−1 in PBS and 200 added to
each well of column B in a 96-well plate (black, Greiner). The BoNT HC domain to be
assayed was diluted in a concentration series to: 600 nM, 300 nM, 150 nM, 75 nM and
37.5 nM. 200 of each concentration was added to respective wells of column D in the
96-well plate. 200 PBS was added to all wells in columns A, C and E. Sensors were
pre-soaked in 200 PBS, 10 min prior to starting the assay. A baseline measurement was
taken with sensors in column A for 100 s. GST-tagged gSV2C was loaded onto the
sensors for 1000 s. A second baseline was measured for 100 s. Sensors were dipped in
wells containing BoNT HC domains for 1000 s before dissociation for another 1000 s.
4.2.6 Analysis
A reference sensor was used to subtract a baseline measurement from all other sensors
in the Analyse (ForteBio) software package. A 2:1 heterogeneous model was fitted to
the data using a global fit across sensors in both the Analyse software (ForteBio) and
GraphPad Prism.
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4.3 Results and Discussion
4.3.1 Purification of Glycosylated SV2C
The luminal domain 4 of SV2 isoform C (SV2C) expression was performed in mam-
malian cells to ensure glycosylation. A large quantity of the SV2 construct DNA
(10 mg) was isolated from E. coli culture and used to transfect two 2 m2 roller bottles
of HEK293T cells. Expressed protein was secreted by the HEK293T cells and recovered
from the cell media. The SV2C was purified from the cell media in a two stage process,
first by affinity chromatography with a GSTrap column (GE Healthcare) and secondly
by size-exclusion chromatography (Figure 4.2). A very small amount of SV2C was
produced per batch indicated by the low protein absorbance levels on the purification
chromatograms (Figure 4.2). The GST-tagged protein had a calculated mass of 38.1
kDa and appeared as a smear of slightly higher molecular weight by SDS-PAGE
(Figure 4.3). A faint, lower molecular weight, band was also present and presumed
to be free GST. A sample sent for mass spectrometry analysis observed the masses
of complex glycans attached to both N534 and N559 of the SV2 protein, the latter is
involved in HC/A1 binding interactions (Yao et al., 2017).
4.3.2 Recording of Binding Data
HC/A1–/A6 were previously purified as presented in Chapter 3. Matching buffers
throughout the experiment are essential. All proteins were buffer exchanged into a
commercially available formulation of phosphate buffer saline (PBS) pH 7.4 before
binding experiments. To ensure stable readings when running assays using the
Octet (ForteBio), the equipment was switched on at least two hours before starting
a run for the temperature to fully stabilise. Running an assay before temperature
stabilisation could cause the baseline to drift significantly. Various concentrations
of HC domains were assayed between 600 nM and 35 nM. At concentrations above
300 nM, non-specific binding was observed and at concentrations below 70 nM the
signal-to-noise was very low. For these reasons, three concentrations were used for
each assay 300 nM, 150 nM, and 75 nM.
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Figure 4.2: Purification of Glycosylated SV2C
(a) Mammalian cell media containing secreted SV2C was purified using affinity chromatogra-































Figure 4.3: Glycosylated SV2C Purification
SDS-PAGE.
10% SDS-PAGE following purification of gly-
cosylated SV2C from mammalian cell culture.
Lane 1: Molecular weight marker. Lane 2:
Crude media before purification. Lane 3: Un-
bound protein after GSTrap column (GE Health-
care) purification. Lane 4: Column wash. Lane
5: Eluted protein from the GSTrap column.
Lane 6: Eluted protein from size-exclusion chro-
matography.
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4.3.3 Processing and Analysis of Binding Data
The post-processing of binding data can have a significant effect on overall values and
curve fitting procedures can be quite sensitive to slight differences between datasets.
To ensure data between BoNT subtypes was comparable, an identical procedure was
followed for each. Data was normalised by reference subtraction. This step can be
prone to systematic errors as we are relying on collecting very good data for our
reference set. To take an incorrect reference subtraction into account when fitting
a model, a parameter was added to provide a global offset to the response values.
For example, a small error in background subtraction can be adjusted for with the
addition of this parameter. In addition to offset adjustments, each biosensor has its
own unique binding capacity due to variances in manufacture. The parameters for
Rmax where not constrained between datasets to account for this. All other parameters
were constrained across all datasets. The data clearly did not fit a 1:1 binding model,
instead a 2:1 heterogeneous binding model was used. A previous assay which utilised
surface plasmon resonance (SPR) to measure the binding of HC/A1 to SV2 also
observed 2:1 binding (Yao et al., 2016). The exact reason for non-1:1 binding is not
clear but we speculate that the HC–glycan interaction and HC–SV2-protein interaction
may occur as two independent events.
Data from three independent runs were collected for HC/A1 to /A6. Binding models
were only able to be fit to collected data from HC/A1, /A2, /A3, and /A6. We
speculate that increased protein aggregation or non-specific binding was causing
variation between protein concentrations. Despite repeated runs from multiple batches
of HC/A4 and HC/A5, stable and consistent binding data could not be achieved.
Previous experience of purifying HC/A4 has shown it to be less stable and more
prone to aggregation than other HC domains (Chapter 3). The 2:1 binding models
appear to fit the other datasets well (Figure 4.4) and binding parameters could be
calculated (Table 4.1). For each protein, two separate dissociation constants, KD1 and
KD2, are calculated from each assay. While all KD values fall within the micromolar
to nanomolar range, there is quite some variation across the HC domains. HC/A6 in
particular, stands out and has a slow dissociation rate compared with the other HC
domains for both binding events in the 2:1 model (Table 4.1).
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Yao et al. (2016) have previously investigated the binding of HC/A1 to glycosylated
SV2 and determined to KD values of 2.2 × 10−7 M and 1.5 × 10−8 M which are near to
the values determined for HC/A1 here. Unfortunately, no other published binding










































































Figure 4.4: HC/A–SV2 Binding
Binding curves (black) for (a) HC/A1, (b) HC/A2, (c) HC/3, and (d) HC/A6 to glycosylated
SV2C using Biolayer interferometry. The calculated model is displayed in red. Displayed
curves represent the mean from 3 independent experiments. Binding is inferred from the
increase in measured optical thickness at the sensor tip in nanometers. The binding curves
shown are a combination of association and dissociation events where dissociation begins at
Time = 1000s.
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Table 4.1: HC/A – SV2C binding parameters
Kinetic binding parameters for the interation between BoNT HC domains and gSV2C. Displayed values represent the mean from 3
independent experiments and a standard error given for each value.
Subtype kon1 (M−1s−1) ko f f 1 (s−1) KD1 (M) kon2 (M−1s−1) ko f f 2 (s−1) KD2 (M)
A1 1.1 ± 0.018 × 104 5.5 ± 1.8 × 10−4 5.2 ± 0.15 × 10−8 6.8 ± 2.1 × 103 9.0 ± 0.18 × 10−3 1.1 ± 0.031 × 10−7
A2 5.1 ± 0.061 × 105 2.9 ± 1.3 × 10−3 5.6 ± 0.63 × 10−7 4.5 ± 0.18 × 103 2.0 ± 0.11 × 10−4 4.5 ± 0.32 × 10−8
A3 4.9 ± 0.330 × 104 3.7 ± 0.0005 × 10−2 7.4 ± 0.48 × 10−7 3.3 ± 0.077 × 103 1.9 ± 0.047 × 10−4 5.7 ± 0.20 × 10−8
A4 – – – – – –
A5 – – – – – –
A6 4.6 ± 0.460 × 104 7.5 ± 69 × 10−7 1.6 ± 0.14 × 10−7 1.1 ± 0.0089 × 104 7.8 ± 0.69 × 10−5 6.8 ± 0.58 × 10−9
Binding parameters could not be determined for HC/A4 or HC/A5.
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4.3.4 2:1 Heterogeneous Binding Model
BLI binding data collected on the Octet (Fortebio) may be processed with the built-in
proprietary software. However, reliance on proprietary software limits the ability
for scientists to share their methods freely as in most cases the software must be
purchased. While the proprietary software in many cases is very good, finding an
alternative method to process data should always be investigated. In this Chapter,
binding data are presented which conform to a 2:1 heterogeneous binding model.
We have written a small software library for analysing heterogeneous binding model
which can be run within the open-source and free software, R (R Core Team, 2018).
The 2:1 model was written using equations 4.1 to 4.6 and an example can be found in
Figure 4.5.









Rassociation = Req[1 − exp(−kobst)] + Req2[1 − exp(−kobs2t)] (4.4)







Rassociation if t < t0
Rdissociation if t ≥ t0
(4.6)
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Figure 4.5: 2:1 Heterogeneous Binding Model
Left panels display an example measured 2:1 binding response (black) and fitted 2:1 hetero-
geneous model (red). Right panels display individual binding components that contribute
to the 2:1 heterogeneous binding, solid and dashed lines respectively. Parameters from the
fitted model were used to simulate each 1:1 binding response using the R package pbm v1.1.0
(Davies, 2018. Unpublished*).
∗Available on The Comprehensive R Archive Network at https://cran.r-project.org/package=pbm
4.4 Conclusions
Accurate measurement of binding parameters is useful for both the development of
novel BoNTs and investigation of existing variant. We successfully expressed and
purified a glycosylated form of SV2C from mammalian cells and measured binding to
a range of BoNT/A HC domains. The binding data presented here for HC/A1 are of
comparable values to a previously reported binding assay (Yao et al., 2017) suggesting
that this is a viable approach to investigate BoNT binding. Two of the proteins assayed,
HC/A4 and HC/A5, failed to produce data of sufficient quality to fit accurate binding
models, possibly due to aggregation or non-specific binding to the sensor tip.
This assay may be useful for a direct comparison of similar variants but there are many
other parameters that are worth noting. Most BoNTs form a dual-receptor complex on
the neuronal cell surface, and there is evidence of specific serotypes (BoNT/B, /DC
and /G) which utilise a loop to add further interaction with the plasma membrane
(Fu et al., 2009; Berntsson et al., 2013; Stern et al., 2018). The approach utilised here
may not be suitable in all cases as a better understanding of BoNT binding may come
from assessment of all binding interactions together. It may be more appropriate to
develop an assay which is capable of measuring direct interaction to the cell surface.
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5. Conformation of Botulinum Neurotoxins in Solution 5.1. Introduction
5.1 Introduction
Botulinum neurotoxins (BoNTs) are a family of proteins that cause the condition
botulism (Coffield et al., 1997; Schiavo et al., 2000; Rossetto et al., 2014). Traditionally
BoNTs have been classified into seven distinct serotypes termed BoNT/A through
BoNT/G. In addition several novel BoNTs and BoNT-like proteins have recently been
discovered which do not fall under these serotypes. BoNTs are composed of two
protein chains, a 50 kDa light chain and a 100 kDa heavy chain, which remain bound
by a single disulfide bond. The LC consists of a zinc-dependent endopeptidase while
the HC contains a translocation domain (HN) and a receptor-binding domain (HC). To
date, the full-length crystal structure has been determined for three BoNT serotypes:
BoNT/A, BoNT/B and BoNT/E (Lacy et al., 1998; Swaminathan and Eswaramoorthy,
2000; Kumaran et al., 2009). The crystal structure of BoNT/A reveals a unique domain
organisation that can be described as a ‘butterfly’ with both the LC and HC extending
from either side of the central HN (Lacy et al., 1998). The BoNT/B crystal structure
also reveals a similar domain organisation to that of BoNT/A (Swaminathan and
Eswaramoorthy, 2000). Unlike both BoNT/A and BoNT/B, the crystal structure of
BoNT/E reveals a distinct domain organisation where the HC wraps around the HN
and LC, resulting in a more compact structural arrangement (Kumaran et al., 2009)
(Figure 5.1). BoNT/E has been found to translocate much more rapidly than BoNT/A
and BoNT/B (Sun et al., 2012; Wang et al., 2008; Kumaran et al., 2009; Keller et al.,
2004).
90°
Figure 5.1: BoNT Domain Organisation
A comparison between the BoNT/A HC (blue) and BoNT/E HC (green) location with respect
to the LC and HN domains. The LC of both structures were superposed and the LC and HN
of BoNT/A are hidden.
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It has been proposed that the increased translocation rate is due to the unique
conformation of BoNT/E as determined by X-ray crystallography (Kumaran et al.,
2009). The suggestion that conformation of BoNTs can affect translocation speed is
particularly interesting for the generation of novel therapeutics. Prior to the release
of the BoNT/E crystal structure, BoNT/E was subject to analysis by negative-stain
electron microscopy (EM) (Fischer et al., 2008). The EM micrographs revealed the
possibility of multiple conformations, one of which compares well with the crystal
structure. These data together suggest the protein may be highly flexible and able
to adopt multiple conformations in solution. In addition, crystallisation experiments
utilise conditions that are designed to favour and stabilise protein-protein interactions
resulting in a highly-ordered crystal, and as a result some crystal structures may
contain interactions which would not be present under physiological conditions
(Dafforn, 2007). As is the case with any X-ray crystal structure, the resulting model
is an interpretation of the protein state within a crystal and in some cases further
evidence must be sought to confirm any structural analyses.
A low-resolution structural biology technique called small-angle X-ray scattering
could be used as a complementary technique to investigate further the full-length
structure of BoNTs and determine whether the compact fold of BoNT/E is also its
structure in the solution state. This technique, as discussed below, may also be useful
for investigating the domain organisation of other BoNTs which do not yet have
full-length crystal structures. As discussed in Chapter 2, crystallography enables the
high resolution structural determination of any protein, provided that protein can be
crystallised in the first place. When investigating different or novel BoNT variants, it is
not realistic to expect the protein to crystallise, indeed many attempts of crystallising
other BoNT serotypes have so far resulted in little reward.
121
5. Conformation of Botulinum Neurotoxins in Solution 5.1. Introduction
5.1.1 Small-Angle X-ray Scattering (SAXS)
Small-angle X-ray scattering (SAXS) is a biophysical technique which can be used to
characterise biological molecules. In contrast to X-ray crystallography, SAXS exper-
iments do not require crystals and are instead performed on molecules in solution.
X-rays interact with individual atoms, generating secondary wavelets which results
in coherent scattering. Small-angle scattering results from the coherent scattering
of individual atoms within an individual molecule or protein in solution (Jacques
and Trewhella, 2010). For biological applications, SAXS is most often used to investi-
gate proteins and other large complexes in solution. The ability to record data from
molecules in solution is one of the key benefits of SAXS. When studying proteins, the
resulting data can provide information to complement crystal structures including
the native oligomeric state, low-resolution solution structure and conformational
information (Neylon, 2008). Exposure of the protein solution to X-rays results in X-ray










Figure 5.2: SAXS Experiment Schematic The incoming x-ray beam of wavelength, λ passes
through the sample in solution within a sample capillary. Some of the x-ray beam is scattered
by the sample at the maximum angle 2θ.
In contrast to X-ray crystallography where proteins are arranged in an ordered and
well-defined lattice, molecules in solution produce scattered X-rays that are rotationally
averaged and at low angles and thus the detector must be positioned far from the
sample, usually 5-15 m. The X-ray scattering distance q is measured along with
the intensity and these data are combined for subsequent analysis. A typical SAXS
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experiment measures the difference in electron density between a protein solution and
that of the bulk solvent. Therefore, it is essential that the protein sample is extremely
pure and monodisperse to ensure that the resulting data are free of contributions
from impurities and aggregates. Protein samples must be reasonably concentrated in
order to improve the signal-to-noise of the recorded SAXS signal, and additionally it
is helpful if the protein of interest is large as larger proteins will scatter more photons.
The photon scattering ability of proteins in solution is extremely weak, for example
an estimation using myoglobin (16.7 kDa) concentrated to 1 mg mL−1 in water will
scatter < 1 in 106 photons (Stuhrmann, 1980). Longer exposure times can increase
signal but also lead to beam-induced radiation damage of the sample and inaccurate
measurements.
The main source of radiation damage is produced after X-ray exposure to the solvent,
resulting in free hydroxyl (OH•) and hydroperoxyl (HO•2) radicals. These free radicals
can attack the peptide chain and drive aggregation. Additionally, having a perfectly
matched buffer solution is necessary to subtract the buffer signal from the protein
solution. Usually, one would collect data from a protein solution exposure, followed by
a buffer exposure. New approaches to improve SAXS data collection have addressed
many of the problems mentioned (Trewhella et al., 2017). One such approach is to
connect a high-performance liquid chromatography (HPLC) system complete with a
size-exclusion chromatography (SEC) column inline with the beamline. This setup,
termed SEC-SAXS, can firstly ensure that signal from a highly-pure non-aggregated
protein sample is collected in addition to a perfect buffer sample which can be collected
before and/or after the protein has eluted. One limitation of using SEC-SAXS is the
reduced protein concentration, caused by dilution through the SEC column and
associated tubing. Beamlines with low-noise detectors and high flux can overcome
this issue but collecting and merging signal from multiple exposures as the eluted
protein passed through the beam.
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SAXS Data Processing
The first step in processing the data recorded by a typical SAXS experiment is to
produce a scatting profile consisting of I(q) versus q, where q = 4π sin θ/λ, for both
the sample solution and buffer. The buffer scattering is then subtracted and the
resulting profile is the scattering of the protein molecule alone. One parameter that
can be calculated directly from the SAXS data is the radius of gyration (Rg) (Guinier,
1939). When plotting the natural logarithm of the intensity, ln[I(q)], against the square
of the scattering vector, q2, the slope of the linear region at low angular range (low






where the intercept at q = 0 is the forward scattering at zero angle, I(0). The values
of Rg can be determined with high accuracy and changes in Rg can be utilised as
a sensitive indicator of the shape of the molecule (Tuukkanen and Svergun, 2014).
A non-linear plot at q.Rg < 1.3 is indicative of polydispersity, poor background
subtraction or unwanted sample interaction effects, either aggregation or repulsion
(Blanchet and Svergun, 2013). Protein aggregation results in a large increase of
scattering intensity at low q angles which results in the overestimation of both I(0)
and Rg. Therefore it is highly important to have monodisperse samples, typically a
range of protein concentrations are measured to ensure that a concentration is chosen
where aggregation is not an issue. As mentioned above, SEC-SAXS may be able to
recover good data where protein samples are likely to aggregate over time. In addition
to Rg calculations, an indirect Fourier transform of the one-dimensional scattering
profile, I(q) vs. q, can be used to estimate the Dmax, that is the largest vector between
any two atoms within the protein. Together, these data provide information about
the 3-dimensional structure of the protein in solution which can be used to directly
compare with existing crystal structures.
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5.1.2 Molecular Dynamics
Molecular dynamics is a computational technique used to analyse molecular motions
motions including protein folding and ligand interactions (Hug, 2013). The motion
of a molecule is simulated in silico through solving of Newton‘s equation of motion
simultaneously for all atoms. As a result, larger systems (i.e. a large protein) need
much more computational power than small systems. To increase the speed and
efficiency of such simulations, forces between atoms are calculated using force fields.
A force field is a mathematical description of the interaction between specific atomic
types in a specific environment that has been empirically determined. This approach
can be described as course-grained, where the nucleus and electrons of an atom
are treated as one and their motion together follow the rules set out within the
force field. Another technique to simulate molecules is by quantum mechanical
molecular dynamics, where atoms are explicitly simulated and there is no reliance
on a simplified force field. As a result of the increase calculations needed, quantum
mechanical simulations are inherently slow compared to classical molecular dynamics
and only suited to small molecules or small portions of a larger molecule.
Force fields describe two types of interaction, bonded and non-bonded (Weiner et al.,
1984). Bonded interactions generally refers to atoms which are covalently bonded
and the force field describes their bond-stretching, bond-rotation and angle-bending
propensity. Non-bonded interactions refers to all other interactions such as electrostatic
and van der Waals interaction. The flexibility of proteins from simulations can also
be quantified following a simulation by calculating the root mean square fluctuation
(RMSF) of atoms over the course of the simulation.
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5.2 Methods
All materials were purchased from Sigma Aldrich unless otherwise specified.
5.2.1 Construct Production
DNA constructs containing BoNT/A1(0), BoNT/F1(0), and BoNT/FA(0) were pro-
vided by Ipsen Bioinnovation Ltd.
5.2.2 E. coli Transformation
A single aliquot containing 50 of chemically competent cells was thawed on ice for 10
min. 1 of DNA (up to 200 ng) was added to the cells which were placed back on ice
for a further 30 min. Cells were incubated at 42◦C for 30 seconds to heat-shock before
returning to ice for 5 min. 950 SOC media, prewarmed to 37◦C was added to each
aliquot which was then placed in an incubator at 37◦C while shaking at 225 rpm for 1
hour. 200 from each transformation culture was spread onto a pre-warmed LB (Miller)
agar plate containing an appropriate antibiotic. The LB (Miller) agar plate was left at
37◦C for 16 hours for colonies to grow.
5.2.3 Protein Expression
A starter culture containing 100 mL mTB was inoculated with E. coli from a glycerol
stock and incubated at 37◦C for 16 hours while shaking at 225 rpm. 10 mL of the
starter culture was used to inoculate flasks each containing 500 mL mTB. The flasks
were incubated at 37◦C while shaking at 225 rpm, when the OD600 reached 0.6 the tem-
perature was decreased to 16◦C. Protein expression was induced in both flasks when
the OD600 reached 1 by the addition of IPTG (Isopropyl β-D-1-thiogalactopyranoside)
to a final concentration of 1 mM. Following induction the culture flasks were left for
a further 16 hours before harvesting cells. Cells were harvested by centrifugation at
4000 xg and cell pastes stored at -80◦C.
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5.2.4 Purification of Full-Length BoNT/A1(0)
Cell pastes were re-suspended in 10 mL g−1 lysis buffer (50 mM Tris-HCl pH 8.0, 25
mM NaCl) plus 2 benzonase (500 units) with stirring for 30 min at 4◦C. Re-suspended
cells were lysed by passing through a cell disruptor (Constant Systems), using a
pressure of 20 kPSI, twice at 4◦C. Cell debris was removed by centrifugation at 30,000
x g for 45 min. Clarified lysate was adjusted to contain 1 M ammonium sulfate by
the slow addition of conditioning buffer (50 mM Tris-HCl, 3 M ammonium sulfate,
pH 8.0). The lysate was incubated at 4◦C for 30 min before centrifugation at 30,000 x
g for 45 min to remove insoluble precipitate. The clarified lysate was loaded onto a
100 mL butyl sepharose HP column (GE Healthcare). Following sample loading, the
column was washed using butyl buffer B (50 mM Tris-HCl, 1 M ammonium sulfate,
pH 8.0). Bound protein was eluted using a gradient to 100% butyl buffer A (50 mM
Tris-HCl pH 8.0) over 10 column volumes (1 L). Fractions containing BoNT/A1(0),
determined by visual inspection of an SDS-PAGE gel (see section 3.2.1), were pooled
and concentrated using a 10 MWCO spin concentrator. The pooled and concentrated
fractions were desalted into butyl buffer A using a HiPrep Desalting Column (GE
Healthcare). Desalted protein was loaded onto a 50 ml Q HP column (GE Healthcare)
using a flow rate of 10 mL min−1. The column was washed with butyl buffer A and
bound protein eluted using a gradient to 20% Q Buffer (50 mM Tris-HCl, 1 M NaCl,
pH 8.0) over 2 column volumes (100 ml).
5.2.5 Purification of Full-Length BoNT/B1(0)
BoNT/B1(0) was purified as described previously (Elliott et al., 2017) and generously
provided by Ipsen Bioinnovation Ltd. Briefly, recombinant BoNT/B(0) was expressed
using E. coli and cells were lysed by ultrasonication in 0.2 M NaCl, 50 mM Tris-HCl, pH
8. Lysate was clarified by centrifugation at 4500 rpm for 30 minutes at 4°C. Clarified
lysate was passed through an anion exchange column before buffer exchanging to 1 M
(NH4)2SO4 in 50 mM Tris-HCl, pH 8. The protein was then purified by hydrophobic
interaction resin (high performance butyl Sepharose, GE Healthcare) using a linear
gradient to 0.5 M (NH4)2SO4 followed by another anion-exchange step. The partially
purified protein was then proteolytically cleaved with 0.2 µg mL−1 Lys-C to yield
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a di-chain and the buffer was adjusted to 1 M (NH4)2SO4 in 50 mM Tris-HCl, pH
8. Finally the protein was further purified with a second hydrophobic interaction
resin (high performance phenyl Sepharose, GE Healthcare) using a gradient to 0.5M
(NH4)2SO4 and desalted into PBS pH 7.2.
5.2.6 Purification of Full-Length BoNT/FA(0)
Full-length BoNT/FA(0) was expressed in 2 L of mTB medium. Cell pastes were
re-suspended in 10 mL g−1 lysis buffer (50 mM Bis-Tris methane-HCl pH 6.8, 0.5 M
NaCl) plus 2 benzonase (500 units) with stirring for 30 min at 4◦C. Re-suspended cells
were lysed by passing through a cell disruptor (Constant Systems) at 4◦C. Cell debris
was removed by centrifugation at 30,000 x g for 45 min. The lysate was loaded onto a
5 mL HisTrap HP column (GE Healthcare) and eluted using a gradient from 0 M to
0.5 M imidazole-HCl. Finally the protein was further purified with by size-exclusion
chromatography (GE Healthcare) using the lysis buffer.
5.2.7 Purification of Full-Length BoNT/F1(0)
Full-length BoNT/F1(0) was expressed in 4 L of mTB medium. Cell pastes were
re-suspended in 6 mL g−1 lysis buffer (50 mM Tris-HCl, 200 mM NaCl, pH 8.0) plus 2
benzonase (500 units) with stirring for 30 min at 4◦C. Re-suspended cells were lysed
by passing through a cell disruptor (Constant Systems) twice at 4◦C. Cell debris was
removed by centrifugation at 30,000 x g for 45 min. Clarified lysate was adjusted to
contain 1.3 M ammonium sulfate by the slow addition of conditioning buffer (50 mM
Tris-HCl, 3 M ammonium sulfate, pH 8.0). The ‘cut lysate’ was incubated at 4◦C for 30
min before centrifugation at 30,000 x g for 45 min to remove insoluble precipitate. The
clarified sample was loaded onto a 50 mL butyl sepharose HP column (GE Healthcare).
Following sample loading, the column was washed using butyl buffer B (50 mM Tris-
HCl, 1.3 M ammonium sulfate, pH 8.0). Bound protein was eluted using a gradient to
100% butyl buffer A (50 mM Tris-HCl pH 8.0) over 20 column volumes (1 L). Fractions
containing BoNT/F1(0), determined by visual inspection of an SDS-PAGE gel (see
section 3.2.1), were pooled and concentrated using a 10MWCO spin concentrator.
Concentrated columns were desalted into butyl buffer A using a HiPrep Desalting
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Column (GE Healthcare). Desalted protein was loaded onto a 50 ml Q HP column
(GE Healthcare) using a flow rate of 10 mL min−1. The column was washed with butyl
buffer A and bound protein eluted using a gradient to 25% Q Buffer (50 mM Tris-HCl,
1 M NaCl, pH 8.0) over 2 column volumes (100 ml).
5.2.8 SAXS Data Collection - Batch Mode
Proteins to be analysed by batch mode SAXS were buffer exchanged into phosphate
buffered saline (PBS). Each protein sample was diluted 10-fold using PBS and con-
centrated to 10% of the diluted sample volume using a 50 MWCO spin-concentrator
(Millipore). The protein sample buffer exchange was repeated four times. The flow-
through was collected at the end of the final buffer exchange and saved for use as the
buffer blank SAXS measurement for perfect background subtraction.
5.2.9 SAXS Data Collection - HPLC Mode
Small-angle X-ray Scattering (SAXS) data were collected at beamline B21 of the Dia-
mond Light Source (Oxon, UK), using a PILATUS-6M detector (Dectris, Switzerland).
An Agilent 1200 HPLC system on beamline B21 at Diamond Light Source was setup
with a Superdex200 column (GE Healthcare) and equilibrated using PBS. Protein sam-
ples were concentrated and loaded onto the column at a flow rate of 0.075 mL min−1.
Eluted protein was run into a capillary which passed directly through the x-ray beam
and data were collected at 15◦C using a beam energy of 12.4 keV. Exposures of 1
second were continuously recorded during the run.
5.2.10 SAXS Data Reduction
For batch-mode SAXS, frames corresponding to the buffer blank were averaged and
the Rg was estimated across the protein exposure using Scatter (Diamond Light Source,
UK). Where the estimated Rg was stable, frames containing protein scattering signal
were averaged and then subtracted by removing the contribution from the averaged
buffer sample. For HPLC-mode SAXS the data were processed using software from the
ATSAS (version 2.8.3) package (“New developments in the ATSAS program package
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for small-angle scattering data analysis.” 2012). HPLC-SAXS frames were input to
Chromixs (ATSAS) and the peak elution scattering from the HPLC run was subtracted
using a stable buffer baseline.
5.2.11 SAXS Data Analysis
To determine the Rg, a Guinier approximation was used by applying a linear fit to
log(I) against q2 within Primus (ATSAS) (“New developments in the ATSAS program
package for small-angle scattering data analysis.” 2012). The Shapiro-Wilks test for
normality was applied to the residuals to ensure a good fit using R (R Core Team, 2018).
Theoretical scattering curves from high-resolution X-ray crystallographic structures
were generated and fit to experimental data using CRYSOL (ATSAS) with a subtraction
constant to account for possible systematic errors.
5.2.12 Molecular Dynamics Simulations
Crystal structures used for molecular dynamics were first manually processed. Ligands
and other non-protein molecules present in the crystal structure were stripped from the
PDB file using PyMol (v1.8, Schrödinger, LLC) and missing loops were modelled using
Rosetta (Simons et al., 1997). All molecular dynamics simulations were performed
using GROMACS (Abraham et al., 2015). The proteins were first solvated in a cubic
box of pre-equilibrated waters which extended at least 10 Å from any protein atom.
The system net charge was neutralised with the addition of Na+ or Cl− ions. All
simulations were run using the Amber99sb-ILDN (Lindorff-Larsen et al., 2010) force
field and the TIP3P water model (Jorgensen et al., 1983; Harrach and Drossel, 2014).
Before the main MD runs were performed, the system was energy minimised using
the steepest method until the target maximum force (Fmax < 1000 kJ mol−1 nm−1) was
reached. The system was further equilibrated under NVT conditions (constant number
of particles, volume, and temperature) for 100 ps with a target temperature of 300 K,
followed by NPT conditions (constant number of particles, pressure, and temperature)
for another 100 ps each with time steps of 2 fs. All production runs were performed at
300 K, out under NPT conditions for 100 ns with a 2 fs time step.
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5.2.13 Molecular Dynamics Analysis
Analysis of each production trajectory was completed using GROMACS (Abraham
et al., 2015). Each trajectory was modified by centering the protein molecule within the
box to correct for positional jumps when the protein left one side of the box boundary.
The corrected trajectories were used to calculate the RMSD, RMSF and Rg. Data were
averaged across trajectories for the RMSF and average Rg calculations using R (R Core
Team, 2018).
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5.3 Results and Discussion
5.3.1 Molecular Dynamics
The crystal structure of BoNT/E1 reveal a compact domain organisation which may
have implications for the speed of translocation during intoxication. Molecular
dynamics was used to further investigate whether the crystal structure is a stable
conformation in solution and is not due to crystal packing. Computational simulation
of BoNT/E1 in a hydrated box was completed in order to assess the stability of
the ‘closed’ crystal structure conformation. The crystal structure (PDB ID: 3FFZ
Swaminathan and Eswaramoorthy (2000)) was initially manually processed to remove
all non-protein atoms with exception to the LC active-site zinc, and missing amino
acid side-chains were added. A small disordered region of the belt (S460–N466), for
which there were no atoms in the crystal structure, was built ab initio using Rosetta
(Simons et al., 1997). The molecular dynamics system was created and the protein
placed in a cubic box, solvated with a 3-point water model which extended at least
10 Å from any protein atom. Chloride ions were also added to ensure the protein
charges remained neutral. The structure was energy minimised until the system





















Figure 5.3: BoNT/E MD Energy Minimisation
The BoNT/E crystal structure was energy minimised within the molecular dynamics system
until the potential energy of the protein was stable.
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The crystal structure of BoNT/A1 was also subjected to molecular dynamic simulation
for comparison against our BoNT/E1 data. The structure was manually processed to
add missing amino-acid side chains and the molecular dynamics system was setup in
the same manner as BoNT/E. The system was energy minimised for ~ 4 ns until the




















Figure 5.4: BoNT/A MD Energy Minimisation
The BoNT/A crystal structure was energy minimised within the molecular dynamics system
until the potential energy of the protein was stable.
Each energy-minimised structure was then used as a starting point to produce three
independent molecular dynamics simulations (trajectories) of 100 ns for analysis. The
simulations progressed at 5.4 ns d−1 on 20 threads of a local server containing an
Intel® Xeon® processor E5-2630v4. The total running time was over 110 days. For both
BoNT/A1 and BoNT/E1, the three trajectories were reasonably stable across the full
time period with an maximum RMSD from the starting model of 5.2 Å (Figure 5.5).
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Figure 5.5: Molecular Dynamics RMSD
The RMSD from the starting energy-minimised structure of (a) BoNT/A1 and (b) BoNT/E1
were calculated over the course of three independent 100 ns molecular dynamics simulations.
To investigate if there is a difference in mobility difference between the domains
of BoNT/A1 and BoNT/E1, the root mean squared fluctuation of each Cα atom
was calculated (Figure 5.6). Comparing two different structures can be challenging,
especially when they contain different protein chain lengths. In the case of BoNTs,
a general comparison is possible due to the distinct domain boundaries. Overall,
BoNT/A1 displays a larger average RMSF value (1.52 Å) than BoNT/E1 (1.25 Å),
alluding to a higher degree of flexibility within the structure. The most striking
differences are observed in the HCC, for which BoNT/E1 has a lower RMSF value
likely due to the additional structural contacts made between the LC and HCN. By far
the largest fluctuation observed for either protein was a disordered loop (BoNT/A1:
Y752–I765; BoNT/E1: Y726–I743;) at one extreme end of the HN domain where the RMSF
> 4 Å. Very little is known about the BoNT HN domain but it is likely to form a pore
which would require a rearrangement of the domain structure.
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Figure 5.6: Molecular Dynamics RMSF
The average root mean squared fluctuation (RMSF) for each residue of (a) BoNT/A1 and
(b) BoNT/E1 over the course of three independent 100 ns molecular dynamics simulations.
Domain boundaries are shown as dashed vertical lines and the average RMSF for each domain
is given. The same RMSF values are represented as a cartoon putty on the crystal structures of
(c) BoNT/A1 and (d) BoNT/E1.
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The trajectory of each run was used to generate clusters which each represent a highly
sampled conformation of BoNT/E. None of the conformations generated represent an
opening of the structure, similar to that of BoNT/A or BoNT/B. The distance between
two residues, one within the HC domain and another within the LC domain, was
calculated for each time point within each of the trajectories. The distance remains
stable, indicating the HC does not move, even transiently, with respect to the LC.
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5.3.2 Purification of Full-length BoNTs
Full-length BoNTs were produced for SAXS analysis. Each protein construct contained
two mutations within the HExxH zinc-binding motif to disable catalytic endopeptidase
activity and ensure that the protein was non-toxic – these are termed endonegative
BoNTs. Such mutations have been shown to have no large effects on the structure of
the protein (Gu et al., 2012).
BoNT/A1
First an endonegative BoNT/A1 was expressed and purified. The protein was pro-
duced without a purification tag and required multiple purification steps including
hydrophobic interaction chromatography and ion exchange chromatography (Fig-
















































































Figure 5.7: Purification of BoNT/A1(0)
(a) HIC purification of BoNT/A1(0) failed to fully separate the protein. (b) Further purification
by IEC removed the contaminants yielding purified BoNT/A1(0).
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BoNT/A1 Figure 5.8: BoNT/A1 Purification SDS-PAGE
4%–12% gradient SDS-PAGE of the final puri-
fied sample of endonegative BoNT/A1.
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BoNT/F1
BoNT/F1 was purified for SAXS analysis using a two step purification procedure 5.9.
A small contaminant was still present after the second purification column 5.10 but
















































































Figure 5.9: Purification of BoNT/F1
(a) Protein was eluted from the a hydrophobic interaction chromatography column using

















Figure 5.10: BoNT/F1 Purification
SDS-PAGE
4%–12% gradient SDS-PAGE of the fi-
nal purified sample of endonegative
BoNT/F1.
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BoNT/FA
BoNT/FA was also purified for SAXS studies. The BoNT/FA construct contained a
10x histidine-tag at the N-terminus which was used for purification by IMAC followed

































































Figure 5.11: Purification of BoNT/FA
(a) IMAC purification of BoNT/FA resulted in a large single peak of eluted protein. Clarified E.
coli lysate was loaded onto a HisTrap column and the column washed before a gradient elution.
(b) Size exclusion chromatography removed small residual contaminants and imidazole from
the IMAC purificaiton.
In addition to SAXS, crystallisation of BoNT/FA(0) was attempted by screening using
the crystallisation screening method described in Chapter 3. Initial concentration of
BoNT/FA(0) resulted in the appearance of thin plate crystals at concentrations above
2 mg mL−1. The crystals were mounted and X-ray diffraction data collection was
attempted at room temperature on a home source. No diffraction was observed and
instead the crystals were crushed for use as a seed stock for crystallisation screening.
Screening resulted in no hits for BoNT/FA(0).
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Figure 5.12: BoNT/FA(0) Purification
SDS-PAGE of each step from the purification of BoN-
T/FA(0). Protein from lysate was captured on a HisTrap
column (GE Healthcare) and the elution desalted. Final
purified protein was diluted to 0.5 mg mL−1.
Figure 5.13: BoNT/FA(0) Crystal Morphology
A 1 µL drop containing thin plate crystals of
BoNT/FA(0) following concentration of the pu-
rified protein.
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5.3.3 BoNT/A1(0) and BoNT/E1(0) SAXS
Data Collection and Processing
The X-ray crystal structures of BoNT/A, BoNT/B and BoNT/E have previously been
determined revealing a unique domain rearrangement of BoNT/E compared with an
open ‘butterfly’ arrangement of BoNT/A and /B. To determine whether the BoNT/A,
BoNT/B and BoNT/E crystal structures are representative of the native conformation
in solution, we collected small-angle x-ray scattering (SAXS) data for each. SAXS data
was collected on beamline B21 at Diamond Light Source in either batch- or hplc-mode.
Initial batch-mode data collected for BoNT/E1(0) showed strong indications of protein
aggregation. At low q the scattering intensity should plateau toward q = 0, but
instead for the batch-mode sample, the intensity increased toward q = 0 (Figure 5.14b).
To improve the data quality, data was collected by another method, SEC-SAXS, for
BoNT/E1(0). Consecutive x-ray exposures were taken for the duration of the SEC
run and a buffer sample from the start of the run was subtracted (Figure 5.14a). To
ensure the largest peak on the SEC run was a single species, the Rg was calculated
across the peak. Buffer-subtracted data for the SEC-SAXS run was significantly better
than data collected for the batch-mode run and protein aggregates were not present
(Figure 5.14b).
Due to the nature of SEC-SAXS, the protein sample BoNT/E1 was less concentrated
than at the start of the run and so the data has a low signal-to-noise and increased noise
at higher q (Figure 5.16). HPLC-mode SAXS data were also collected for BoNT/A1,
BoNT/B1 and BoNT/F1 (Figure 5.15). The X-ray scattering intensity was recorded over
the duration of the HPLC run and can therefore be plotted to display the purification
chromatogram. Immediately clear is the difference in elution profiles between BoNT/E
and the other BoNTs (/A, /B and /F), suggesting it is a smaller or more compact
molecule. The molecular weight of BoNT/E1 (143.8 kDa) is smaller than BoNT/A
(149.5 kDa), /B (150.8 kDa), and /F (147.1 kDa) and therefore this may also cause
a shift toward the right of the size exclusion chromatography peak. The Rg value
was calculated across the peak of each HPLC run and the data for each protein was
background subtracted. Guinier plots were used to find the linear scattering region at
low q in order to determine an approximate radius of gyration (Rg) (Figure 5.16).
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Figure 5.14: BoNT/E1 SEC-SAXS
(a) Intensity of X-ray scattering over time as the BoNT/E1(0) preparation passed through
a Superdex200 (GE Healthcare) size-exclusion chromatography column. A series of buffer
exposures (area 1) were integrated, averaged, and subtracted from integrated protein exposures
(area 2) to produce the final subtracted dataset. The Rg (red points) was calculated for each
exposure along the elution peak. (b) Buffer-subtracted intensities for X-ray scattering data



















Figure 5.15: HPLC-SAXS Elution Profiles The HPLC-SAXS elution profiles were inferred
from measured X-ray scattering during the purification run. Intensities have been scaled
and translated to aid visual appearance. The elution peaks for BoNT/A, /B, and /F are
approximately indicated by the vertical dashed line.
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Figure 5.16: BoNT SAXS Data and Guinier Approximation
Guinier fit and residuals (Left) and recorded SAXS data (Right) for BoNT/A1 (a), BoNT/B1
(b), BoNT/E1 (c), BoNT/f1 (d), and BoNT/FA (e).
144
5. Conformation of Botulinum Neurotoxins in Solution 5.3. Results and Discussion
The crystal structures of BoNT/A and BoNT/B display an ‘open’ domain organisation
similar to each other, therefore we would expect them to have a similar Rg in solution.
Indeed, the experimental Rg of BoNT/A1 and BoNT/B1 was 41.37 Å and 40.79 Å
respectively (Table 5.1). An approximate Rg was also calculated from full-length
crystal structures (Rg PDB). The BoNT/E1 crystal structure displays a ‘closed’ domain
organisation, if the crystal structure was similar to the solution structure then a smaller
Rg would be expected. The experimental Rg of BoNT/E1 was 35.95 Å, smaller than
both BoNT/A and BoNT/B, and near to the calculated Rg from its crystal structure
(Table 5.1). These initial data indicate strongly that BoNT/E1 adopts a more compact
structure than BoNT/A1 in solution. The data collected for for BoNT/A1, /B1, and
/E1 can be used as standards for the investigation into the solution fold of other
BoNTs. It is feasible that collection of SAXS data for any BoNT will enable us to
confidently determine if the BoNT is globular in nature (such as BoNT/E1) or in the
‘open butterfly‘ fold (such as BoNT/A1), or anywhere in between.
Table 5.1: Small-angle X-ray Scattering Parameters
BoNT/A BoNT/B BoNT/E BoNT/F BoNT/FA
I0 0.025 0.028 0.15 0.05 0.021
Rg (Å) 41.37 40.79 35.95 43.01 45.62
Rg PDB (Å) 39.31a 40.59b 35.23c – –
Rg MD (Å) 39.72 – 35.81 – –
Dmax 138.64 139.84 115.11 133.65 NC
Model Fit χ2
BoNT/Aa 1.064 1.073 6.089 1.174 2.969
BoNT/Bb 1.178 0.949 6.183 1.221 2.404
BoNT/Ec 2.666 3.689 0.968 3.226 9.085
a PDB: 3BTA. b PDB: 1S0E. c PDB: 3FFZ. †
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Calculated Theoretical Scattering
The existing crystal structures of BoNT/A1, /B1, and /E1 can be used to generate
theoretical SAXS data and then compared directly to the experimental scattering data.
Theoretical data were calculated using Crysol and compared to the experimental
data for each BoNT, χ2 values were produced detailing their agreement (Table 5.1).
To emphasise the agreement between the experimental scattering and theoretical
scattering curves, the data can be presented as a normalised, dimensionless-Kratky
plot, where the scattering intensities are scaled and presented as (qRg)2 I(q)/I(0)
versus qRg (Figure 5.17). A dimensionless-Kratky plot emphasises the low q region of
data and allows examination of the overall shape of the molecule. This normalised
plot gives an indication of protein conformation, showing peak maxima at qRg =
√
3
and (qRg)2 I(q)/I(0) = 1.104 for globular particles independent of the concentration
and size of the sample. Peak deviations suggest higher levels of protein flexibility are
present.
The theoretical scattering data for both BoNT/A and BoNT/B fit experimental scat-
tering data for either BoNT/A or BoNT/B very well (χ2 ≈ 1, Table 5.1), suggesting
both proteins adopt a similar conformation in solution. In addition, the theoretical
scattering data for BoNT/E matches its respective experimental data very well too.
Neither theoretical data for BoNT/A nor BoNT/B fit the BoNT/E experimental data
or vice versa. The degree to which the crystal structures match their respective solu-
tion scattering data is impressive and clearly confirms the existence to two distinct
conformations across these BoNT serotypes.
Domain Organisation of BoNT/F1 and BoNT/FA
No full-length crystal structures exist of BoNT/F1 or BoNT/FA despite our attempts.
SAXS-data was collected for BoNT/FA using batch-mode but unfortunately some
aggregation was observed at low q. SAXS data collected for BoNT/F1 was good
and appeared to have no-aggregation issues. The experimental Rg for BoNT/F1
was 43.01 Å, much higher than the Rg of BoNT/E1 and closer to BoNT/A1 and /B1
(Table 5.1). The theoretical scattering from the full-length crystal structures were also
compared to the scattering of BoNT/F1 and the χ2 values indicate a strong similarity
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Figure 5.17: SAXS Normalised Kratky Plot
A normalised Kratky plot of the SAXS from samples of (a) BoNT/A1, (b) BoNT/B1, and (c)
BoNT/E1. Solid and dashed lines indicate the calculated scattering values from the crystal
structures of BoNT/A, /B, and /E.
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to both the BoNT/A1 and /B1 structures. We suggest that BoNT/F1 in solution has
an ‘open’ domain organisation as opposed to the ‘closed’ domain organisation present
in BoNT/E1.
Unfortunately, due to the aggregation present in BoNT/FA we cannot be confident in
any of the calculated parameters. However, despite poor χ2 values for each crystal
structure fit to the SAXS data (Table 5.1), there does appear to be a indication that
BoNT/FA likely also has an ‘open’ domain organisation. Improved SAXS data, which
would likely be possible through the use of HPLC-SAXS, is needed to remove the
present aggregation and provide increased confidence.
5.4 Conclusions
Understanding translocation is one of the few unknowns remaining in the botulinum
neurotoxin field. The crystal structure of BoNT/E revealed a novel arrangement of the
domains in the molecule when compared with other BoNTs and it has been suggested
that this may allow the protein to translocation faster into the cytoplasm. While the
BoNT/E structure had this conformation in crystallo, it was not known whether the
similar conformation existed in solution or whether it was a result of a crystallogaphic
artefact. We first investigated the stability of the BoNT/A1 and BoNT/E1 crystal
structures in silico using molecular dynamics simulations. After multiple repeats of
100 ns trajectories for each protein, the stability of their domain organisation was
analysed. The domain organisation of both proteins was found stable over the course
of 100 ns. The simulations suggest that the HC domain of BoNT/E may be structurally
more stable than BoNT/A due to the increased hydrogen bonding with the rest of the
molecule. No domain reorganisation was present during the simulation period.
To further investigate the stability of the BoNT/E1 structure, we turned to SAXS –
a technique for investigating protein structure in solution. We first determined the
solution state of BoNT/E1 using SAXS and compared with other BoNTs with a known
crystal structure. Our work confirmed that BoNT/E does indeed have the same
structure in solution as in the crystal as determined by a comparison of the scattering
data with calculated scattering from the crystal structure (χ2 0.968). The SAXS data
for BoNT/A1 and /B1 also correlate with their respective crystal structures very well,
148
5. Conformation of Botulinum Neurotoxins in Solution 5.4. Conclusions
confirming that there are two unique domain organisations present across these three
serotypes. Further, we propose that SAXS is an excellent technique for investigating
the domain organisation of other full-length BoNTs from natural or engineered sources
in the future. We assessed the structure of a BoNT with an unknown crystal structure,
BoNT/F1 and suggest that the solution structure is the same as BoNT/A and BoNT/B.
Investigation of another protein, BoNT/FA, was less successful due to aggregation
issue which could have been potentially avoided through the use of HPLC-mode SAXS.
In our experience, all full-length BoNTs display some aggregation at concentrations
above 1 mg mL−1 and therefore we recommend always utilising HPLC-mode SAXS if
available ensure the best possible data collection.
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6. Creation of a Botulinum Neurotoxin Database 6.1. Introduction
6.1 Introduction
Botulinum neurotoxins (BoNTs) are categorised into serotypes based on a system
of anti-sera recognition (serotyping) and then further divided in subtypes. The first
Clostridum botulinum genome was sequenced in 2007 and since then many more
unique BoNT variants have been identified (Sebaihia et al., 2007; Hill and Smith, 2013).
While the method of serotyping BoNTs remains, newly identified proteins can now be
accurately characterised into a specific subtype through sequence comparison. The
recent improvements in DNA sequencing has meant it is not uncommon to sequence
entire genomes and this has lead to many novel BoNT discoveries (Shendure et al.,
2017; Brunt et al., 2018; Zhang et al., 2017b).
The current nomenclature holds that if a protein sequence has greater than 2.5%
sequence variation to its closed neighbour then it must be a new subtype (Peck et al.,
2017). Unfortunately, this system results in multiple unique proteins sharing the same
subtype name – for example, there are fourteen sequences identified as BoNT/B2
which differ by up to 2.17% (28 amino acid residues of 1291 total). It has been
established that BoNT subtypes may display differences of intoxication however it is
less well understood if highly similar sequences of the same subtype may also display
intoxication differences. There are certainly some examples where relatively a single
residue changes can have a drastic effect. For example, the binding domain (HC) of
BoNT/FA has low solubility which can be increased significantly through a M1148R
mutation (Yao et al., 2017). The variations found between BoNTs of the same subtype
may hold useful information for future protein design. Another problem with some
BoNT literature currently is that it is common to refer to the toxin used for research by
simply its subtype or even serotype name. Here, it is difficult to determine the exact
protein sequence used, and in many cases impossible without contacting the authors
directly. On occasion the bacterial strain which produces the toxin of interest, may be
named which can aid identification of the sequence but searching existing databases
with only a strain can be very difficult. Further confusing the BoNT nomenclature, are
bacterial strains which produce multiple toxin types (Franciosa et al., 2009).
A recent review, authored by many in the BoNT field, has proposed the use of
a database of protein sequences for the purpose of categorising and identifying
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novel BoNTs and their variants (Peck et al., 2017). Presented in this chapter is the
development of a new BoNT database which may fulfil this need and encourage
responsible reporting of specific BoNT sequences in future.
6.2 Methods
6.2.1 Automated Protein Sequence Retrieval
Known BoNT protein sequences are used for BLAST searches against the National
Center for Biotechnology Information (NCBI) non-redundant protein database using
the BLAST search binaries (Camacho et al., 2009) wrapped in a custom Python script.
Returned protein sequences and associated publications are retrieved through pro-
grammatic access to the Entrez system (NCBI, 2018). Associated UniprotKB accession
codes are retrieved through programmatic access to the Uniprot application program-
ming interface (API) (Nightingale et al., 2017). Non-duplicate sequences are added to
the BoNTbase database using a custom Python script which has access to the internal
MySQL database. Sequence searches are performed automatically on a weekly basis
but only if the NCBI database contains an update.
6.2.2 Development of BoNTbase
The BoNTbase website was built manually using a combination of PHP, Python, HTML,
and CSS languages. The full source code will be made available to an researchers
wishing to view it.
152
6. Creation of a Botulinum Neurotoxin Database 6.3. Results and Discussion
6.3 Results and Discussion
6.3.1 Automated Sequence Retrieval
The process of searching protein sequence databases, such as those at the NCBI or
UniProtKB, can be time consuming and tedious when looking for every protein within
a specific family. In many cases, proteins found within these databases lack some
or most of the appropriate annotations, making it difficult to determine the protein
origin, subtype or serotype. To address these problems first we decided to produce our
own directory of BoNT protein sequences. A custom workflow was written in Python,
termed ‘BoNTblast’, that allowed automation of the search process and included
validation of the returned sequences (Figure 6.1). The first step involves searching
the National Center for Biotechnology Information (NCBI) non-redundant protein
sequence database. For the workflow to begin, it was provided with a representative
protein sequence from each BoNT serotype (BoNT/A–/G). The initial stages of the
workflow utilised BLAST search binaries (Camacho et al., 2009) to query the remote
BLAST database hosted at the NCBI. One problem with automating deep database
searches such as we are here, is that along with desired protein sequences, there can
be many unrelated and unwanted sequences returned. For example, the bont gene in
C. botulinum is normally found immediately adjacent to the ntnha gene which encodes
a protein of about ~ 20% to 30% identity to its related BoNT (Gu et al., 2012). The
NTNHA protein is similar enough that it sometimes appears in BLAST results when
querying against a BoNT sequence. Filtering must be carefully planned as too much
will result in missed targets. A list of NTNHA protein sequences were manually
added to the BoNTblast filter to remove then from the workflow. In future it may
be worth incorporating these sequences into the database for added functionality. A
total of 151 non-redundant BoNT sequences have been found using the automated
sequence retrieval method outlined here (Table 6.1).
6.3.2 Development of a BoNT Database
It was necessary to organise the retrieved data in a manner that was organised and
accessible and so the open-source database software, MySQL, was chosen. Non-
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1000 < Length < 1400
Contains HExxH motif
Generate BoNTbase ID
Figure 6.1: Automated BoNTblast sequence retrieval workflow.
(a) The NCBI BLAST database is first queried using known BoNT sequences. (b) Protein
sequences and GenBank IDs are retrieved from BLAST hits. (c) Non-redundant sequences are
passed through a rule-based filter to remove unlikely BoNT sequences. (d) New sequences are
finally checked against the BoNTbase database to determine if they already exist. (e) New
sequences are annotated with their respective UniProtKB IDs (if exists), a list of associated
publications from PubMed Central (PMC), and a new unique BoNTbase ID. (f) Resulting data
and metadata is added to BoNTbase and (g) manually annotated to correct any errors.
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Table 6.1: Number of identified non-redundant BoNT sequences.
Percentage identities are given for full-length and HC domain sequence alignments of each
BoNT/A subtype†. For the HC alignments, sequences aligned to BoNT/A1 K870 – L1296 were
used.











† BoNT/Wo, BoNT/En, BoNT/HA, BoNT/X.
redundant BoNT sequences discovered using BoNTblast were added to the backend
database (MySQL) which allowed fast and simple querying by any other application
with programmatic access. Organisation of the database was considered a priority to
ensure no protein sequences could be mistaken for one another. There are many ways
to refer to each sequence, including by its UniProtKB ID, NCBI reference sequence
ID, strain name etc., however these methods are not consistent as each sequence
may have multiple identifiers on each service. Peck et al. (2017) propose keeping an
arbitrary 2.6% amino acid cut-off value when deciding whether or not a BoNT is
a new subtype. This may increase confusion surrounding the use of specific BoNT
sequences in research and ideally each sequence should be addressable by a single
unique identifier which will never change. To address this concern, each sequence
was allocated a BoNTbase ID when added to the database. A BoNTbase ID consists of
four alphanumeric characters which are case insensitive and assigned at random (e.g.
C9KA). If a protein sequence should be removed from BoNTbase, the ID would never
be reused. This combination gives a total of 364 = 1679616 possibilities and is unlikely
to ever be expended. All sequences were subjected to manual curation in order to
remove unwanted sequences that passed through the filter and assign BoNT subtype
names based on associated literature.
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6.3.3 Development of an Online User Interface
The BoNTblast workflow described above lead to a database that contained many
BoNT sequences and associated metadata, however this data was not easily accessible
to users without a knowledge of the SQL language. To address this, a graphical
front-end website was developed using modern web languages to ensure all users
could have access through any chosen web browser. The website was called BoNTbase
– short for the Botulinum NeuroToxin Database – and the domain https://bontbase.org
was acquired. The website backend was written in PHP which interfaces with the
MySQL database, allowing easy and customisable searching of all available data for
the end user. When developing the user interface, the ability to quickly retrieve
BoNT sequences using any available information was a priority. On the home page
(https://bontbase.org), users are able to search the database by serotype, subtype,
strain name, bacterial species, or by protein sequence. When a user selects a protein
of interest, they are directed to a page which contains a range of information relevant
to that specific sequence (Figure 6.2).
Firstly, the protein sequence is provided in a format which allows the user to directly
copy the sequence from the page for their own use. An option is also given that
converts the plain sequence directly into FASTA format, containing an appropriate
sequence header which is suitable for many online services such as protein sequence
alignment using CLUSTAL (Sievers et al., 2011).
It is also useful for users involved in research to have direct and fast access to
information about the biochemical properties of the protein. A range of information
about the protein sequence is provided to the user including the protein length,
molecular weight, estimated absorbance (280 nm) and calculated pI. The absorbance
is calculated as the extinction coefficient normalised by molecular weight where the
extinction coefficient is estimated from the number of Tyr, Trp, and Cys residues
within the protein (Equation 6.1) (Edelhoch, 1967; Gill and von, 1989). The absorbance
(of a 0.1% protein solution) can thus be calculated using EMW .
E = 1490(No. Tyr) + 5500(No. Trp) + 125(No. Cystine) (6.1)
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Figure 6.2: BoNTbase protein information.
An example of the layout from a BoNT summary page. (a) The subtype name and BoNTbase
unique ID. (b) The protein sequence. (c) Citations for publications which have used this
specific protein in their research. (d) Information about this page and protein sequence
including the molecular weight, length, absorbance (280 nm), and calculated pI. (e) A list of
all the bacterial strains which produce this protein. (f) Links the same sequence in external
databases. (g) Links to other proteins of the same subtype and their sequence identity.
157
6. Creation of a Botulinum Neurotoxin Database 6.3. Results and Discussion
Where the molar exctinction coefficients of Tyr, Trp and Cystine are 1490 M−1 cm−1,
5500 M−1 cm−1, and 125 M−1 cm−1 respectively. The calculated pI is also provided and
is calculated using parameters for individual amino acids as described in Bjellqvist
et al. (1993). In addition to the full-length protein sequence the information includes a
list of associated publications that have referred to the protein within their research.
The list of publications are automatically annotated, to gather them the BoNTblast
workflow searches the PubMed Central (PMC) database using all known identifiers
associated with the protein sequence (Figure 6.1). This method is prone to false
positives however and publications need to be manually checked for relevance. A full
list of publications within our database, sorted by the date of release, is also made
available.
When accessing a specific BoNT entry, users are also provided with an up-to-date list
of all known bacterial strains from our database (Figure 6.3). It is common for many
different bacterial strains to produce a BoNT with the same protein sequence and
many publications refer to a specific toxin by its associated bacterial strain identifier.
In some cases, knowledge of a bacterial strain is useful as some strains are bivalent
meaning they can produce two different BoNTs, for example the strain 111 encodes
both BoNT/B and BoNT/X proteins (Zhang et al., 2017b). In an effort to make
searching our database as user friendly as possible, we compiled a list of all bacterial
strains from the NCBI database which produce a BoNT. A custom script queries the
NCBI using previously retrieved accession codes and pulls out information regarding
individual strains. Each strain is entered into our database and associated with its
respective BoNT.
Figure 6.3: BoNTbase Strain Information
An example of the bacterial strains associated with
a BoNT/A1 subtype. When accessing information
regarding a specific BoNT, the user is provided a
list of bacterial strains which all encode the selected
protein.
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6.3.4 User Contributions
Users of BoNTbase are encouraged to upload relevant publications through the web
interface if they are aware of missing entries (Figure 6.4). In an effort to keep the list
of publications in our database organised, users are simply asked for a Pubmed ID
or a digital object identifier (DOI). The website will use the provided information
and automatically retrieve all publication information, including author names, the
title, and the journal, from the NCBI Pubmed database. The new publication entry is
manually curated before it it fully integrated into the database.
Figure 6.4: BoNTbase User Contribution Form
Users of BoNTbase may provide publication information that is relevant to specific BoNT
entries in BoNTbase through an online form requiring only the Pubmed ID or DOI.
6.3.5 Identification of a BoNT-like protein
In addition to collecting all available known BoNT sequences, the BoNTblast workflow
also managed to uncover a protein sequence that had the hallmarks of a BoNT but was
previously unknown to the BoNT community. The protein was found in a Enterococcus
fecalis genome (strain 3G1 DIV0629), uploaded to the NCBI in May 2017 by members
of The Broad Institute Genomic Center for Infectious Diseases (USA). Annotation
of the genome revealed its source to be cow faeces. Our workflow had uncovered
a hypothetical protein of 149 kDa in size which had only 31% sequence identity to
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its nearest BoNT (BoNT/X) and another 143 kDa protein which we identified as a
likely NTNHA protein. Initial analysis of the BoNT-like protein revealed the classic
HExxH motif, found in all other BoNTs. This protein was subsequently co-discovered
by other groups and was determined to be a BoNT-like protein (Zhang et al., 2018;
Brunt et al., 2018). Despite not intending to identify novel proteins the methods used
in BoNTbase have proven that this is possible and the identification of further related
proteins already in protein databases will be explored in future work.
6.4 Conclusions
BoNTbase is a new protein database that aims to contain every known BoNT sequence
and display them in a user friendly and easily searchable way. What was initially
designed as a local database to aid research, has now grown into an online resource
which is used regularly by scientific groups around the world. The methods used
to identify all BoNT sequences could easily be transferred to other areas of research
and may help others to also identify novel protein variants that are hidden in the
wealth information provided by whole-genome sequencing projects. We hope that this
database proves useful to researchers in the BoNT community and feel it has addressed
some concerns as reviewed by Peck et al. (2017). While BoNTbase is an independent
database, it sources all information from a range of other publicly accessible databases
and as such, will always remain an open resource for all.
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7. General Discussion and Future Work
Botulinum neurotoxins are a marvel of protein evolution, every step of their mech-
anism throughout intoxication is tailored specifically to the host in order to cause
efficient and specific inhibition on SNARE-mediated exocytosis (Mansfield and Doxey,
2018). The main causative agent of botulism is the bacteria C. botulinum which is
found natively in soil all over the world. The sequencing of bacterial genomes from
patients suffering the symptoms of botulism or from soil samples has led to over 150
unique BoNT variants having been identified (Sebaihia et al., 2007; Mansfield and
Doxey, 2018). These BoNTs are categorised into serotypes and then subtypes based on
protein sequence differences. Despite the availability of a large number of variants, up
until recently commercially available BoNTs for therapeutic use have only focussed
on two BoNT subtypes, A1 and B1 (Kane et al., 2015; Fonfria et al., 2018). Other
subtypes have been found to have different intoxication properties and they should be
investigated as a potential source of novel therapeutics. The work presented in this
thesis has resulted in the determination of nine protein crystal structures of BoNT HC
domains to very high resolution (Figure 7.1). In doing so the precise atomic locations
and organisation of the BoNT receptor-binding sites have all been mapped and are
available to other researchers. Each displays high levels of structural similarity to all
of the other HC domains reported in this thesis (Table 7.1) indicating their different
characteristics are the result of subtle changes to sequence and structure alone.
90°
Figure 7.1: Overlay of Reported HC Crystal Structures
All structures described in Chapter 3 superposed and displayed as ribbons. The ganglioside
binding site is enlarged to highlight variation in the region.
162
7. General Discussion and Future Work
Table 7.1: HC domain RMSD values
Each HC crystal structure from chapter 3 was superposed using PyMOL (Schrödinger, LLC,
2015) and the RMSD values are reported below.
A1(1) A1(2) A2 A3 A4 A5 A6 FA
A1(1) –
A1(2) 0.554 –
A2 0.511 0.887 –
A3 0.637 0.969 0.331 –
A4 0.496 0.400 0.637 0.750 –
A5 0.439 0.524 0.677 0.739 0.494 –
A6 0.356 0.563 0.447 0.569 0.387 0.390 –
FA 0.584 0.423 0.586 0.899 0.501 0.581 0.614 –
The high structural conservation found within the structures published here, also
suggest that the BoNT HC may tolerate attempts to modify receptor binding sites.
The targeting of different ganglioside types for example, would change neuronal cell
specificity which may prove to have therapeutic benefits. Our crystal structures of
BoNT/A HC domains provide a starting point for investigating residues involved in
binding to both the ganglioside and SV2-protein receptor. The structures can serve as
a basis for future protein engineering and will aid in guiding specific mutations which
may improve binding affinity. Further structures of the HC domains in complex with
receptors should be investigated and, as seen in our reported structure of HC/A3 in
complex with the ganglioside GD1a, can give information about the impact of natural
variation on receptor-binding. A key variation in the HC/A3 ganglioside binding site,
which also occurs in HC/A2 and /A6, is tolerated and does not affect the location
of the bound ganglioside despite the loss of hydrogen bonding to the Sia5 moiety of
GD1a. The generation of a mutant to replicate the HC/A1 GBS is worth pursuing to
determine if this variation effects ganglioside binding in vivo.
The role of a disulfide bond within the HC domain also raises as to its importance in
vivo. Some of our determined crystal structures contained the C1235 to C1280 covalent
bond while others did not, despite their high conservation among all BoNT subtypes
the role is unknown. These residues may play a part in stabilising the protein fold
which could potentially have implications on ganglioside binding due to the location
being near to the ganglioside binding site. We determined the crystal structures
from to crystal forms of HC/A1 in the same crystallisation condition from the same
batch of protein with each structure displaying either the disulfide bond or not. This
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raises questions as to whether both forms are produced during protein expression
or if the subsequent handling and crystallisation causes some of the total protein to
become oxidised or reduced. Analysis such as mass spectrometry may be able to
determine the oxidation state. This may have major implications for the production
of recombinant BoNTs, especially those produced outside of the native host in E. coli
for example, of which there now exist some in clinical trials (Fonfria et al., 2018). The
high resolution crystal structures of HC/A5 and HC/A6 also pose further peculiarities
with respect to this disulfide. In neither structure is a C–C bond present, instead a
neighbouring residue Lys forms a covalent bond with C1280, in the case of HC/A5 this
is through a methylene-bridge while in HC/A6 the Nζ of the Lys is bound directly to
the Sγ of the Cys. Whether or not these bonds are as a direct result of the conditions
experienced in crystallo including the X-ray radiation is unknown. However, low-dose
X-ray diffraction data still indicates the presence of the bond. Determining if these
covalent bonds are present in native BoNTs would be quite a challenge and different
approaches including NMR and mass spectrometry have been listed as possible
methods.
In addition to determining high resolution crystal structures, we also investigated
binding of the protein receptor, SV2C, to the HC/A1 to /A6 subtypes. Purification of
glycosylated SV2C was successful but the binding assay used had some limitations
and was unable to generate binding parameters for HC/A4 or HC/A5. Other methods
to determine the binding affinity of BoNTs to their receptors should be explored and
would generate valuable information which would aid any future protein design.
Due to the multiple protein-receptors and different types of ganlgiosides involved
it may be advantageous to explore the characterisation of receptor-binding to whole
cells. SV2 is a glycoprotein when expressed in mammalian cells. The glycosylation is
heterogeneous and BoNTs may have a preference for a specific glycosylation pattern –
this is yet to be determined. The specific glycosylation pattern in HEK293T cells (as
used for SV2 production in this thesis) may differ from the pattern seen in the motor
neuron and this would give rise to limitations of using any recombinant expression
system outside of neuronal cells.
Of all the BoNT serotypes, only three (BoNT/A, /B, and /E) have their full-length
crystal structures determined. The crystal structure of BoNT/E revealed a compact
domain organisation in contrast to the ‘butterfly’ structure observed in BoNT/A and
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BoNT/B. We explored the use of small-angle X-ray scattering (SAXS) to determine the
structure of BoNTs in solution and examine whether the crystal structure of BoNT/E
is similar. Our work has confirmed the existence of two unique domain organisations
across BoNT serotypes as previously identified through X-ray crystallography (Lacy et
al., 1998; Kumaran et al., 2009; Swaminathan and Eswaramoorthy, 2000) and provided
a robust method for determining the solution structure of other BoNTs. Using easily
determined parameters directly from the measured SAXS data and from comparisons
to existing crystal structures, it is immediately obvious which domain organisation
is present. The HPLC-mode of SAXS measurements is ideal for the investigation of
full-length BoNTs as they are prone to low levels of aggregation at relatively low
protein concentration which would otherwise interfere with SAXS measurements.
This method can be extended to collect SAXS data a various pH levels, simulating
the pH gradient found within the endosome during BoNT intoxication, and could
potentially give rise to new data toward understanding BoNT translocation. Very little
is understood about the mechanism of BoNT translocation and any method that can
provide some insight into the process would be of benefit.
We have also presented BoNTbase – a botulinum neurotoxin database which aims to
contain all known BoNT protein sequences and provide easy access to their associated
publications. The database is programmed to automatically update itself and add
new BoNT sequences as soon as they are present in other databases such as Uniprot.
In doing so we hope the resource helps researchers to identity all BoNTs and ensure
accurate reporting with regard to the specific sequence used. Currently the database
holds only information relevant to BoNTs and the bacterial strains which produce
them but this could be extended in the future to include other related molecules. The
methods and scripts used to retrieve all known sequences can be easily transferred to
other fields and will be shared freely. Hopefully to aid researchers in their analyses
and potentially discover novel related proteins relevant to them.
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ABSTRACT
The binding specificity of botulinum neurotoxins (BoNTs) is primarily a consequence
of their ability to bind to multiple receptors at the same time. BoNTs consist of three
distinct domains, a metalloprotease light chain (LC), a translocation domain (HN)
and a receptor-binding domain (HC). Here we report the crystal structure of HC/FA,
complementing an existing structure through the modelling of a previously unresolved
loop which is important for receptor-binding. Our HC/FA structure also contains a
previously unidentified disulphide bond, which we have also observed in one of two
crystal forms of HC/A1. This may have implications for receptor-binding and future
recombinant toxin production.
Subjects Biochemistry, Biophysics, Microbiology
Keywords SV2, Crystal structure, Botulinum neurotoxin, Targeted secretion inhibitor, FA
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INTRODUCTION
Botulinumneurotoxin (BoNT) is the active agent that causes the deadly condition botulism.
It is expressed as a single polypeptide chain of approximately 150 kDa and is cleaved post-
translationally to yield an active di-chainmolecule held together by a single disulphide bond.
The smaller 50 kDa light chain (LC) possesses a single zinc-endopeptidase domain whereas
the larger 100 kDa heavy chain is comprised of two domains—a target cell receptor binding
(HC) domain and a translocation (HN) domain (Schiavo et al., 1992; Montecucco, 1986).
BoNTs are the most poisonous biological substances known to man and their remarkable
toxicity is a result of their highly specific and modular mechanism of action. The toxins
target neuronal cell membranes through the formation of a dual receptor binding complex
(Montecucco, 1986) which allows for internalisation by endocytosis (Colasante et al., 2013).
The HN domain then translocates the LC into the cytoplasm where it cleaves a specific
SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) protein
which consequently inhibits vesicle release. Many immunologically distinct BoNTs have
been discovered over the years—serotypes /A through to /G; although, only serotypes
/A, /B, /E and /F have been reported to cause botulism in humans (Coffield et al., 1997).
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Each serotype can be further subdivided into different subtypes based on their amino acid
sequence (Rossetto, Pirazzini & Montecucco, 2014).
The BoNTHC domain is responsible for targeting the toxin to a specific cell type and the
specific receptors involved have been identified formost serotypes. For example, serotype /A
binds to a glycosylated luminal domain of the synaptic vesicle 2 (SV2) protein, preferentially
to the C isoform (SV2C) (Dong et al., 2006;Mahrhold et al., 2006), as well as a ganglioside,
namely GT1b (Rummel et al., 2004; Yowler & Schengrund, 2004; Stenmark et al., 2008).
X-ray crystallography has revealed protein-backbone hydrogen-bond interactions between
β-strands of the BoNT/A1 HC and the fourth luminal domain of SV2C (SV2C-LD4),
as well as electrostatic interactions between charged surfaces (Benoit et al., 2014). This
is supplemented by additional interactions with the N-linked glycans present on the
native SV2 molecule—this network of glycan interactions is key for BoNT potency
(Yao et al., 2016).
BoNTs have been exploited for therapeutic use in many neurological indications such
as dystonia and overactive bladder (Dressler, 2012). More recently, BoNTs have been
re-engineered to target different cell types and treat specific clinical indications (Masuyer
et al., 2014; Masuyer et al., 2015)—these are known as targeted secretion inhibitors (TSIs).
A detailed understanding of the structural aspects of the different BoNT subtypes will prove
useful in identifying regions of variability that may help uncover conserved mechanisms of
binding, which in turn will guide efforts in developing novel BoNT therapeutics. Therefore,
high-resolution, three-dimensional structural analysis of naturally occurring BoNTs, their
mosaics and subtypes, would be of great value. Of particular interest are the structural
differences arising from sequence differences between subtypes.
Recently, a new bivalent strain of Clostridium botulinum, IBCA10-7060, was reported
to produce BoNT/B2 and a previously unknown BoNT serotype—‘‘BoNT/H’’ (Barash &
Arnon, 2014). This novel toxin is a mosaic molecule and is now more commonly referred
to as BoNT/FA (as well as BoNT/HA) due to a LC similar to that of BoNT/F5, a HN domain
similar to that of BoNT/F1, and a HC domain similar to that of BoNT/A1 (Maslanka et al.,
2015;Gonzalez-Escalona et al., 2014;Kalb et al., 2015). The crystal structure of the BoNT/FA
binding domain was recently reported (Yao et al., 2017). Here, we present a new crystal
structure of HC/FA at 1.95 Å resolution which reveals further structural information that
is unresolved in the reported structure. Specifically, our structure reveals a loop previously
unmodeled due to lack of density, which is of high importance, and we also observe a
disulphide bond which was not present within the previous structure. To this end we
have produced two crystal forms of HC/A1 (determined to 1.45 Å and 1.7 Å respectively)
differing by the presence of this disulphide bond.
MATERIALS AND METHODS
Cloning and constructs
The genes encoding the binding domain of BoNT/A1 (HC/A1) and BoNT/FA (HC/FA)
were provided by Ipsen Bioinnovation Ltd. Each was cloned into the pJ401 expression
vector (DNA 2.0, Menlo Park, CA, USA) with an N-terminal 6× histidine tag using
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standard molecular biology techniques and confirmed by sequencing (Eurofins Genomics,
Germany).
Protein expression
His6-HC/A1 and His6-HC/FA were expressed in E. coli strain BL21(DE3) (Novagen,
Madison, WI, USA) using the following protocol. A glycerol stock was used to inoculate
100 mL TB medium containing 50 µg/mL kanamycin, and grown at 37 ◦C for 16 h. From
this, 10mLof culturewas used to inoculate 1 LTBmediumcontaining 50µg/mL kanamycin
and grown at 37 ◦C to an OD600 of 0.6. The temperature was reduced to 16 ◦C and the cells
grown to an OD600 of 1.0 at which point 0.5 mM isopropyl-d-1-thiogalactopyranoside
(IPTG) was added to induce expression. Cells were grown for an additional 16 h at 16 ◦C
and then harvested by centrifugation at 4,000× g for 30 min.
Protein purification
Expression cell pastes were resuspended in 0.5 M NaCl, 50 mM Tris–HCl pH 7.4, 20
mM imidazole and lysed using a Constant Systems cell disruptor at 20 kPSI. Cell debris
were removed by centrifugation at 80,000× g for 30 min and the supernatant was filtered
through a 0.22 µm membrane syringe filter. The clarified lysate was loaded onto a 5 mL
HisTrap column (GE Healthcare, Little Chalfont, UK), washed, and the target protein
eluted with 0.5 M imidazole. His6-HC/A1 and His6-HC/FA were further purified by SEC
using a Superdex 200 16/60 column (GE Healthcare, Little Chalfont, UK) and 0.5 M NaCl,
50 mM Tris-HCl pH 7.4. Purified samples were concentrated to 10 mg/mL using a 10 kDa
MWCO centrifugal filter (Millipore, Billerica, MA, USA).
Crystallography
Crystals of His6-HC/FA and His6-HC/A1 were grown at 16 ◦C using a 1:1 ratio of
protein solution (10 mg/mL) to well solution using the sitting-drop vapour-diffusion
method—4 M sodium formate, 0.1 M sodium acetate pH 5.5 for the former, and 0.1 M
MIB pH 4.0, 25% w/v PEG 1500 for the latter. Crystals were soaked in cryoprotectant
(equal volume of reservoir solution and 50% glycerol) before vitrification in liquid
nitrogen. Complete datasets were collected on beamline I03 and I04, respectively, at the
Diamond Light Source (Didcot, UK). Diffraction images were processed using DIALS
(Gildea et al., 2014) and scaled using AIMLESS (Evans & Murshudov, 2013) from the
CCP4 suite (Winn et al., 2011). Data collection statistics are summarised in Table 1. A
combination of Rpim and CC1/2 value were used to determine the resolution cut-off
of 1.95 Å and 1.45 Å, respectively. Phase information was determined by molecular
replacement using PHASER (McCoy et al., 2007) and a previous structure of HC/A1
(PDB: 2VUA; Stenmark et al., 2008) as the initial search model. Multiple rounds of
structure refinement were performed by manual correction in COOT (Emsley et al.,
2010) followed by restrained refinement with REFMAC5 (Murshudov et al., 2011). Final
validation was performed with MolProbity (Chen et al., 2010). Secondary structures
were annotated using Stride (Frishman & Argos, 1995) and figures were prepared using
PyMol (Schrödinger, LLC, New York, NY, USA) and CCP4mg (McNicholas et al., 2011).
Davies et al. (2018), PeerJ, DOI 10.7717/peerj.4552 3/13
186





Space Group P422 P212121 P21
Cell dimensions
a, b, c (Å) 118.0, 118.0, 173.8 39.8, 107.3, 107.6 61.4, 53.9, 62.7







Rmerge (%) 20.1 (168.6)a 7.6 (69.2)a 14.2 (53.9)a
Rmeas (%) 20.8 (176.0)a 9.7 (92.0)a 15.0 (58.8)a
Rpim (%) 5.6 (50.2)a 5.8 (60.1)a 4.6 (22.5)a
CC1/2 0.999 (0.832)a 0.997 (0.357)a 0.962 (0.954)a
<I/σ (I)> 12.6 (2.3)a 6.9 (1.3)a 14.4 (3.7)a
Completeness (%) 100.0 (100.0)a 95.3 (95.1)a 98.6 (89.1)a
Multiplicity 26.0 (23.7)a 3.3 (2.7)a 20.4 (11.7)a
Rwork (%) 18.0 17.6 18.8
Rfree (%) 20.9 22.1 22.3
No. of atoms
Protein 6,907 3,511 3,263
Water 609 421 322
RMSD bond length (Å) 0.007 0.002 0.005
RMSD bond angle (◦) 0.89 0.44 0.73
Wilson B factor (Å2) 24.6 15.9 13.4
Average B factors (Å2)
Protein 28.2, 30.0 21.2 22.5
Solvent 33.8 34.1 28.0
Ramachandran plot
Favoured (%) 96.7 96.3 96.4
Allowed (%) 3.4 3.5 3.6
Disallowed (%) 0.0 0.2 0.0
PDB code 5MK8 5MK6 5MK7
Notes.
aValues in parentheses are for the highest resolution shell.
RESULTS AND DISCUSSION
Crystal structure of BoNT/FA HC domain
We identified crystallisation conditions which yielded crystals of HC/FA in space group
P422, with two molecules related by non-crystallographic symmetry in the asymmetric
unit. This is different to a recently reported structure, PDB: 5V38 (Yao et al., 2017) and
reveals an important loop that is involved in receptor binding (average temperature factor
(B-factor) 74 Å2). A high-multiplicity dataset was collected containing 360 degrees of
data over 3,600 images. No significant radiation damage was observed over the course of
data collection and thus all data were used. The CC1/2 value for the outer shell was 0.832,
indicating there was still very usable data at this resolution (Evans & Murshudov, 2013).
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Figure 1 Crystal structures of HC domains. (A) HC/A1 domain (crystal form 1, PDB: 5MK6), (B)
HC/A1 domain (crystal form 2, PDB: 5MK7), (C) HC/FA domain (PDB: 5MK8), and (D) overlay
with a different crystal form of HC/FA (PDB:5V38; Yao et al., 2017). The position of loop R1261–
R1268 indicated with an ellipse. All structures represented as a ribbon diagram, generated using PyMol
(Schrödinger, LLC, New York, NY, USA).
Full-size DOI: 10.7717/peerj.4552/fig-1
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Figure 2 Ganglioside binding site. (A) Electron density from a composite omit map for HC/FA. The lo-
cation of a disulphide bond is marked with an asterisk. (B) The equivalent loop from HC/A1 (2VU9) with
GT1b shown in glycoblock representation. Map produced using Phenix package (Terwilliger et al., 2008).
Full-size DOI: 10.7717/peerj.4552/fig-2
The overall structure of HC/FA is shown in Fig. 1C and the crystallographic statistics are
listed in Table 1. As with all reported structures of the BoNT receptor binding domain,
present is a characteristic β-jellyroll fold at the N-terminal half and a predominantly
β-trefoil fold at the C-terminal half of the protein (Figs. 1A–1D). Both molecules in the
asymmetric unit overlay well with a root mean square deviation (RMSD) value of 0.35 Å
between all atoms. The B-factors for each chain are low overall (24.74 Å2 and 26.84 Å2
respectively) with a corresponding overall Wilson B-factor of 24.55 Å2. As expected, our
structure is highly similar to PDB: 5V38 with an RMSD value for combinations of chains
between structures ranges from 0.54 Å to 0.36 Å (Fig. 1D). However, it further reveals the
presence of a loop (R1261–R1268) that has been shown in other subtypes to be involved in
ganglioside receptor binding (Fig. 2A). Crystal packing has enabled neighbouring chains
to interact directly with this loop, provide sufficient stabilisation to produce good electron
density. Yao et al. (2017) suggested that the lack of density was due to high flexibility, which
is consistent with the high B-factors we observed in this region relative to the rest of the
protein.
The specific ganglioside receptor for BoNT/FA is not yet known; however, considering
that GT1b binds with high affinity to BoNT/A1 (Fig. 2B) and that HC/FA and HC/A1 are
structurally very similar, we propose that BoNT/FA possesses a similar binding specificity.
The overall conformation of this region is also similar to that of BoNT/A1 in complex with
a ganglioside receptor (Fig. 2). The detailed conformation of this loop is important for
understanding receptor binding and our structure confirms that BoNT/FA could bind to
gangliosides in a similar manner to BoNT/A. Proximate to the ganglioside binding region,
we observe the presence of a disulphide bond between Cys1227 and Cys1272 (Fig. 3C)
which is also not present in the structure 5V38. The equivalent bond has been observed
Davies et al. (2018), PeerJ, DOI 10.7717/peerj.4552 6/13
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Figure 3 Location of Cys1235 and Cys1280 residues. (A) Cys1235 and Cys1280 are not covalently
bound in the HC/A1 crystal form 1, (B) disulphide bond formation in crystal form 2 and (C) a similar
disulphide bond is seen in the HC/FA crystal structure between equivalent cysteines. Composite OMIT
maps were produced using Phenix (Terwilliger et al., 2008). And are shown for each model at 1 σ. Figure
generated using CCP4mg (McNicholas et al., 2011).
Full-size DOI: 10.7717/peerj.4552/fig-3
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Figure 4 Amino acid sequence alignment of BoNT subtypes emphasising the strong conservation
of two cysteine residues near the protein C-terminus.UniprotKB accession numbers—A1: A5HZZ9,
A2: Q45894, A3: Q3LRX9, A4: Q3LRX8, A5: C1IPK2, A6: C9WWY7, A7: K4LN57, A8: A0A0A7PDB7,
HA(FA): WP_047402807*, B1: P10844, B2: A0A0B4W2B0, B3: A2I2S2, B4: A2I2S4, B5: A0A0E1L271,
B6: H3K0G8, B7: H9CNK9, B8: M9VUL2, E1: Q00496, E2: A2I2S6, E3: A0A076L133, E4: P30995,
E5: Q9K395, E6: A8Y878, E7: G8I2N7, E8: G8I2N8, E9: WP_017352936*, E10: A0A076JVL9, E11:
A0A076K0B0, E12: A0A0A7RCR1, F1: A7GBG3, F2: Q9ZAJ5, F3: D2KHR6, F4: D2KHQ8, F5: D2KHQ9,
F6: D2KHS6, F7: D2KHS9, F8: WP_076177537*, F9: A0A1P8YWK9, G: Q60393, X: WP_045538952*
(*indicates NCBI accession code where UniprotKB accession is not available).
Full-size DOI: 10.7717/peerj.4552/fig-4
previously in some, but not all crystal structures of BoNT HC Domains; therefore, it is
uncertain what role, if any, it may have towards BoNT function.
Crystal structures of the BoNT/A1 binding domain
We have identified a single crystallisation condition that produced two crystal forms of
HC/A1—one possessed the equivalent disulphide bond whereas the other did not. Using
25% w/v PEG 1500 and 0.1 M MIB pH 4.0, HC/A1 crystallised into orthorhombic crystals
with the space group P212121 (crystal form 1) that diffracted to a resolution of 1.45 Å.
No disulphide bond was observed in this structure (Fig. 1A). Instead, Cys1235 rotated
away from the junction due to a backbone rotation, bringing the neighbouring Lys1236
toward Cys1280 (Fig. 3A). This is consistent with previous HC/A1 structures either in
complex with GT1b (PDB: 2VU9; Stenmark et al., 2008), SV2-LD (PDB: 4JRA, 5JLV;
Benoit et al., 2014; Yao et al., 2016) or in the apo form (PDB: 2VUA; Stenmark et al., 2008).
Using the same conditions, monoclinic crystals were obtained six months later with the
space group P21 (crystal form 2) that diffracted to 1.8 Å resolution. Inspection of this
structure (Fig. 1B) revealed the presence of a disulphide bond between C1235 and C1280,
the equivalent of which was also observed in our HC/FA crystal structure (Figs. 3A and
3B) and in a full-length BoNT/A1 crystal structure (PDB: 3BTA; Lacy & Stevens, 1999).
Our findings suggest that the crystallisation condition is not the only determinant as to
whether the bond is present or not. The conservation of these cysteine residues across
the BoNT sub-serotypes suggests they are very important (Fig. 4); however, their precise
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function is unknown. Almost all BoNT subtypes that cause human botulism contain the
two residues. They may be required for disulphide bond formation for structural stability
or for efficient function of a nearby ganglioside-binding pocket. It must be noted that the
expression system does not appear to select for reduced or non-reduced forms of these
cysteine residues—each have been observed in different structures of BoNT/A purified
from the native Clostridium botulinum (Garcia-Rodriguez et al., 2007; Stenmark et al., 2008;
Fu et al., 2009; Gu et al., 2012; Przedpelski et al., 2013; Benoit et al., 2014; Yao et al., 2017;
Davies et al., 2017).
CONCLUSION
The high-resolution crystal structures of the binding domains (HC) from BoNT/FA and
BoNT/A1 are reported here. The former complements a recently published structure
(Yao et al., 2017) and resolves a loop which is highly important for receptor binding. For
the latter, two structures were determined from two crystal forms obtained from the
same crystallisation condition. These HC/A1 structures differed from one another by the
presence or absence of a disulphide bond. This bond was also observed in our structure of
HC/FA. Considering their location near the ganglioside-binding pocket, and conservation
across BoNT subtypes, the redox status of these conserved cysteines may have implications
in BoNT stability and manufacture. Botulinum neurotoxins are used therapeutically for
many indications and their production is currently from the native host Clostridium
botulinum. However, considering the safety implications and the advent of engineered
BoNT derivatives, such as TSIs, production from a recombinant source would be highly
desirable. The importance of these two cysteine residues is being further investigated.
Abbreviations
BoNT/X botulinum neurotoxin serotype X
BoNT/FA botulinum neurotoxin hybrid of /F and /A serotypes
HC receptor binding domain of BoNT
LC light chain of BoNT, catalytic domain
HN translocation domain of BoNT
SV2C synaptic vesicle 2 protein, isoform C
TSI targeted secretion inhibitor
ACKNOWLEDGEMENTS
The authors would like to thank Diamond Light Source, Didcot (Oxon, UK) for beamtime
(proposals mx8922 and mx12342) and the staff of beamlines i03 and i04 for assistance with
crystal testing and data collection.
Davies et al. (2018), PeerJ, DOI 10.7717/peerj.4552 9/13
192
ADDITIONAL INFORMATION AND DECLARATIONS
Funding
K. Ravi Acharya received a Research Fellowship from Ipsen Bioinnovation Limited and
Jonathan R. Davies is supported by a joint post-graduate studentship between University
of Bath and Ipsen Bioinnovation Limited. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Grant Disclosures
The following grant information was disclosed by the authors:
Ipsen Bioinnovation Limited.
Joint post-graduate studentship between University of Bath and Ipsen Bioinnovation
Limited.
Competing Interests
Sai Man Liu is an employee of Ipsen Bioinnovation Limited. Gavin S. Hackett is a former
employee of Ipsen Bioinnovation Limited.
Author Contributions
• Jonathan R. Davies conceived and designed the experiments, performed the experiments,
analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the
paper, approved the final draft.
• Gavin S. Hackett analyzed the data, authored or reviewed drafts of the paper, approved
the final draft.
• Sai Man Liu and K. Ravi Acharya conceived and designed the experiments, analyzed the
data, contributed reagents/materials/analysis tools, authored or reviewed drafts of the
paper, approved the final draft.
Data Availability
The following information was supplied regarding data availability:
Accession codes: The atomic coordinates and structure factors (codes 5MK6, 5MK7,
5MK8) have been deposited in the Protein Data Bank (http://www.pdb.org).
Supplemental Information
Supplemental information for this article can be found online at http://dx.doi.org/10.7717/
peerj.4552#supplemental-information.
REFERENCES
Barash JR, Arnon SS. 2014. A novel strain of Clostridium botulinum that produces
type B and type H botulinum toxins. Journal of Infectious Diseases 209:183–191
DOI 10.1093/infdis/jit449.
Benoit RM, Frey D, Hilbert M, Kevenaar JT,Wieser MM, Stirnimann CU, McMillan D,
Ceska T, Lebon F, Jaussi R, Steinmetz MO, Schertler GF, Hoogenraad CC, Capitani
Davies et al. (2018), PeerJ, DOI 10.7717/peerj.4552 10/13
193
G, Kammerer RA. 2014. Structural basis for recognition of synaptic vesicle protein
2C by botulinum neurotoxin A. Nature 505:108–111 DOI 10.1038/nature12732.
Chen VB, Arendall 3rdWB, Headd JJ, Keedy DA, Immormino RM, Kapral GJ, Murray
LW, Richardson JS, Richardson DC. 2010.MolProbity: all-atom structure valida-
tion for macromolecular crystallography. Acta Crystallographica Section D: Biological
Crystallography 66:12–21 DOI 10.1107/S0907444909042073.
Coffield JA, Bakry N, Zhang RD, Carlson J, Gomella LG, Simpson LL. 1997. In vitro
characterization of botulinum toxin types A, C and D action on human tissues:
combined electrophysiologic, pharmacologic and molecular biologic approaches.
Journal of Pharmacology and Experimental Therapeutics 280:1489–1498.
Colasante C, Rossetto O, Morbiato L, Pirazzini M, Molgo J, Montecucco C. 2013.
Botulinum neurotoxin type A is internalized and translocated from small synaptic
vesicles at the neuromuscular junction.Molecular Neurobiology 48:120–127
DOI 10.1007/s12035-013-8423-9.
Davies JR, Rees J, Liu SM, Acharya KR. 2017.High resolution crystal structures of
Clostridium botulinum neurotoxin A3 and A4 binding domains. Journal of Structural
Biology Epub ahead of print Dec 26 2017 DOI 10.1016/j.jsb.2017.12.010.
DongM, Yeh F, TeppWH, Dean C, Johnson EA, Janz R, Chapman ER. 2006.
SV2 is the protein receptor for botulinum neurotoxin A. Science 312:592–596
DOI 10.1126/science.1123654.
Dressler D. 2012. Clinical applications of botulinum toxin. Current Opinion in Microbiol-
ogy 15:325–336 DOI 10.1016/j.mib.2012.05.012.
Emsley P, Lohkamp B, Scott WG, Cowtan K. 2010. Features and development of Coot.
Acta Crystallographica Section D: Biological Crystallography 66:486–501
DOI 10.1107/S0907444910007493.
Evans PR, Murshudov GN. 2013.How good are my data and what is the resolution?
Acta Crystallographica Section D: Biological Crystallography 69:1204–1214
DOI 10.1107/S0907444913000061.
Frishman D, Argos P. 1995. Knowledge-based protein secondary structure assignment.
Proteins 23:566–579 DOI 10.1002/prot.340230412.
Fu Z, Chen C, Barbieri JT, Kim JJ, BaldwinMR. 2009. Glycosylated SV2 and gan-
gliosides as dual receptors for botulinum neurotoxin serotype F. Biochemistry
48:5631–5641 DOI 10.1021/bi9002138.
Garcia-Rodriguez C, Levy R, Arndt JW, Forsyth CM, Razai A, Lou J, Geren I, Stevens
RC, Marks JD. 2007.Molecular evolution of antibody cross-reactivity for two
subtypes of type A botulinum neurotoxin. Nature Biotechnology 25:107–116
DOI 10.1038/nbt1269.
Gildea RJ, Waterman DG, Parkhurst JM, Axford D, Sutton G, Stuart DI, Sauter NK,
Evans G,Winter G. 2014. New methods for indexing multi-lattice diffraction
data. Acta Crystallographica Section D: Biological Crystallography 70:2652–2666
DOI 10.1107/S1399004714017039.
Gonzalez-Escalona N, Thirunavukkarasu N, Singh A, ToroM, Brown EW, Zink D,
Rummel A, Sharma SK. 2014. Draft genome sequence of bivalent Clostridium
Davies et al. (2018), PeerJ, DOI 10.7717/peerj.4552 11/13
194
botulinum strain IBCA10-7060, encoding botulinum neurotoxin B and a new FA
mosaic type. Genome Announcements 2:e01275–14.
Gu S, Rumpel S, Zhou J, Strotmeier J, Bigalke H, Perry K, Shoemaker CB, Rummel
A, Jin R. 2012. Botulinum neurotoxin is shielded by NTNHA in an interlocked
complex. Science 335:977–981 DOI 10.1126/science.1214270.
Kalb SR, Baudys J, Raphael BH, Dykes JK, Lúquez C, Maslanka SE, Barr JR. 2015.
Functional characterization of botulinum neurotoxin serotype H as a hybrid
of known serotypes F and A (BoNT F/A). Analytical Chemistry 87:3911–3917
DOI 10.1021/ac504716v.
Lacy DB, Stevens RC. 1999. Sequence homology and structural analysis of the clostridial
neurotoxins. Journal of Molecular Biology 291:1091–1104
DOI 10.1006/jmbi.1999.2945.
Mahrhold S, Rummel A, Bigalke H, Davletov B, Binz T. 2006. The synaptic vesicle
protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves.
FEBS Letters 580:2011–2014 DOI 10.1016/j.febslet.2006.02.074.
Maslanka SE, Luquez C, Dykes JK, TeppWH, Pier CL, Pellett S, Raphael BH, Kalb
SR, Barr JR, Rao A, Johnson EA. 2015. A novel botulinum neurotoxin, previously
reported as serotype H, has a hybrid-like structure with regions of similarity to the
structures of serotypes A and F and is neutralized with serotype A antitoxin. Journal
of Infectious Diseases 213:379–385 DOI 10.1093/infdis/jiv327.
Masuyer G, Chaddock JA, Foster KA, Acharya KR. 2014. Engineered botulinum
neurotoxins as new therapeutics. Annual Review of Pharmacology and Toxicology
54:27–51 DOI 10.1146/annurev-pharmtox-011613-135935.
Masuyer G, Davies JR, Moore K, Chaddock JA, Acharya KR. 2015. Structural analysis
of Clostridium botulinum neurotoxin type D as a platform for the development of
targeted secretion inhibitors. Scientific Reports 5:13397 DOI 10.1038/srep13397.
McCoy AJ, Grosse-Kunstleve RW, Adams PD,WinnMD, Storoni LC, Read RJ. 2007.
Phaser crystallographic software. Journal of Applied Crystallography 40:658–674
DOI 10.1107/S0021889807021206.
McNicholas S, Potterton E,Wilson KS, Noble MEM. 2011. Presenting your structures:
the CCP4mg molecular-graphics software. Acta Crystallographica Section D: Biologi-
cal Crystallography 67:386–394 DOI 10.1107/S0907444911007281.
Montecucco C. 1986.How do tetanus and botulinum toxins bind to neuronal mem-
branes? TiBS 11:314–317.
Murshudov GN, Skubák P, Lebedev AA, Pannu NS, Steiner RA, Nicholls RA,Winn
MD, Long F, Vagin AA. 2011. REFMAC5 for the refinement of macromolecular
crystal structures. Acta Crystallographica Section D: Biological Crystallography
67:355–367 DOI 10.1107/S0907444911001314.
Przedpelski A, TeppWH, Kroken AR, Fu Z, Kim JJ, Johnson EA, Barbieri JT. 2013.
Enhancing the protective immune response against botulism. Infection and Immunity
81:2638–2644 DOI 10.1128/IAI.00382-13.
Davies et al. (2018), PeerJ, DOI 10.7717/peerj.4552 12/13
195
Rossetto O, Pirazzini M, Montecucco C. 2014. Botulinum neurotoxins: genetic,
structural and mechanistic insights. Nature Reviews. Microbiology 12:535–549
DOI 10.1038/nrmicro3295.
Rummel A, Mahrhold S, Bigalke H, Binz T. 2004. The HCC-domain of botulinum
neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype
specific carbohydrate interaction.Molecular Microbiology 51:631–643.
Schiavo G, Rossetto O, Santucci A, DasGupta B, Montecucco C. 1992. Botulinum
neurotoxins are zinc proteins. Journal of Biological Chemistry 267:23479–23483.
Stenmark P, Dupuy J, Imamura A, KisoM, Stevens RC. 2008. Crystal structure
of botulinum neurotoxin type A in complex with the cell surface co-receptor
GT1b-insight into the toxin-neuron interaction. PLOS Pathogens 4:e1000129
DOI 10.1371/journal.ppat.1000129.
Terwilliger TC, Grosse-Kunstleve RW, Afonine PV, Moriarty NW, Adams PD, Read
RJ, Zwart PH, Hung LW. 2008. Iterative-build OMIT maps: map improvement by
iterative model building and refinement without model bias. Acta Crystallographica
Section D: Biological Crystallography 64:515–524.
WinnMD, Ballard CC, Cowtan KD, Dodson EJ, Emsley P, Evans PR, Keegan RM,
Krissinel EB, Leslie AG, McCoy A, McNicholas SJ, Murshudov GN, Pannu NS,
Potterton EA, Powell HR, Read RJ, Vagin A,Wilson KS. 2011. Overview of the
CCP4 suite and current developments. Acta Crystallographica Section D: Biological
Crystallography 67:235–242 DOI 10.1107/S0907444910045749.
Yao G, LamKH, Perry K,Weisemann J, Rummel A, Jin R. 2017. Crystal structure of the
receptor-binding domain of botulinum neurotoxin type HA, also known as type FA
or H. Toxins 9:93–105.
Yao G, Zhang S, Mahrhold S, Lam KH, Stern D, Bagramyan K, Perry K, KalkumM,
Rummel A, DongM, Jin R. 2016. N-linked glycosylation of SV2 is required for
binding and uptake of botulinum neurotoxin A. Nature Structural & Molecular
Biology 23:656–662 DOI 10.1038/nsmb.3245.
Yowler BC, Schengrund CL. 2004. Glycosphingolipids-sweets for botulinum neurotoxin.
Glycoconjugate Journal 21:287–293 DOI 10.1023/B:GLYC.0000046271.64647.fd.




Variations in the Botulinum Neurotoxin Binding
Domain and the Potential for Novel Therapeutics
Jonathan R. Davies 1 , Sai Man Liu 2 and K. Ravi Acharya 1,*
1 Department of Biology and Biochemistry, University of Bath, Bath BA2 7AY, UK; jd769@bath.ac.uk
2 Ipsen Bioinnovation Limited, Abingdon OX14 4RY, UK; sai.man.liu@ipsen.com
* Correspondence: k.r.acharya@bath.ac.uk; Tel.: +44-1225-386-238
Received: 21 September 2018; Accepted: 18 October 2018; Published: 20 October 2018


Abstract: Botulinum neurotoxins (BoNTs) are categorised into immunologically distinct serotypes
BoNT/A to /G). Each serotype can also be further divided into subtypes based on differences in
amino acid sequence. BoNTs are ~150 kDa proteins comprised of three major functional domains:
an N-terminal zinc metalloprotease light chain (LC), a translocation domain (HN), and a binding
domain (HC). The HC is responsible for targeting the BoNT to the neuronal cell membrane, and each
serotype has evolved to bind via different mechanisms to different target receptors. Most structural
characterisations to date have focussed on the first identified subtype within each serotype (e.g.,
BoNT/A1). Subtype differences within BoNT serotypes can affect intoxication, displaying different
botulism symptoms in vivo, and less emphasis has been placed on investigating these variants.
This review outlines the receptors for each BoNT serotype and describes the basis for the highly
specific targeting of neuronal cell membranes. Understanding receptor binding is of vital importance,
not only for the generation of novel therapeutics but also for understanding how best to protect
from intoxication.
Keywords: botulinum neurotoxins; binding domain; ganglioside; SV2; synaptotagmin; neurones
1. Botulinum Neurotoxins
Botulinum neurotoxins (BoNTs) are produced mainly by Clostridium botulinum, under anaerobic
conditions [1], and are the causative agent of botulism—a rare disease that can lead to paralysis
and eventually death. The C. botulinum taxon can be divided into four groups (I, II, III, and IV),
based on phenotypic differences between the bacteria [2]. C. botulinum group I (proteolytic) and
group II (non-proteolytic) are mostly responsible for human botulism, whereas C. botulinum group
III is responsible for botulism in other animal species, and C. botulinum group IV does not appear
to cause botulism [2,3]. Across these phenotypes, a range of serologically distinct BoNTs have been
identified and classified within different serotypes. Until recently, all BoNTs have been categorised into
one of seven serotypes ranging from BoNT/A to BoNT/G. The recent identification of novel BoNTs
and BoNT-like proteins, which are not neutralisable by existing anti-sera, has lead to classification
that does not currently continue from the classical nomenclature (e.g., BoNT/X). Some C. botulinum
strains have also been identified which express more than one serotype and/or chimeric neurotoxins
(e.g., BoNT/CD and BoNT/DC).
Each BoNT is expressed as a single polypeptide chain of ~150 kDa (Figure 1a), after which it is
cleaved post-translationally by a protease to yield an active di-chain molecule consisting of a ~50 kDa
light chain (LC) and a ~100 kDa heavy chain (HC) linked by a disulphide bond. Some serotypes
are cleaved into a di-chain by an endogenous host protease, while others may be cleaved in the
target organism [4,5]. For example, BoNT/A purified from C. botulinum culture after 8 h is mostly
as a single-chain peptide, but when purified from a 96 h culture it is in the nicked di-chain form [6].
Toxins 2018, 10, 421; doi:10.3390/toxins10100421 www.mdpi.com/journal/toxins
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The clostridial protease responsible for cleaving BoNT/A has been partially characterised, but not
yet identified [7]. The disulphide bond connecting the LC and HC is vital for the mechanism of
intoxication [8,9]. The LC possesses a zinc endopeptidase from the M27 family of peptidases, while the
HC consists of two domains—a translocation domain (HN) and a receptor-binding domain (HC).
The HC domain can be further divided into two distinct folds: a carboxyl-terminal β-trefoil (HCC)
with an amino-terminal lectin-like jelly roll (HCN). The crystal structure of BoNT/A1 shows that the
domains are arranged in a “butterfly” arrangement where the LC and HC are the “wings” attached to
the central HN “body” (Figure 1b) [10]. Each domain appears to be structurally and mechanistically
distinct from one another, with the exception of a large loop, termed the belt, which wraps around
the LC. The structure of BoNT/B follows the same arrangement of BoNT/A, whereas the structure of
BoNT/E appears to adopt a “closed wing” compact conformation where the HC is rotated around the
HN and LC (Figure 1c) [11,12]. The HC domain is responsible for targeting the protein to the neuronal
membrane by binding to receptors present on the cell surface. All classical BoNT serotypes (/A to /G)
bind to one or more polysialogangliosides, and most also bind to a protein receptor and together form





Figure 1. (a) Schematic of botulinum neurotoxin (BoNT) domain organisation. The crystal structures of
(b) BoNT/A [10] and (c) BoNT/E [11] show different orientations of the receptor-binding domain (HC)
with respect to the rest of the molecule. HN: translocation domain; HC: heavy chain; LC: light chain.
Polysialogangliosides consist of a hydrophilic complex polysaccharide with many sialic acid
residues, bound to a hydrophobic ceramide tail. Different forms of these gangliosides can be found
embedded in the cell membrane with the various sugar moieties displayed on the cell surface. The most
common examples found on neuronal membranes include GT1b, GD1a, GD1b, and GM1. Two types
of BoNT protein receptors have been identified to date: three isoforms of synaptic vesicle glycoprotein
2 (SV2A-C) and two isoforms of synaptotagmin (SytI-II). Both types are involved with the regulated
secretion of neurotransmitter from synaptic vesicles [15,16]. SV2A-C contribute to the modulation of
exocytosis, although their exact role is yet to be determined, while SytI and SytII are calcium-sensitive
membrane proteins also involved in exocytosis [15,17–19]. Their involvement in synaptic vesicle
endocytosis also requires them to be recycled back into the cell through endocytosis, making them
excellent targets for BoNTs.
Once the BoNT has bound to its target receptors, it is internalised into a vesicle by endocytosis.
The vesicle then matures into an endosome, and proton pumps reduce the internal pH which may cause
the BoNT to undergo a conformational change. The exact mechanism of translocation is still not
well understood, but it is proposed that the HN forms a pore through which a partially unfolded LC
passes into the neuronal cytosol [20–22]. The LC remains bound to the HN on the cytosolic side due
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to a single disulphide bond, and requires host protein thioredoxin (Trx) and its partner thioredoxin
reductase (TrxR) to release the LC (Figure 2). Disulphide cleavage is essential to intoxication, and
inhibition of Trx is sufficient to block the LC release [23,24]. The free LC is then able to cleave
a soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE), which prevents



























Figure 2. Mechanism of BoNT intoxication. (a) BoNT binds the neuronal cell membrane through
a dual-receptor complex. (b) The BoNT–receptor complex is endocytosed and enclosed within a
vesicle. (c) Acidification of the endocytic vesicle causes a conformational change, allowing the LC to be
translocated through the membrane. (d) Thioredoxin (Trx), bound to the vesicle membrane, catalyses
the reduction of a disulphide bond that releases the LC into the cytoplasm where it can cleave its
soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) substrate. Cleavage of
any one of the SNARE proteins of the SNARE complex inhibits membrane fusion and acetylcholine
(ACh) release, thus stopping muscle contraction. ACh: acetylcholine; AChE: acetylcholine esterase; Trx:
thioredoxin; TrxR: thioredoxin reductase.
2. Receptor-Binding Domain Variation
2.1. BoNT/A
Within the BoNT/A serotype there are currently eight subtypes BoNT/A1 to /A8 which differ
by between 3% and 16% at the amino acid level (Table 1). The most thoroughly characterised BoNT
subtype is BoNT/A1—this is in part due to its use as a therapeutic for several conditions such as
spasticity, dystonias, and glabellar lines [25,26]. The carboxyl-terminal half of the BoNT HC domain
(HCC) contains the peptide motif, H. . . SxWY. . . G, which constitutes the core of the ganglioside-binding
site (GBS) [27]. In contrast to the dual ganglioside binding sites identified on the related TeNT HC,
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the GBS of BoNT/A1 can only bind one ganglioside at a time [28], but is capable of recognising more
than one type, specifically GT1b, GD1a, and to a lesser extent GM1 [29,30]. The exact interactions
between ganglioside and the GBS were first determined from the crystal structure of the HC domain
in complex with GT1b [31] (PDB ID: 2VU9). This revealed extensive hydrogen-bonding with four of
the seven individual monosaccharides within GT1b. Depletion of gangliosides in neuroblastoma cells
completely prevents entry of BoNT/A1 [29]. However, gangliosides alone do not mediate cellular
entry—for this, BoNT/A also requires the protein receptor SV2 [32,33]. Of the three SV2 isoforms
found in humans, BoNT/A1 has the greatest affinity for SV2C [32]. BoNT/A1 binds specifically to the
luminal domain 4 of SV2 (SV2-LD4) via direct backbone–backbone interactions between a β-strand
of SV2-LD4 and a β-strand of BoNT HC [34], and also through interactions with an N559-linked
glycan [35]. The significance of the latter is highlighted by the inability of BoNT/A1 to bind to
bacterially-expressed (i.e., non-glycosylated) SV2A or SV2B, and a reduced affinity for non-glycosylated
SV2C [33,36]. The crystal structure of BoNT/A1–gSV2C-LD4 revealed a large range of interactions
between the HC and the SV2 glycan, which extended away from the backbone–backbone interactions,
almost doubling the contact surface area [37].
The other subtypes of BoNT/A are predicted to bind the same receptors as BoNT/A1 due to their
high sequence identity between the binding domains (Table 1). The crystal structure of the BoNT/A2
HC domain in complex with a non-glycosylated SV2C-LD4 showed that the binding mode is conserved,
and despite some residue differences, it still binds SV2C [38,39]. F563 of SV2-LD4 forms a π-stacking
interaction with R1156 of BoNT/A1, while a glutamic acid residue in BoNT/A2 (E1156) causes F563
to adopt a different conformation and the BoNT instead interacts directly with H564 of SV2C-LD4.
Such mutations indicate flexibility with respect to the backbone–backbone interaction of SV2, which
may also be tolerated due to extra interactions with the N-linked glycan [37]. BoNT/A2 has also been
shown to have a higher affinity for gangliosides than BoNT/A1, although the interactions mediating
this difference have not yet been identified [40]. The crystal structures of the BoNT/A3 and /A4 HC
domains suggest a similar mode of interaction to ganglioside compared to BoNT/A1—the GBS of the
former shows a potential loss of a hydrogen bond to one of the terminal sialic acids due to a difference in
amino acid (phenylalanine rather than a tyrosine), whereas the latter is conformationally conserved [41].
With regard to the SV2 binding site, both structures show slight differences in conformation compared
to that of BoNT/A1 due to differences in the primary sequence. Whether this will affect interactions
with the SV2 glycan is yet to be determined. Despite high sequence identity between BoNT/A subtypes,
significant differences in their intoxication properties have been identified. For example, BoNT/A2 is
more potent in neuronal cells than BoNT/A1, possibly due to faster cell entry [42–44], and BoNT/A4
has been reported to be three orders of magnitude less potent than BoNT/A1 [44]. It is difficult to
attribute these differences to just interactions between the HC and receptors, and is instead likely to
be as a result of contributions from the HC, HN, and LC combined. Uncovering the subtle structural
changes resulting from sequence variation which may affect receptor affinity requires further work
through structural studies of individual HC domains and their complexes with receptors.
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Table 1. BoNT/A subtype primary sequence identities. Percentage identities are given for full-length
and HC domain sequence alignments of each BoNT/A subtype. For the HC alignments, sequences
aligned to BoNT/A1 residues 870–1296 were used. Uniprot accession codes for BoNT/A1 to /A8 are
A5HZZ9 [45–47], Q45894 [48], Q3LRX9 [49], Q3LRX8 [49], C7BEA8 [50], C9WWY7 [51], K4LN57 [52],
and A0A0A7PDB7 [53], respectively.
A1 A2 A3 A4 A5 A6 A7 A8







tyA2 90.04 – 98.83 88.47 89.65 90.12 90.35 93.43
A3 84.66 93.19 – 88.24 88.94 89.65 89.88 92.72
A4 89.19 88.12 84.29 – 86.85 85.92 85.92 90.14
A5 97.15 90.50 85.21 87.34 – 93.43 92.72 89.91
A6 95.68 91.74 86.29 87.72 95.91 – 91.08 87.32
A7 93.75 89.81 84.90 86.64 94.37 92.98 – 89.67
A8 93.36 93.44 87.69 88.81 93.60 93.06 91.36 –
Full-length identity
2.2. BoNT/B
There are currently eight subtypes within the BoNT/B serotype (BoNT/B1 to /B8), and they
differ by between 1.5% and 7% at the amino acid level (Table 2) [54]. Although the crystal structure
of BoNT/B1 exists in an open conformation similar to that of BoNT/A [11], the BoNT/B serotype
targets a different protein receptor on the neuronal cell membrane, namely SytI or SytII [55–58].
Crystal structures of the HC domain from BoNT/B in complex with murine SytII revealed the high
specificity of the binding interface where the SytII peptide forms a helix and binds to a hydrophobic
groove via six hydrophobic residues [59,60]. Interestingly, BoNT/B displays a much lower affinity
toward human SytII than murine SytII due to a single mutation at residue 54-Phe in rodents and Leu
in humans [59,61,62]. Considering that SytII is more abundant on human motor neurons than SytI,
a significantly larger dose of BoNT/B needs to be administered in order to achieve a similar therapeutic
effect to that of BoNT/A. To overcome this issue, the BoNT/B binding domain has been engineered
(E1191M,S1199Y) to increase its binding affinity—this molecule showed an 11-fold higher functional
efficacy in human cells compared to wild-type BoNT/B1 [63]. BoNT/B is only capable of entering
cells once it has bound to both its synaptotagmin receptor and its ganglioside receptor, either GT1b or
GD1a [28,55,64]. The crystal structure of the BoNT/B1 binding domain in complex with both SytII
and GD1a show strong interactions with the Sia5 moiety [65]. Although there is no direct contact
between SytII and GD1a, there is some evidence that each can influence binding to the other, possibly
due the spatial arrangement of both binding sites [66]. In addition to the dual receptors, BoNT/B
has been reported to interact directly with the cell membrane through an exposed hydrophobic loop
(“lipid-binding loop”) located between the ganglioside and Syt binding sites on the HC [67].
Table 2. BoNT/B subtype primary sequence identities. Percentage identities are given for full-length and
HC domain sequence alignments of each BoNT/B subtype. For the HC alignments, sequences aligned to
BoNT/B1 residues 862–1291 were used. UniprotKB accession codes for BoNT/B1 to /B8 are P10844 [68],
A2I2R7 [69], A2I2S2 [69], A2I2R6 [69], A2I2R9 [70], A8R089 [71], H9CNK9 [72], I6Z8G9 [54], respectively.
B1 B2 B3 B4 B5 B6 B7 B8







tyB2 95.66 – 96.05 91.16 91.40 96.74 93.02 93.02
B3 95.97 98.45 – 90.47 92.79 96.28 92.79 92.79
B4 93.41 94.19 94.03 – 88.60 89.77 90.70 89.07
B5 96.13 95.20 95.51 92.87 – 93.26 90.23 91.86
B6 96.20 98.45 98.22 93.49 95.41 – 91.86 92.56
B7 94.81 95.89 95.74 93.88 94.19 95.20 – 90.70
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Table 2. Cont.
B1 B2 B3 B4 B5 B6 B7 B8
B8 95.51 95.97 95.82 93.34 94.50 95.66 94.58 –
Full-length identity
2.3. BoNT/C
BoNT/C (specifically known as BoNT/C1) is predominantly associated with botulism in animals
rather than humans [2,73]. There are no subtypes of the BoNT/C serotype—only two distinct protein
sequences have been identified to-date (UniProtKB: P18640 [74], Q93HT3 [75]) which share 99.9%
identity. Perhaps confusingly, there are two other botulinum toxins called “C2 toxin” and “C3” which
are not “traditional” neurotoxins, but rather refer to different gene products—a binary AB toxin and an
exoenzyme, respectively [76–78]. The mechanisms of cell-binding is of great interest because unlike the
majority other BoNTs, no protein receptor for BoNT/C1 has yet been identified [79,80]. Interestingly,
while the conserved SxWY ganglioside-binding motif is absent from the HC domain, BoNT/C1 is still
able to bind gangliosides [81]. Indeed, an extended hydrophobic loop termed the “ganglioside binding
loop” (GBL) was reported to be essential for neuronal binding, but the specific interactions have yet
to be determined [80]. Crystal structures of the BoNT/C1 HC domain in complex with sialic acid
revealed two potential binding sites that are independent of the GBS identified in other BoNTs [82,83].
2.4. BoNT/D
Like BoNT/C, there are no subtypes of BoNT/D, of which there are multiple sequences that share
a primary sequence identity of >96%. BoNT/D appears to recognise all three isoforms of SV2 [81,82].
Cells lacking SV2 do not get intoxicated by BoNT/D, but this can be restored by the expression of any of
the three SV2 isoforms (SV2A, B, C) [84]. It was further demonstrated that SV2A/B knockout neurones
displaying a chimeric form of SV2-LD4 (SV2A, B, or C) alone were unable to mediate BoNT/D entry
despite rescuing intoxication for BoNT/A and /E. Mutation of the N537 N-linked glycosylation site
also had no effect on BoNT/D entry, despite blocking entry to BoNT/E [84]. This suggests that the
SV2 receptor-binding domain in BoNT/D may be distinct from other SV2-interacting BoNTs such as
BoNT/A. Gangliosides are also required for BoNT/D cell entry [85], however like BoNT/C, BoNT/D
does not contain an SxWY motif in the GBS, although the site is still able to recognise gangliosides [86].
It is also proposed to contain a second binding site termed Sia-1, since mutation of this site results in
reduced ganglioside binding [87].
2.5. BoNT/E
There are currently twelve known BoNT/E subtypes (BoNT/E1 to /E12) whose amino acid
identities vary by up to 12% (Table 3). The protein receptor for BoNT/E is SV2, although only isoforms
SV2B and SV2C are capable of mediating entry [36,88], and in the presence of gangliosides [89].
The SxWy motif is conserved in the BoNT/E GBS, and direct binding of GT1b has been observed [90].
No crystal structures of BoNT/E in complex with receptor or ganglioside have yet been solved.
Therefore, the precise molecular basis of their interactions have yet to be determined. The native
crystal structure of BoNT/E has been solved, and it reveals a conformation that is significantly different
from that of BoNT/A and BoNT/B [12]. In this structure, the HC domain wraps around the toxin,
giving the protein more compact shape overall. BoNT/E is capable of entering cells much more
quickly than BoNT/A [91], and this domain organisation has been proposed to prime the toxin for
translocation, resulting in a faster onset of paralysis [12]. However, investigations using various
chimeras of BoNT/A1 and BoNT/E1 showed that the speed of translocation is not affected by the
binding domain [92].
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Table 3. BoNT/E primary sequence identities. Percentage identities are given for full-length and
HC domain sequence alignments of each BoNT/E subtype. For the HC alignments, sequences
aligned to BoNT/E1 residues 848–1252 were used. Uniprot accession codes for BoNT/E1 to /E12
are K7S1V3 [93], A2I2S6 [93], A2I2S5 [93], C4IHM1 [94], Q9K395 [95], A8Y878 [96], G8I2N7 [93],
G8I2N8 [93,97], K7S9Y2 [93], A0A076JVL9 [98], A0A076K0B0 [98], W8FNB6 [99], respectively.
E1 E2 E3 E4 E5 E6 E7 E8 E9 E10 E11 E12








E2 99.20 – 97.53 97.28 91.34 96.79 97.53 99.75 84.16 95.80 95.31 88.61
E3 98.16 97.36 – 97.78 92.82 97.28 100.0 92.28 83.17 94.57 93.58 87.87
E4 97.28 97.12 95.69 – 90.84 99.51 97.78 97.53 82.67 94.07 93.09 86.88
E5 96.88 96.40 95.20 95.04 – 90.84 92.82 91.09 83.91 88.86 89.60 90.84
E6 96.96 96.81 95.93 96.96 94.88 – 97.28 97.04 82.67 93.83 93.09 86.88
E7 97.92 97.12 97.36 96.25 94.88 96.41 – 97.28 83.17 94.57 93.58 87.87
E8 96.25 97.04 95.69 96.17 94.16 96.81 98.32 – 83.91 96.05 95.56 88.37
E9 89.05 89.37 88.73 90.01 89.45 88.25 89.21 89.45 – 83.66 85.15 88.37
E10 95.37 95.77 94.81 94.97 93.53 95.69 96.88 97.84 89.45 – 97.04 87.38
E11 93.29 93.85 92.57 92.73 92.01 93.13 93.45 94.41 89.05 95.61 – 87.62
E12 92.97 93.21 92.65 92.65 93.61 91.21 92.57 92.09 91.45 92.01 91.13 –
Full-length identity
2.6. BoNT/F
In addition to BoNT/F1, there are eight other BoNT/F subtypes (BoNT/F2 to /F9) which
differ by up to 30% sequence identity (Table 4). The exact protein receptor for BoNT/F1 has been
reported to be glycosylated SV2 [81,100], but this remains to be established conclusively. For example,
one study showed that BoNT/F activity decreased when HC/A was introduced as a competitor
molecule [81], whereas a separate study demonstrated that BoNT/F1 entry in neurones was unaffected
by a double SV2A/B knockout in cortical neurones (which have negligible expression of SV2C) [101].
For ganglioside binding, BoNT/F1 requires gangliosides containing an α2,3-linked sialic acid on the
terminal galactose (i.e., GT1b or GD1a) [81,100]. The SxWY motif is conserved in BoNT/F, and the
crystal structure of the HC domain from BoNT/F1 in complex with GD1a confirmed the existence of a
GBS [102].
Table 4. BoNT/F subtype primary sequence identities. Percentage identities are given for full-length
and HC domain sequence alignments of each BoNT/F subtype. For the HC alignments, sequences
aligned to BoNT/F1 residues 866–1278 were used. Uniprot accession codes for BoNT/F1 to /F9
are A7GBG3 [103], D2KHQ7 [103], D2KHR6 [103], D2KHQ8 [103], D2KHQ9 [103], D2KHS4 [103],
D2KHS9 [103], KEJ01913 ∗ [104], A0A1P8YWK9 [105], respectively. ∗ GenBank accession code given
where UniProtKB code not available.
F1 F2 F3 F4 F5 F6 F7 F8 F9








F2 83.71 – 96.37 81.51 92.03 93.89 72.02 83.70 90.34
F3 84.25 97.19 – 82.44 93.46 93.64 73.17 84.39 92.49
F4 92.33 83.71 84.09 – 82.00 81.03 76.40 88.56 83.45
F5 70.31 74.37 74.35 69.84 – 90.22 73.48 84.18 92.03
F6 88.05 90.20 90.04 87.42 74.11 – 72.17 82.27 88.75
F7 74.43 69.53 69.91 72.77 64.45 70.84 – 79.32 73.48
F8 96.24 83.71 84.17 93.19 69.84 87.81 73.01 – 84.67
F9 84.27 89.92 81.63 84.03 73.75 87.37 69.85 84.18 –
Full-length identity
203
Toxins 2018, 10, 421 8 of 18
2.7. BoNT/G
Only two protein sequences of BoNT/G are currently known to exist, and they share 99.9%
amino acid identity. The protein receptor for BoNT/G is either SytI or SytII, although interestingly the
interface diverges from BoNT/B and it has a lower binding affinity [58,106,107]. Only 5 of 14 residues
involved in the BoNT/B–SytII interaction are conserved [57,106]. BoNT/G also displays a low affinity
for the human SytII receptor due to a human/chimpanzee-specific mutation [61]. The BoNT/B HC
domain was successfully engineered to improve human SytII binding, and a similar approach would
be worth investigating here [63]. BoNT/G possesses the conserved SxWY motif in its GBS, and binds
preferentially to GT1b [108]. In addition to the dual-receptor interactions, BoNT/G also contains a
“lipid-binding loop” (residues 1252–1256) similar to that of BoNT/B which can directly interact with
the cell membrane to further contribute binding affinity [67,106], and deletion of this loop dramatically
decreased neurotoxicity [67].
2.8. Mosaic/Chimeric BoNTs
BoNTs composed of domains from different serotypes also exist in nature. The most common of
these chimeric toxins are discussed below.
2.8.1. BoNT/CD
BoNT/CD is a mosaic toxin composed of a LC domain and a HN domain that is most similar
to BoNT/C and a HC domain that is most similar to BoNT/D. Interestingly the binding domain of
BoNT/CD binds synaptosomes more tightly than BoNT/D [79]. This may be due to residues K1118
and K1136 (which differ from the equivalent residues in BoNT/D, E1114 and G1132) since mutation of
these lysines results in a dramatic loss in synaptosome binding affinity [109]. Protein residues which
may also interact with a ganglioside have also been identified through crystallisation with a sialic acid
molecule [110].
2.8.2. BoNT/DC
The BoNT/DC chimera possesses an LC domain and a HN with 96% sequence identity to
BoNT/D and a HC domain similar to that of BoNT/C (74% sequence identity) [111,112]. Botulism
caused by BoNT/DC is usually found outside of humans in birds and other mammals, but it is
also capable of binding human neuronal cells [62,112]. Despite having a binding domain similar to
BoNT/C, BoNT/DC binds to either SytI or SytII. This interaction is mediated by hydrophobic residues,
and is distinct from that of BoNT/B [113]. The BoNT/DC protein is particularly interesting, as it
appears that it may not require complex gangliosides to enter target neurones [114,115]. However,
the crystal structure of BoNT/DC in complex with Sialyl-T suggests that BoNT/DC is capable of
recognising a single sialic acid, and thus potentially a range of membrane-bound sugars. The structure
also reveals the presence of an extended “lipid-binding loop” that is also observed in BoNT/B and
BoNT/G [67,114].
2.8.3. BoNT/HA(FA)
BoNT/FA was recently identified in 2014 from a case of infant botulism [116,117]. At the
time it was referred to as BoNT/H (and sometimes still as BoNT/HA) due to its non-neutralisable
antigenicity [116], and phylogenetic analysis of the bont sequences placed the gene in a lineage distinct
from other serotypes [117]. The sequence was finally released to the scientific community after a
protracted period of data restriction due to supposed safety concerns [118–120]. It was determined
that the molecule was a mosaic toxin composed of an LC similar to that of BoNT/F5, an HN domain
similar to that of BoNT/F1, and an HC domain similar to that of BoNT/A1 [121]. Direct binding of the
BoNT/FA HC domain has been confirmed for glycosylated SV2C-LD4 [122], and crystal structures
of this binding domain show some slight differences with respect to BoNT/A1 which would be
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consistent with a decreased affinity towards the protein backbone of SV2 [122,123]. Although no
ganglioside-bound structure of BoNT/FA has yet been solved, the structure of the GBS appears to
maintain the same fold as that observed for BoNT/A1 [123]. SV2 is likely the protein receptor for
BoNT/FA, and direct binding has been confirmed for glycosylated SV2C-LD4 [122]. The BoNT/FA
sequence contains mutations with respect to BoNT/A1 which result in decreased affinity towards the
protein backbone of SV2, as determined by a pull-down assay against non-glycosylated SV2C, while the
equivalent residues involved in glycan binding remain unchanged [122]. The effect of these mutations
towards different isoforms of SV2 remains to be seen. The ganglioside-binding site is able to maintain
the same fold as BoNT/A1, but no ganglioside-bound structures yet exist, so the exact interactions
remain to be determined [123]. In recent assays using cultured rat embryonic spinal cord neurones
and rat cortical neurones, BoNT/FA was found to be much more potent than BoNT/A1. However,
counterintuitively the toxin was much less potent when assayed using an ex vivo mouse phrenic
nerve hemidiaphragm (mPNHD). These results, along with the methods used for each assay, point
toward a toxin that may have a slow speed of onset despite a highly active LC [124]. Understanding
the interactions of BoNT/FA with its receptors is crucial to both determining what causes intoxication
differences and for developing novel therapeutics.
2.9. BoNT/X
A strain of C. botulinum that was already known to express BoNT/B was recently found to contain
the gene for another BoNT molecule that shared low primary sequence identity to other serotypes
(<30%)—this was named BoNT/X [125]. It is unknown whether this molecule is capable of causing
human botulism, but interestingly, its LC cleaved non-canonical substrates such as VAMP4, VAMP5,
and Ykt6 [125]. This suggests that this toxin significantly diverged from other serotypes during its
evolution. Despite this, recent structural characterisation of the LC has revealed a core fold common to
all BoNTs [126]. Little is known about the BoNT/X HN and HC domains, and considering the novel
characteristics of LC, attempts are underway to determine the specific receptor(s) that it targets and
how it functions in vivo. The BoNT/X HC does contain an SxWY sequence motif, indicating that it
potentially shares similar ganglioside binding characteristics with other BoNTs. Due to its divergence
and low sequence similarity to existing BoNTs, structural and functional characterisation could lead to
new insights into receptor binding that could be exploited for future therapeutics.
2.10. BoNT-Like Proteins
Considering that BoNTs are the deadliest biological agents that exist, it was surprising to find
BoNT-like proteins produced by non-Clostridium species. The first was found in 2015 and is referred to
as “BoNT/Wo”, named after the bacterium that produced it, Weissella oryzae SG25 [127,128]. BoNT/Wo
cleaves VAMP at a unique location (Trp89–Trp90) [129], but it does not contain any typical BoNT
motifs in the receptor-binding domain. This would be consistent with zero reported cases of botulism
in humans. Indeed, it has been speculated that BoNT/Wo may instead target SNARE-mediated plant
defence systems [128]. More recently, another BoNT-like gene cluster was discovered in the bacterium
Enterococcus faecium, which is a ubiquitous commensal microorganism commonly found in the gut of
mammals. The BoNT-like protein, referred to as BoNT/En or eBoNT/J, possesses many traditional
BoNT motifs, including a HExxH zinc-binding motif in the LC and a ganglioside-binding SxWY motif
in the HC domain [130,131]. Early studies indicate that rodents do not possesses the receptor(s) for
BoNT/En intoxication [130].
3. Conclusions
BoNTs are highly specific and potent exotoxins that are being exploited for therapeutic gain.
Our knowledge of the molecular aspects of botulinum neurotoxin, such as mechanism of cell targeting
and internalisation, is incomplete and mostly limited to only one or two serotypes (i.e., BoNT/A1 and
BoNT/B1). We have yet to fully understand the binding mechanism of others and also how subtle
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amino acid differences may result in differences of intoxication (i.e., between subtypes). From what
we know so far, X-ray crystallography has suggested that the mechanism of binding is more complex
than was initially thought. It is possible that BoNTs may accommodate heterogeneous glycosylation of
their protein receptors and target a variety of gangliosides to ensure successful binding to their target
cell type. It is not a trivial task to determine how BoNTs bind to their receptors on neuronal cell
membranes, especially when trying to replicate the conditions in vivo. With the recent discovery
of new BoNTs and BoNT-like molecules in other bacterial species, this raises questions regarding
the evolution of the bont gene cluster, their ability to be transferred between species, the potential
implications for biosafety, and the need for an agreed-upon consistent naming convention to avoid
confusion and ambiguity [132,133]. Fast characterisation and the generation of neutralising antibodies
against these novel toxins is required. Despite the potential dangers posed, the knowledge may lead
to the generation of new and safer therapeutics. In particular, atomic data of the receptor-binding
domains from individual subtypes could be used for structural and functional analyses, providing
insights for the design of novel BoNTs [134]. In summary, this review highlights the need for further
functional and structural characterisation of different BoNT subtypes to improve our understanding of
what determines the toxicological differences and how they may be used in therapeutics.
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A B S T R A C T
Clostridium botulinum neurotoxins (BoNTs) cause the life-threatening condition, botulism. However, while they
have the potential to cause serious harm, they are increasingly being utilised for therapeutic applications. BoNTs
comprise of seven distinct serotypes termed BoNT/A through BoNT/G, with the most widely characterised being
sub-serotype BoNT/A1. Each BoNT consists of three structurally distinct domains, a binding domain (HC), a
translocation domain (HN), and a proteolytic domain (LC). The HC domain is responsible for the highly specific
targeting of the neurotoxin to neuronal cell membranes. Here, we present two high-resolution structures of the
binding domain of subtype BoNT/A3 (HC/A3) and BoNT/A4 (HC/A4) at 1.6 Å and 1.34 Å resolution, respec-
tively. The structures of both proteins share a high degree of similarity to other known BoNT HC domains whilst
containing some subtle differences, and are of benefit to research into therapeutic neurotoxins with novel
characteristics.
1. Introduction
Botulinum neurotoxins (BoNTs) comprise a family of proteins pro-
duced predominantly by Clostridium botulinum. There are seven distinct
serotypes termed BoNT/A through BoNT/G that cause the deadly
condition botulism in vertebrates (Schiavo et al., 2000, Johnson and
Montecucco, 2008, Rossetto et al., 2014). Of these serotypes, /A, /B, /E
and /F are most commonly associated with human botulism (Coffield
et al., 1997). BoNTs are composed of three major domains that are
organised into two chains: a 50 kDa light chain (LC) and a 100 kDa
heavy chain (HC), that are linked by a disulphide bond. The LC com-
prises a single zinc-endopeptidase domain while the HC comprises the
other two domains – a translocation domain (HN) responsible for
transporting the LC across a plasma membrane, and a binding domain
(HC) responsible for forming a receptor complex with the target neu-
ronal cell. All BoNTs bind polysialogangliosides found on neuronal cell
membranes. In addition, BoNT/A, /D, /E and /F also bind the luminal
domain of the transmembrane synaptic vesicle 2 (SV2) protein, while
BoNT/B, /DC (a mosaic toxin) and /G instead bind to the luminal do-
main of the protein synaptotagmin I and II (Syt).
Each BoNT serotype can be further categorised into subtypes based
on amino acid sequence identity. For BoNT/A there are currently eight
known subtypes (BoNT/A1-8) which share between 84% and 97% se-
quence identity amongst them. The most widely used therapeutic BoNT
is the subtype A1. Some subtypes have been reported to exhibit dif-
ferent properties to BoNT/A1 such as onset of symptoms and duration
of action (Tepp et al., 2012; Whitemarsh et al., 2014; Henkel et al.,
2009). For example, BoNT/A3 has been shown to be less effectively
neutralised by anti-BoNT/A1 antibodies whilst also inducing symptoms
of intoxication in mice that are distinct from BoNT/A1 (Mazuet et al.,
2010; Tepp et al., 2012). It has been suggested that these differences are
due to structural differences within the binding domain of BoNT/A3
(HC/A3) (Tepp et al., 2012). Here we provide structural insight into the
subtype differences of the HC domains from BoNT/A3 and also BoNT/
A4, and provide a plausible explanation on how structural differences
may play a role in receptor binding.
2. Materials and methods
2.1. Protein expression and purification
The binding domains of BoNT/A3 (residues 866-1292) and BoNT/
A4 (residues 870-1296) were cloned into the pJ401 vector (Atum) from
their respective full-length sequences (Genbank: ABA29017.1 and
ABA29018.1) with an N-terminal 6xHis tag. Constructs were trans-
formed into E. coli BL21 cells, which were grown in 0.5 L LB at 37 °C,
and induced at an OD600 of 0.6 with 1mM IPTG at 16 °C for 16 h. For
purification, cells expressing HC/A3 were lysed in 50mM Tris pH 7.4,
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0.5M NaCl, whereas those expressing HC/A4 were lysed in 50mM Tris
pH 7.4, 0.2M NaCl, 10mM Trehalose. Each protein was captured on a
HisTrap column (GE Healthcare) and further purified by size-exclusion
chromatography on a Superdex 200 column (GE Healthcare).
2.2. Crystallisation
Protein crystallisation conditions were screened using the sitting-
drop vapour diffusion method at 16 °C. HC/A3 (6mg/mL) and HC/A4
(4mg/mL) were dispensed using an Art Robbins Phoenix crystal
screening nano dispenser into 96-well 3-drop Intelliwell plates
(Molecular Dimensions, England). Multiple screening kits from
Molecular Dimensions were used. HC/A3 crystals were obtained after
one week with 0.1M MIB pH 4.0 25% w/v PEG 1500 from the PACT
premier screen (condition B1). Individual crystals were mounted in a
loop and dipped in a solution containing reservoir and 50% glycerol in
a 1:1 ratio for cryoprotection before vitrification and storage in liquid
nitrogen. HC/A4 crystals were also obtained after one week, but using
the Morpheus II screen (Gorrec, 2015) (Molecular Dimensions, Eng-
land). The best crystal of approximately 60 µm3 was produced in 10mM
Spermine tetrahydrochloride, 10mM Spermidine trihydrochloride,
10 mM 1,4-Diaminobutane dihydrochloride, 10mM D-L-Ornithine
monohydrochloride, 0.1 M MOPSO/bis-tris pH 6.5, 15%(w/v) PEG 3 K,
20%(v/v), 1,2,4-butanetriol, 1%(w/v) NDSB 256 (condition H1). This
was mounted in a loop and then flash-cooled for storage in liquid ni-
trogen.
2.3. X-ray data collection and structure determination
Diffraction data for HC/A3 and HC/A4 (7200 images total) were
collected using 0.1° oscillations and exposures of 0.02 s at beamline IO3
(Diamond Light Source, Didcot, UK) and processed using DIALS
(Waterman et al., 2016). The structures of both proteins were solved by
molecular replacement with PHASER (McCoy et al., 2007) using the
binding domain of BoNT/A1 (PDB 2VUA; Stenmark et al., 2008) as a
search model. Both models were manually fitted using COOT (Emsley
et al., 2010) and refined with REFMAC (Murshudov et al., 1997) in the
CCP4 suite of programs (Winn et al., 2011). The structures were vali-
dated with MolProbity (Chen et al., 2010). Crystallographic data pro-
cessing and refinement statistics are given in Table 1. Figures were
prepared using CCP4MG (McNicholas et al., 2011).
3. Results and discussion
3.1. Structure of the BoNT/A3 binding domain (HC/A3)
Crystals of HC/A3 diffracted to 1.6 Å resolution, and belonged to
space group P212121 with one molecule in the asymmetric unit. A re-
solution cut-off was imposed based on CC1/2 (Evans and Murshudov,
2013). The electron density map obtained following molecular re-
placement was very good except for three loop regions 1198-1201,
1268-1277 and 1227-1231, which could not be modelled completely.
The crystal structure of HC/A3 contains two motifs common to all
BoNTs – a jelly-roll fold consisting of 14 β-strands, and a β-trefoil fold
which are predicted to contain a conserved ganglioside and SV2 re-
ceptor binding site (Fig. 1a). The HC/A3 sequence is most similar to that
of the BoNT/A2 subtype, where both binding domains share 98.8%
identity. This is reflected with a high structural similarity where the
RMSD with HC/A2 is 0.83 Å between Cα atoms.
The ganglioside binding site of BoNT/A1 is mostly conserved in the
HC/A3 structure (Fig. 2i) except for a tyrosine at position 1117 (instead
of phenylalanine) and an undetermined conformation of R1276 due to
poor electron density. Considering that BoNT/A1 binds to GT1b, it is
predicted that BoNT/A3 might do so as well; however, the different
residue at position 1117 may affect this since it would no longer be able
to form a hydrogen bond to a sialic acid of GT1b (Stenmark et al.,
2008).
Recent structures of both HC/A1 and HC/A2 bound to their protein
receptor, SV2 isoform C (SV2C), suggest that the overall binding mode
is generally conserved (Benoit et al., 2014; Yao et al., 2016; Benoit
et al., 2017). The high conformational similarity with our structure
suggests that HC/A3 may also bind SV2C in the same manner
(Fig. 2b and c). One notable point of variation, however, is position
1152 which is a methionine (and also for subtypes /A4 to /A8) that has
the potential to form an electrophilic interaction with H563 of SV2C
(Fig. 2c) (Pal and Chakrabarti, 2001). BoNT/A1, however, has an ar-
ginine at the equivalent position (Fig. 2a) that forms a cation-π stacking
interaction, whereas BoNT/A2 has a glutamate that forms a salt bridge
with the equivalent histidine of SV2C. Under normal physiological
conditions SV2 is glycosylated, and N-linked glycosylation of SV2C is
important for binding of BoNT/A1 to the neuronal cell membrane (Yao
et al., 2016; Mahrhold et al., 2016). The glycans form an array of in-
teractions with BoNT residues that neighbour those which interact with
the protein chain directly. Within BoNT/A3 (and subtypes /A2, /A6 and
/A8), an arginine residue at position 1060 (Fig. 2f), may cause a change
to glycan binding specificity compared to BoNT/A1, which has a his-
tidine in the equivalent position (Fig. 2e).
3.2. Structure of the BoNT/A4 binding domain (HC/A4)
Despite the lower protein concentration of HC/A4 (due to a lower
solubility than HC/A3) used in the crystal screens, it was possible to
grow high quality crystals that diffracted to 1.34 Å resolution, and be-
longed to space group P213 with one molecule in the asymmetric unit.
The exceptional quality of the electron density map allowed modelling
Table 1
X-ray data collection and refinement statistics. Inner and outer shell statistics are given in
square and curved brackets respectively.
HC/A3 HC/A4
Diamond Beamline I03, DLS I03, DLS
Wavelength (Å) 0.9763 0.9763
Crystallographic Statistics
Space Group P212121 P213
Unit-cell parameters:
a,b,c (Å) 39.8, 96.5, 111.0 116.0, 116.0, 116.0





Rmerge (%) [0.076] 0.126 (1.352) [0.038] 0.091 (2.306)
Rmeas (%) [0.080] 0.131 (1.416) [0.039] 0.093 (2.424)
Rpim (%) [0.024] 0.036 (0.408) [0.008] 0.020 (0.740)
CC1/2 (%) [0.998] 0.997 (0.639) [1.000] 0.999 (0.421)
Mean< I/σ(I)> [24.3] 10.3 (1.9) [68.1] 17.5 (1.1)
Completeness (%) [99.6] 96.9 (79.6) [100.0] 100.0 (100.0)




No. unique reflections [4 3 0] 55445 (2169) [7 9 4] 116165 (5700)
Multiplicity [10.9] 12.9 (11.6) [21.4] 21.7 (10.5)
Refinement Statistics
Rwork/Rfree 0.179/0.214 0.144/0.158
RMSD bond lengths (Å) 0.016 0.001












PDB Code 6F0O 6F0P
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of all residues, as well as identification of a single disulphide bond
between C1235 and C1280. As described previously for HC/A3, the
structure of HC/A4 contains a jelly-roll fold and a β-trefoil fold
(Fig. 1b), and all the equivalent residues involved in ganglioside
binding for BoNT/A1 (Stenmark et al., 2008) remain unchanged in HC/
A4. This suggests that BoNT/A4 may also share the same ganglioside
preference as that of BoNT/A1.
Of all the different subtypes of BoNT/A, the binding domain of
BoNT/A4 is most similar to that of BoNT/A1 with 91.78% sequence
identity and a RMSD of 0.72 Å between Cα atoms. When comparing
binding sites, not only is BoNT/A4 predicted to have the same gang-
lioside preference as BoNT/A1 (Fig. 2j), it is also predicted to bind to
SV2C, according to sequence alignment with BoNT/A1 (Fig. 2a). Most
interactions to the SV2C peptide are likely unchanged owing to the
nature of backbone-backbone interactions between β-strands, however
like HC/A3, the HC/A4 structure shows a methionine at position 1156
rather than an arginine at the equivalent position for HC/A1, which
may form an important interaction with SV2C (Fig. 2d). Interactions
with SV2C glycans may also be affected by an arginine at position 1292
which protrudes into the binding pocket (Fig. 2g). We, therefore, sug-
gest that, as for BoNT/A3, the binding mode of BoNT/A4 to SV2C itself
is likely unchanged when compared to BoNT/A1 but mutations may
cause a change to the glycan binding specificity.
4. Conclusion
Subtle structural differences found in both HC/A3 and HC/A4 may
account for some of the differences in intoxication, such as onset of
symptoms and duration of action (Tepp et al., 2012). However, the
effect of having different residues within the receptor binding sites,
compared to BoNT/A1, has yet to be fully determined. For example,
although the variation of glycosylation for recombinant SV2 has been
investigated (Mahrhold et al., 2016), the same has not been performed
for the native protein receptor at physiological conditions. Differen-
tially glycosylated SV2C may have implications for BoNT receptor
targeting and this is one avenue that we are exploring. In addition, the
generation of future novel therapeutics relies on the availability of
atomic-resolution structures to aid protein engineering, modelling and
understanding. Our high-resolution crystal structures, therefore, pro-
vide a platform for exploratory work into detailed molecular basis of
BoNT binding, as well as structure-based design of novel BoNT ther-
apeutics.
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structural analysis of Clostridium 
botulinum neurotoxin type D as a 
platform for the development of 
targeted secretion inhibitors
Geoffrey Masuyer1,3, Jonathan R. Davies1, Kevin Moore2, John A. Chaddock2 & K. Ravi 
Acharya1
the botulinum neurotoxin type D is one of seven highly potent toxins produced by Clostridium 
botulinum which inhibit neurotransmission at cholinergic nerve terminals. A functional fragment 
derived from the toxin, LHn, consisting of the catalytic and translocation domains, has been 
heralded as a platform for the development of targeted secretion inhibitors. these secretion 
inhibitors are aimed at retargeting the toxin towards a specific cell type to inhibit vesicular secretion. 
Here we report crystal structures of LHn from serotype D at 2.3 Å, and that of sXN101959 at 3.1 Å 
resolution. sXN101959, a derivative that combines LHn from serotype D with a fragment of the 
growth hormone releasing hormone, has previously revealed promising results in inhibiting growth 
hormone release in pituitary somatotrophs. These structures offer for the first time insights into the 
translocation domain interaction with the catalytic domain in serotype D. Furthermore, structural 
information from small-angle X-ray scattering of LHn/D is compared among serotypes A, B, and 
D. taken together, these results demonstrate the robustness of the ‘LHn fold’ across serotypes 
and its use in engineering additional polypeptide components with added functionality. our study 
demonstrates the suitability of botulinum neurotoxin, and serotype D in particular, as a basis for 
engineering novel secretion inhibitors.
Toxins from Clostridium botulinum species are the causative agent of the rare neuroparalytic illness 
botulism. Seven distinct serotypes (A–G) of botulinum neurotoxins (BoNTs) affect humans and other 
species to varying degrees. Once inside the neuronal cell, BoNTs block the release of neurotransmitters 
leading to paralysis1. Although they are highly toxic, various BoNTs are available commercially as ther-
apeutic agents2.
BoNTs are synthesized as a single polypeptide chain (150 kDa), which is post-translationally cleaved 
into a di-chain molecule composed of light chain (LC, 50 kDa) and heavy chain (HC, 100 kDa). LC is 
the catalytic domain and a zinc-endopeptidase, while HC is further divided into two sub-domains of 
equal molecular mass called the translocation domain (Hn) and the membrane binding domain (Hc). 
On binding to the nerve terminals, BoNTs are endocytosed into a vesicle, where the acidic environment 
causes some conformational changes allowing LC to enter the cytosol3. Inhibition of neurotransmission 
takes place by proteolysis of one of the SNARE proteins1 that mediate cell secretion4.
Of the seven types of botulinum toxin, A, B, E and F are known to cause the disease in human while 
C and D have only been observed in animal cases. More particularly, D has been responsible for several 
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recent outbreaks of botulism in cattle5. This has raised some interest in this serotype and understanding 
its precise mechanism of action. No cases of type D human botulism have ever been recorded. Coffield 
et al.6 investigated the impact of serotype D on human tissues and demonstrated its inability to block 
neuromuscular transmission when tested at a level 10 times higher than that of serotype A. This limited 
activity was recently confirmed in vivo by electrophysiological study on human muscles7 and may be 
linked to differences in the receptor binding domain8,9. BoNT/D however, acts similarly to the other 
botulinum neurotoxins by targeting one of the intracellular SNARE proteins. Synaptobrevin (or VAMP) 
was identified as the BoNT/D specific substrate10 and is cleaved at the Lys59-Leu60 position.
BoNT/A and /B are currently the only serotypes approved for medical uses. With the emergence 
of immuno-reactivity and resistance among patients11, other serotypes such as BoNT/D can provide a 
useful alternative. The successful retargeting of BoNT activity for therapeutic purposes, by association 
of the LHn fragment (catalytic and translocation domains) with various ligands has been described12. In 
particular, a targeted secretion inhibitor (TSI) combining a growth hormone releasing hormone (GHRH) 
receptor targeting domain with the LHn/D fragment, called qGHRH-LHn/D, was shown to specifically 
inhibit pituitary somatotroph growth hormone release13. This molecule demonstrated efficient intracellu-
lar activity on VAMP-3 in rat pituicytes and thus encouraging potential in the treatment of Acromegaly14. 
The latest LHn/D derivative, SXN101959, which combines the functional BoNT fragment with a GHRH 
ligand domain [qGHRH(1–40)], presented potent and reversible inhibitory action on the somatotropic 
axis and such features are well aligned with treating overproduction of growth hormone15. The arrange-
ment of the functional domains within SXN101959 involves a novel orientation in which the GHRH 
ligand is located centrally between the LC and HC in the single chain polypeptide expressed in E. coli 
and with a protease cleavage site located between the GHRH ligand and the LC, such that following 
protease activation to generate the active di-chain TSI the GHRH ligand is at the amino-terminus of the 
HC domain. This arrangement, termed central presentation, was necessitated by the requirement of the 
GHRH ligand to have a free N-terminus to be able to bind and activate its receptor. It means, however, 
that the relative arrangement of the binding domain relative to the LC and Hn domains is different to 
that in BoNT and previously reported TSI proteins16. The resulting TSI protein is functional in respect 
to binding its receptor, internalising into the cytosol of target cells, cleaving its substrate SNARE pro-
tein and inhibition of growth hormone secretion14,15. However, the consequence of this novel domain 
arrangement upon the structure of the TSI protein is not known.
Structural and biochemical characterisation of the LHn fragments from serotypes A and B17,18 have 
provided a molecular basis for their functionality, representing an important step forward for the design 
of novel molecules based on these frameworks. In order to assess its applicability for further pharmaceu-
tical development, the structure of LHn/D was analysed by X-ray crystallography (solid crystalline state) 
and small angle X-ray scattering (SAXS, in the solution state). The X-ray crystal structure showed key 
elements of BoNT/D including the flexibility of the translocation domain and the elaborate interaction 
with its catalytic partner. The SAXS analysis corroborates the relevance of the crystal structures and the 
stability of the LHn template in solution. The X-ray crystal structure of SXN101959 at 3.1 Å further con-
firmed the rigidity of LHn/D’s structural framework and its ability to accommodate novel arrangements 
of the domain subunits such as central presentation, although the GHRH ligand domain was not visible. 
This study should thus provide the structural basis for the development of BoNT/D-based Targeted 
Secretory Inhibitor (TSI) which could prove useful in the treatment of hypersecretory disorders.
Results and Discussion
structure of LHn/D. This is a mutant endo-negative form of LHn/D in which the catalytic domain 
is inactivated by a two amino acid substitution in the zinc-binding site (H233Y, E230Q). The crystal of 
LHn/D diffracted at 2.3 Å resolution in space group P6422 with cell dimensions a = b = 173, c = 222 Å; 
α = β = 90, γ = 120° (Table  1). Despite the large unit cell, a single molecule was present in the asym-
metric unit corresponding to an unusually high solvent content of 75%. The X-ray crystal structure pre-
sents the two domains, LC and Hn, in a close interaction. No electron density was observed for regions 
442–457 (between the two domains), residues 494–510, and the C-terminal poly-histidine tag (last fifteen 
residues), all in solvent-accessible areas (Fig. 1).
LHn/D share 34 to 35% identity with the corresponding fragment of BoNT/A, /B and, /E, for which 
the full length structures are available19,20,21. LHn/D presents a similar overall fold as previously observed 
for LHn/A and /B17,18. The translocation domain of serotype D is shown for the first time and includes 
two long coiled-coil helices with additional short helical segments on both sides. The catalytic domain 
has the globular fold typical of other light chains but shows key differences in flexible loop regions. 
Additionally, one of the most intriguing features of BoNT, the ‘belt’ region (residues 458–547), which 
is part of Hn and surrounds LC, was visible in the electron density map (despite high solvent content 
in the crystal) in the structure presented here and highlights the intricate interactions between the two 
domains. A PISA22 analysis shows that the LC-belt interaction is supported by over 40 potential hydrogen 
bonds and 2 salt bridges, making up a 3373 Å2 contact area. Additionally LC and Hn (excluding the belt) 
make a further 1392 Å2 buried interface area principally involving hydrophobic interactions.
the light chain. The structure of the catalytically inactive mutant light chain superposes well with 
the high-resolution structure of a recombinant form previously reported (PDB code 2FPQ23) with a root 
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mean square deviation (rmsd) of 2.3 Å (over 411 Cα atoms; Fig. 2). Loss of the zinc ion was confirmed 
with a local rearrangement of the active site residues (Fig. 2B,C). Mutation of the zinc-coordinating H233 
to tyrosine caused displacement of the catalytic ion, replaced in its position with the Y233 hydroxyl 
group. Overall, the role of the zinc ion appears mostly catalytic with little impact on the structural 
integrity of the light chain.
The 2FPQ23 structure (hereafter referred to as ‘2FPQ’) corresponds to residues 1–424 of the light chain 
and thus do not include some of the elements interacting with the rest of the toxin. In this structure, res-
idues 166–170 of the catalytic channel appear in two possible conformations, one is a random coil close 
to the zinc atom and the second a short β -strand completing the catalytic pocket. Furthermore, residues 
173–179 were disordered. The present LHn/D structure, in contrast, was stable across residues 166 to 
179 where segments 168–172 and 178–184 take on an α -helical arrangement (Fig.  2D). The multiple 
conformations of this area across the crystal structures, in vicinity of the active site, indicate a degree of 
flexibility that may provide the necessary space for substrate interaction24.
The most noticeable differences between the new structure and 2FPQ reside in flexible loop regions, 
particularly those at the interface with the translocation domain. For example, loop 63–70, which is 
surface accessible in 2FPQ, still presents a random coil in LHn/D but is stabilised by the extended 
carboxyl-terminal end of LC (residues 429–431) on one side (S70) and by the end of the ‘belt’ (F539) on 
the other (R63) (Fig. 2D). Additionally, loop 250, which presents low sequence identity with other light 
chains23 but is visible in 2FPQ, adopts a different conformation in LHn/D with a 10 Å and 25° movement 
(Fig.  2D). The loop is stabilised through hydrophobic interactions involving residues 256–258 (GFF) 
with Hn, and potential electrostatic interactions of residues Q260-D261 with the belt which occludes the 
catalytic pocket. A third area of interest is the flexible loop at positions 205–217 which was completely 
disordered in 2FPQ and is visible in LHn/D. The hydrophobic part of the loop (V205-T206) fits within 
the aromatic pocket composed of Y731 and Y734 of one of the long Hn helices, while the backbone of 
LHn/D SXN101959
Resolution (Å)a 2.3 (2.3–2.34) 3.1 (3.1–3.25)
Space group P6422 P212121
Cell dimensions (Å; a, b, c); angle (°; α , β , γ ) 173, 173, 222; 90, 90, 120 88, 144, 173; 90, 90, 90
Total/Unique reflections 321,682/86,306 122,006/35,774
Completeness (%)a 98.8 (97.7) 89.0 (81.2)
Rmerge
a,b 0.059 (1.09) 0.127 (1.02)
Rpim
a,c 0.048 (1.04) 0.101 (0.859)
I/σ (I)a 8.1 (0.5) 6.0 (1.0)
CC1/2d 0.998 (0.214) 0.990 (0.331)





Rmsd in bond lengths (Å) 0.011 0.007
Rmsd in bond angles (°) 1.45 0.97
B- factor statistics (Å2)
Protein all atoms 79.1 94.6/110.3g
Protein main chain atoms 78.3 95.0/110.7
Protein side chain atoms 79.9 94.2/109.8
Zinc ion N/A 64.9/85.4




PDB code 5BQN 5BQM
Table 1.  X-ray crystallography: data collection and refinement statistics. aValues in parentheses refer to 
the highest resolution shell. bRmerge = Σ Σ i|Ih − Ihi|/Σ Σ iIh, where Ih is the mean intensity for reflection h.  
cRpim = Σ h (1/nh − 1) Σ l |Ihl − (Ih)|/Σ hΣ l(Ih). dCorrelation coefficient between random half datasets35. 
eRcryst = Σ ‖ Fo| − |Fc‖ /Σ |Fo|, where Fo and Fc are measured and calculated structure factors, respectively. 
fRfree = Σ ‖ Fo| − |Fc|/Σ |Fo|, calculated from 5% of the reflections selected randomly and omitted during 
refinement. gThe two B-factor values recorded here correspond to two molecules in the asymmetric unit.
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residues 212–214 is stabilised by hydrophobic interactions with the other helix (V776-S779) (Fig.  2E). 
Although crystal packing might influence some of these interactions, the observed changes could partly 
be attributed to the complex interface between the two domains compared to the structure of the single 
light chain (in 2FPQ).
The interaction between the catalytic domain and its VAMP substrate involves several binding sites 
based on the information provided by the structure of LC/F with a VAMP-inhibitor complex25 and recent 
mutagenesis work24. Several sub-sites of the catalytic pocket of LC/D have been shown to be essential for 
substrate binding. Interestingly the LHn/D structure highlights the plasticity of LC within the context of 
the whole toxin at these particular sites. For example R372 of S2′ (Fig. 2D) presents a double conforma-
tion but is expected to form a hydrogen bond with the P2′ site of VAMP. Additionally, the hydrophobic 
S1′ pocket and the S3 loop of the catalytic domain in LHn/D present new alternative conformations 
which were shown to cause at least a 50-fold loss of catalytic activity when mutated to Y168A/L200D 
and R63A, respectively (Fig. 2D)24.
The long substrate requirement of all BoNT serotypes is atypical to other zinc proteases and involves 
several binding sites distal from the catalytic pocket26. Guo and Chen identified and labelled these 
exosites B1 to B5 in LC/D24. None of these sites present any conformational changes in LHn/D. While 
B1 is buried within LC, 15 Å away from the active site, the hydrophobic patches B4 to B5 show the 
extent of substrate recognition at the accessible surface of the free light chain. In LHn/D these pockets 
are interacting with the belt (Fig. 3) and implies a potential substrate inhibiting role for this region as 
also hypothesised for BoNT/A and /B27.
the translocation domain and the belt. The catalytic domain is normally linked to the translo-
cation domain through a single disulphide bridge after activation of BoNT into a di-chain molecule. 
Although the construct used for crystallisation experiment was not activated, residues 442–457, corre-
sponding to the engineered cleavage site and flexible linker between the two domains, were not visible. 
The cysteine bridge is however stabilised by formation of a small β -sheet between the C-terminus of LC, 
the N-terminus of Hn and the end of the belt segment (Fig. 1).
The belt region in /D is overall similar to the corresponding segments in serotypes /A, /B and /E 
(Fig. 3). It surrounds LC following a hydrophobic groove along its surface. Interestingly, the belt in the 
other known BoNT structures has been observed in its entirety and takes on a conserved α -helical 
arrangement at a position where LC/A was shown to bind its substrate (SNAP-25) in a similar second-
ary conformation21,26. In LHn/D, seventeen amino acids of this area are missing altogether (residues 
494–510), indicative of a flexible loop region which is unlikely to interact with LC/D. Remarkably, LC/D 
is known to recognise a shorter substrate than its counterparts28, and this site is therefore not expected 
to play a role in VAMP binding. The full function of the belt region in BoNT is not yet completely 
Figure 1. Crystal structure of LHn/D. Ribbon diagram representation of LHn/D structure, LC in cyan, belt 
region in grey and Hn in blue. C-terminus of LC and N-terminus of Hn are marked with a cyan and grey 
asterisk, respectively. The disordered region of the belt is presented as a grey-dashed line. The disulphide 
bond between LC and Hn is highlighted in orange.
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understood but evidence suggests a possible role beyond protection of LC, and towards a chaperone-like 
mechanism for translocation and membrane insertion27,29.
The main components of the translocation domain are the two coiled-coil helices of approximately 
105 Å (Fig.  1). While the secondary α -helical structure is conserved across serotypes, the two helices 
all have a central bending point which curves to various degrees (Fig.  4). Of the four serotypes (with 
known Hn structures thus far), D appears the straightest. It should also be noticed that Hn/D presented 
particularly high B-factor at the extremities of these helices (Fig.  5D), with weak electron density for 
the random-coiled loop linking them. This is likely an indication of flexibility within these regions. The 
smaller helices flanking the main frame are also well conserved and similarly positioned across serotypes. 
Additionally the visible C-terminal end forms a small α -helix which is involved in crystal packing with 
a symmetry-related molecule and appears in a different orientation to the similar segment in LHn/A 
and /B.
structure of sXN101959. SXN101959 differs from LHn/D, and from natural BoNT molecules at the 
linker region between the two domains. It includes a Factor Xa cleavage site, a GHRH ligand domain 
(qGHRH[1–40]) and a GGGGS repeat (totalling an additional 56 residues). The engineered protein was 
crystallised as an activated di-chain molecule and diffracted up to 3.1 Å resolution (Table  1). The two 
molecules of the asymmetric unit are overall similar (rmsd of 1.05 Å over 828 Cα atoms) and present 
the same disordered regions which correspond to 66 amino acids of the linker peptide (described above), 
and 17 residues of the belt region. Both these areas were also not visible in LHn/D (Fig. 5).
Figure 2. Comparison of the LC structure of LHn/D with LC/D. (A) Ribbon diagram representation of 
LHn/D structure with its light chain in cyan, belt region in grey and translocation domain in blue. PDB 
2FPQ23 is shown in yellow with the zinc ion as a grey sphere. (B) Residues of the catalytic pocket of LHn/D 
are shown with sticks to highlight the effect of the double mutation E230Q and H233Y. The 2Fo-Fc electron 
density map countered at 1σ level is shown in blue. (C) Residues of the catalytic pocket of LC/D presenting 
the classic zinc coordination motif HEXXH. (D) and (E) Close-up views of loop 250 and 210, respectively. 
Residues involved in loop interactions are shown in sticks and labelled.
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Figure 3. The belt of BoNT/D. (A) Crystal structure of LHn/D with the belt region represented with grey 
sticks. The rest of the translocation domain is shown in blue, the light chain in shown as a cyan surface. The 
structure of LC/F in complex with a VAMP peptide inhibitor (PDB 3FIE25) was superposed to LHn/D and 
VAMP is represented as a pink ribbon. (B) Superposition of the belt regions of LHn/A (PDB 2W2D17),  
/B (PDB 2XHL18), /D and BoNT/E (PDB 3FFZ21), in blue, magenta, cyan and grey ribbon, respectively. The 
amino- and carboxyl-end of the belt are labelled.
Figure 4. Comparison of BoNT translocation domains. Superposition of the translocation domains 
(without the belt) of LHn/A, /B, /D and BoNT/E, in blue, magenta, cyan and grey ribbon, respectively. The 
amino- and carboxyl-end of the domain are labelled.
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Although the targeting ligand could not be observed, the crystal structure still provides valuable 
information on LHn/D as a framework for protein engineering. Indeed addition of a large peptide seg-
ment at the LC-Hn interface, which is essential for BoNT activity3, did not affect the LHn/D scaffold 
(each molecule superposes to LHn/D with rmsd of 1.08 (821 Cα ) and 1.40 Å (828 Cα atoms), respec-
tively). The light chains of SXN101959 and LHn/D are identical, with little variation in the solvent acces-
sible loop regions. No noticeable difference was seen in the backbone of the active site (Fig. 5) despite 
SXN101959 being catalytically active. Clear electron density provided evidence of the zinc ion at the cat-
alytic site, which is coordinated as per the classical HEXXH motif. Unsurprisingly, the more noticeable 
difference between SXN101959 and LHn/D resides in the translocation domain where the extremities of 
the coiled-coil helices are showing signs of flexibility, confirming what was observed in LHn/D (Fig. 5).
The linker region (residues 438–513 in SXN101959) was engineered to provide ease of access of the 
targeting GHRH ligand for its receptor. It is flanked with an N-terminal protease cleavage site that allows 
activation of the whole molecule into its di-chain form, and frees the amino end of the peptide chain. 
The biological activity of GHRH is retained by the 29 N-terminal amino acids for recognition by the 
Figure 5. Crystal structure of SXN101959 and comparison with LHn/D. (A) The crystal structure of 
SXN101959, in dark red, was superposed with LHn/D, in cyan. The disulphide bridge between LC and Hn is 
highlighted in orange. The zinc ion of SXN101959 is shown as a grey sphere. (B) Close-up view of the 
domain interface in SXN101959 and LHn/D. The C-terminal end of LC and N-terminus of Hn are labelled. 
The location of the targeting ligand is represented with the missing part of the linker shown as a dashed 
line. (C) The visible part of the linker region of SXN101959 is highlighted with the 2Fo-Fc electron density 
map countered at 1σ level shown in blue. (D) Temperature factor (B-factor) analysis. Ribbon diagram 
representation of LHn/D and SXN101959 structures, with a gradient colouring from low (cyan) to high 
(red) B-factors. Gradients were adjusted independently to highlight the less ordered area for each structure. 
(E) Activation of the human GHRH receptor. The receptor activation was detected by the intracellular 
accumulation of cAMP in CHO-K1-hGHRH-R cells incubated with hGHRH(1–44) (•) or SXN101959 ( ). 
Data are mean ± sem of triplicate samples from one experiment.
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GHRH receptor30. In order to give the system more structural flexibility, three GGGGS repeat motifs 
were included on the C-terminal side of the peptide. This allows for the targeting peptide to be optimally 
and centrally presented while it remains covalently linked to the translocation domain. This flexible 
segment, was disordered in the crystal structure. It is located in a solvent accessible area where it could 
be easily accommodated within the crystal packing (Supplementary Figure). It should also be noticed 
that the observable part of the linker, consisting of the LC’s carboxyl and Hn’s amino ends (438–443 
and 509–513, respectively), is stabilised through the formation of an anti-parallel β -sheet conformation 
(Fig.  5) so that one of the GGGGS repeats is visible. The targeting peptide is not interacting with the 
rest of the molecule, which is encouraging from a biological perspective, as it relies on this freedom of 
movement to activate the GHRH receptor. SXN101959 is known to activate GHRH receptor in rat pri-
mary pituicytes which leads to internalisation and intracellular cleavage of VAMP314.
Integrity of the sample used for structural study was tested by measuring the intracellular accumu-
lation of the second messenger cAMP in human GHRH receptor-expressing cells. SXN101959 elicited 
a concentration-dependent increase in cAMP accumulation with a pEC50 (potency) of 8.73, compared 
with the pEC50 of hGHRH(1–44) of 9.54. The maximum response of SXN101959 was the same as 
hGHRH(1–44), indicating that the TSI is a full agonist of hGHRH receptor. Activation of the target 
receptor confirms the presence of the qGHRH(1–40) ligand within the structure of SXN101959 (Fig. 5E). 
Thus the crystal structure of SXN101959 highlights the validity of LHn/D in the context of a biologically 
active TSI.
small-angle X-ray scattering studies on LHn. The botulinum neurotoxin has been extensively 
studied by X-ray crystallography but little information is available on the relevance of these structures in 
solution. Small-angle X-ray scattering (SAXS) experiments were carried out on LHn/A, /B and /D. All 
data were collected on station X33 at DESY (Germany) and the solution scattering curves are provided 
in Fig. 6A. The purified samples were all in their activated di-chain form.
A Guinier analysis of the scattering curves was consistent with the distance distribution function 
(P(r)) in determining the radius of gyration (Rg) for each LHn serotypes with values of approximately 
32, 34 and 34 Å for A, B and D, respectively (Table 2; Fig. 6B). Interestingly, LHn/B and /D also share 
a similar maximum dimension (Dmax) of 110 Å, slightly longer than LHn/A at 102 Å. The comparable 
Figure 6. Small-angle X-ray scattering (SAXS) on LHn. (A) Scattering curve of LHn/A, /B and /D, from 
left to right. (I is a relative unit, s is expressed in nm−1). (B) The interatomic distance function (P(r)) was 
calculated (x axis, r in nm) with GNOM43 (left) and Guinier plot is presented for each samples. (C) Ab 
initio solution scattering models. SAXS bead models were generated with DAMMIF44 and averaged in 
DAMAVER45. The models are compared to the samples’ respective X-ray crystal structures.
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features of the three samples correlate with the known crystal structures. The theoretical scattering curves 
extrapolated from the high-resolution structures were calculated with CRYSOL31 and fitted well with the 
experimental values (Table 2) although the corresponding Rg were somewhat lower than the experimen-
tal ones (between 31 and 32 Å). Ab initio models were generated from the scattering curves (Fig.  6C, 
Table 2), and present the overall shape of LHn in solution.
Manual docking allowed the comparison between the ab initio bead models and the crystal structures. 
The distinctive shape of the two domains forming the LHn molecules can be clearly noticed in all three 
samples. Indeed the atypical long coiled-coil helices of the translocation domain give the models an 
extended form over 100 Å long whereas the light chain accounts for the globular central shape. In accord-
ance with the statistical comparison (Table  2), LHn/B appears to show the best resemblance between 
crystal and solution structures. The smaller dimensions of LHn/A in solution might be the reflection 
of the more pronounced central kink of its translocation domain (Fig. 4). Additionally, LHn/D presents 
a less defined upper region which might be an indication of domain movement, considering the bead 
model represents an averaged form of the solution state. Interestingly the extremities of the translocation 
domain were also showing signs of mobility in the crystal structures of LHn/D and SXN101959.
Overall, the information collected for LHn/A, /B and /D showed that the fragments have conserved 
the LHn fold in the solution state although the resolution of the data may not allow the visualisation of 
small variations.
Conclusion
Botulinum neurotoxins (BoNTs) are some of the most potent protein toxins and their modular archi-
tecture have made them molecules of choice for the design of a novel class of biopharmaceuticals 
labelled Targeted Secretion Inhibitors. The intracellular activity of BoNT towards members of the solu-
ble N-ethylmaleimide-sensitive factor-attachment protein receptor family, a critical element of vesicular 
secretion, can be redirected towards specific cell types. This concept relies on the functionality of the 
LHn fragment which consists of the catalytic and translocation domains of BoNT. The distinct but var-
iable properties of each serotype, such as substrate specificity and duration of action, have led to the 
development of tailor-made TSI with optimised applicability. Recent report of the biological activity of 
SXN101959 in inhibiting GH secretion has demonstrated the significance of using LHn/D as a frame-
work for protein engineering. The crystal structures of the LHn fragment and SXN101959 present for the 
first time the properties of the combined translocation and catalytic domains of BoNT/D. The data pro-
vided have highlighted the plasticity of the light chain and its extensive interaction with the translocation 
domain. The translocation domain appears as a ‘solid scaffold’ on which to build on a retargeting partner. 
Indeed the structure of SXN101959 showed that addition of a long peptide ligand in a central position 
did not cause any significant structural conformational changes, thus demonstrating the robustness of 
LHn structural framework, and its ability to accommodate novel arrangements of the domain subunits, 
such as central presentation, within TSI proteins. Finally, the solution scattering analysis confirmed the 
structural integrity of the LHn fragment across serotypes. Altogether this study has provided useful 
information on the structure of BoNT/D, and the LHn fragment in general, that will be essential for the 
development of the next generation of protein therapeutics based on the TSI technology.
Methods
LHn/A, /B and /D cloning, expression and purification.  Cloning, expression and purification were 
carried out following methods described previously17,18. Briefly, LHn constructs were cloned into modified 
pET26b expression vector (Novagen, Madison, WI, USA) with a C-terminal 6 x His-tag and expressed 
into E. coli BL21 (DE3) cells. The LHn genes were engineered to encode for an enterokinase or factor Xa 
cleavage site between the LC and Hn domains. Proteins were purified by affinity chromatography using 
Ni2+-charged chelating sepharose column (GE Healthcare, UK) and hydrophobic interaction (Phenyl 
sepharose column, GE Healthcare, UK). Samples were kept in 0.05M HEPES pH 7.2 with 0.2 M NaCl.
Guinier1 P(r) function1 Crystal structures2 Structural modeling3
Rg (Å) Rg (Å) Dmax (Å) Rg (Å) Fit (χ2) Discrepancy (χ2) NSD
LHn/A 32.1 32.0 102 31.3 1.5 0.88 0.60
LHn/B 33.9 33.9 110 32.3 1.0 0.81 0.60
LHn/D 33.7 33.7 110 31.4 2.0 0.97 0.62
Table 2.  Small angle X-ray scattering data statistics for LHn serotypes /A, /B and /D. 1The Guinier analysis 
and distance distribution function (P(r)) were performed with PRIMUS42 and used to calculate the maximum 
dimension (Dmax) and the radius of gyration (Rg). 2The X-ray crystal structures of LHn/A, /B and /D were used 
for theoretical scattering calculation and compared to experimental data using CRYSOL43. 3The discrepancy 
(χ2) between experimental and ab initio data was calculated by the program DAMMIF44 with the average of 
10 models (NSD = normalized spatial discrepancy).
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The LHn/D construct used for X-ray crystallography correspond to the catalytically inactive LHn/D 
double-mutant E230Q and H233Y. Standard site directed mutagenesis techniques employing PCR ampli-
fication and subsequent sequencing were used to create the mutated DNA construct. In addition to the 
mutations required to eliminate catalytic activity, this construct contains an engineered enterokinase 
cleavage site between LC and Hn but was kept as a single chain sample for crystallisation. Expression 
and purification were performed as per the other LHn samples described above.
sXN101959 preparation. This protein was prepared as previously reported15. SXN101959 was 
designed using the LC and Hn of BoNT/D (Entrez protein database accession number P19321), a GHRH 
ligand domain, a lead sequence spacer, and a factor Xa protease activation site located between the two 
domains, as previously reported.
GHRH  receptor  activation  assay  (cAMP  second messenger  accumulation).  Frozen CHO-K1 
cells recombinantly expressing the human GHRH receptor were rapidly thawed, collected by centrifuga-
tion and re-suspended in assay buffer Hams F-12 (Life Technologies) , 5 mM HEPES (Life Technologies), 
1 mM 3-isobutyl-1-methylxanthine (IBMX, from Calbiochem), 0.05% BSA (Perkin Elmer), pH 7.4). Cell 
suspension (5,000 cells well-1) was incubated in white 384-well microplates in triplicate with increasing 
concentrations of human GHRH(1–44, from Bachem) (final concentration 1 pM—100 nM) or SXN101959 
(10 pM—1 µ M), which had been serially diluted in buffer. Plates were incubated at 21 ± 3 °C for 90 min-
utes. Following ligand incubation, detection mix (consisting of cell lysis buffer, Lance Eu-W8044–labelled 
streptavidin, cAMP-biotin, and Alexa Fluor 647–anti-cAMP antibody) (kit from Perkin Elmer) was 
added to each well. Plates were incubated at room temperature for 24 hours, and the fluorescence emit-
ted at 665 and 615 nm following excitation at 320 nm was measured using an EnVision microplate reader 
(PerkinElmer). Raw data was plotted as 615/665 nm emission ratio and converted to percentage of the 
maximum response (Emax) defined by hGHRH(1–44). Dose response curves were fitted using a variable 
slope model (using GraphPad Prism software) using equation (1).
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where Y is the RFU, top and bottom are plateaus in the units of the Y axis, X is the log molar concen-
tration and nH is the Hill slope. EC50 value is the negative log of the mid-point location of the curve.
X-ray crystallography. Crystals of LHn/D were grown with 2 µ l of protein at 56 mg/ml mixed with 
1 µ l of reservoir solution consisting of 30% v/v pentaerythritol ethoxylate (15/4 EO/OH), 0.1 M HEPES 
7.5, 6% w/v polyvinylpyrrolidone (MIDAS D2, Molecular Dimensions) and suspended above the well as 
a hanging drop. Crystals grew within 7–10 days into pear-like shapes of 50 to 500 µ m in length.
SXN101959 crystals were grown from the sitting drop method against 0.1 M sodium actetate pH 
5.5, 0.8 M sodium formate, 10% w/v polyethylene glycol 8000, 10% w/v polyethylene glycol 1000 (Clear 
Strategy Screen 1, B6, Molecular Dimensions). A drop of 200 nl of protein at 10 mg/ml was mixed with 
equal amount of reservoir and incubated at 16 °C.
Diffraction data were collected at station I03 of the Diamond Light Source (Oxon, UK), equipped 
with a PILATUS-6M detector (Dectris, Switzerland). A complete dataset to 2.3 Å and 3.1 Å were collected 
from single crystals at 100 K for LHn/D and SXN101959, respectively. Raw data images were processed 
and scaled with DIALS32, and AIMLESS33 using the CCP4 suite 6.534. The resolution cut-off chosen was 
based on the CC1/235 as adding weak high-resolution data beyond the commonly used limits recorded 
on the highly sensitive detector showed significant improvements in electron density maps. For LHn/D, 
initial molecular replacement was performed with the coordinates of LC/D (PDB code 2FPW23) to deter-
mine initial phases for structure solution in PHASER36. The translocation domain was built in from a 
partial poly-alanine model of the secondary structures of LHn/B (PDB code 2XHL18) and extended 
with BUCCANEER37. The refined LHn/D structure was then used for molecular replacement to solve 
SXN101959. The working models were refined using REFMAC538 and manually adjusted with COOT39. 
Water molecules were added at positions where Fo− Fc electron density peaks exceeded 3σ , and potential 
hydrogen bonds could be made. Validation was performed with MOLPROBITY40. Crystallographic data 
statistics are summarized in Table 1. All figures were drawn with PyMOL (Schrödinger, LLC, New York).
small-angle X-ray scattering. Protein samples of LHn/A, LHn/B, and LHn/D were kept in 0.05 M 
HEPES 7.2, 0.2 M NaCl for SAXS analysis and checked for monodispersity by dynamic light scattering 
(Malvern Instruments). Samples were diluted to give three final concentrations at 5, 2.5 and 1 mg/ml. 
These dilutions were checked by absorbance measurement at 280 nm using a NanoDrop ND-1000 
(Thermo Scientific), and concentration discrepancies were corrected for data analysis.
Solution scattering (SAXS) data for the three LHn molecules were collected at DESY, (Germany), 
EMBL Hamburg, beamline X3341. For each sample, a buffer measurement was performed before and 
after the sample at room temperature, using a PILATUS-1M (Dectris, Switzerland) detector. SAXS meas-
urements were performed for each sample at three concentrations. Calibration was carried out with 
BSA at 5 mg/ml in 0.05 M HEPES pH 7.5 as a molecular weight standard. The data were processed and 
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averaged with PRIMUS42 followed by particle distance distribution function P(r) analysis using GNOM43. 
Data were further treated by using DAMMIF44 to produce twenty ab initio models that were averaged 
with DAMAVER45.
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